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Abstract 
Jennifer J. Jordan 
Diversity within the master regulatory p53 transcriptional network:  
impact of sequence, binding motifs and mutations 
(Under the direction of Michael A. Resnick, PhD) 
 
In response to cellular stress and DNA damage, the master regulatory gene p53 
directly controls the differential expression of target genes within its extensive transcriptional 
network through promoter response elements (REs) to elicit many biological responses, 
including cell cycle arrest and apoptosis.  Tetrameric p53 binds the consensus sequence 
RRRCWWGYYY (n= 0-13) RRRCWWGYYY, where R=purine, W=A/T and 
Y=pyrimidine.  Phenotypic diversity within the p53 transcriptional network occurs as a result 
of a variety of factors including cell type, post-translational modifications, stress-inducing 
stimuli, and mutations in p53 that alter transactivation function through changes in the 
strength of gene activation or spectra of genes regulated.  We have developed an isogenomic 
diploid yeast-based reporter system to evaluate the contribution of target binding sequence, 
organization and level of p53 on transactivation at target REs by wild-type and mutant p53.  
The chromosomal position for all of the human derived REs was identical and the number of 
p53 molecules/cell could be varied over a hundred-fold using an integrated rheostatable 
GAL1::p53 promoter that is sensitive to level of galactose in the medium.  We confirm 
transactivation by WT p53 differs between REs where small differences in sequence can  
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contribute significantly to levels of transactivation.  Through deconstruction of the canonical 
RE and evaluating transactivation from various sequences and binding motifs, we have 
challenged the view of what constitutes a functional p53 target.  We show small increases in 
distance between decamer half-sites greatly reduce p53 transactivation. Furthermore, we 
demonstrate that substantial sequence-dependent transactivation can occur from ½- and ¾-
site REs.  Importantly, the presence of these noncanonical REs greatly expands the p53 
master regulatory network.  In addition, we have determined the functional fingerprints of 
missense mutations to demonstrate that altered function p53 mutations can occur in breast 
cancers and the transcriptional effects are often subtle.  Finally, we have identified super-
trans sequences which enhance the efficiency of p53 transactivation by greatly lowering the 
number of molecules required.  These sequences provide a useful tool for addressing wild-
type and mutant p53 function.  Overall, our findings demonstrate that RE sequence, 
organization, level of p53 and mutations can strongly impact the ability of the master 
regulator p53 to transactivate downstream targets, thus diversifying its transcriptional 
network.  
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CHAPTER 1 
INTRODUCTION 
p53 from oncogene to tumor suppressor 
While the discovery of TP53 in 1979 provoked an interest in a protein involved in the 
role of cancer development, the natural function of p53 in tumorigenesis was thought to be 
that of an oncogene since it was first identified complexed with the SV40 large T protein in 
transformed cells [1-3].  The understanding that p53 was a tumor suppressor began to arise 
years later when wild type (WT) p53 was found to suppress transformation of cells, whereas 
mutant p53 was associated with cellular transformation [4, 5].  Furthermore, genetic 
alterations in p53, which mostly occurred as point mutations were found frequently in human 
cancers [6-9].  In agreement with Knudson’s two-hit hypothesis for tumor suppressors [10], 
the p53 knockout mouse developed normally, but had an increased incidence of tumors 
where WT, heterozygous and homozygous mice developed neoplasias at ~18, 9 and 6 
months, respectively [11].  
Several major findings contributed to the understanding that p53 executed its role as a 
tumor suppressor through functioning as a transcription factor.  The p53 protein was found to 
be induced in response to DNA damage or cellular stress to stimulate either cell cycle arrest 
or apoptosis [12-15].  Stimulation of these biological responses was dependent upon the 
ability of p53 to bind DNA, where loss in DNA binding resulted in the loss of its ability to 
suppress growth [16-22].  In addition, an intact transactivation domain and transactivation 
activity were necessary for p53 to function as a tumor suppressor [20, 21, 23, 24].   
Currently, it is accepted that p53 plays a critical role as a master regulatory gene by 
directly controlling the transcriptional regulation of greater than 100 target genes in a 
sequence-specific manner in response to intra- and extra-cellular stresses (Figure 1.1) [25, 
26]. Cell cycle regulation, apoptosis, angiogenesis, replication and repair are processes 
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interconnected within the p53 transcriptional network.  Aberrations within the p53 
transcription network are a hallmark of cancers, where mutations in p53 itself are found in 
greater than 50% of all cancers [27].  To date over 24,800 somatic p53 mutations and ~400 
germline p53 mutations have been reported within the International Agency for Research on 
Cancer’s (IARC) TP53 mutations database [27].  In terms of transactivation, p53 binds to a 
consensus binding sequence [RRRCWWGYYY (n) RRRCWWGYYY] (where R=purine, 
W= A or T, Y= pyrimidine and n is 0-13 bases) [28-30] to recruit the basal transcriptional 
machinery and additional cofactors in order to regulate the expression of the associated target 
gene [31].  However, p53 does not recognize and regulate each of its downstream targets in 
an equivalent fashion (Figure 1.2)[32].  Differential induction is dependent upon the target 
gene of interest, stress stimuli and cell type and is influenced by many factors including the 
chromatin environment, post-translational modifications, availability of transcriptional 
cofactors, and concentration or duration of activated p53 protein [26, 32, 33].  At the DNA 
level, regulation of target genes is dependent on the sequence of response elements (RE), 
number of REs in a promoter region, distance of the RE from the transcriptional start site and 
intrinsic binding with a RE [26].  
The Resnick lab recently established, using an isogenic, in vivo yeast-based model 
system, that these latter influences can lead to greater than a 1000-fold variation in p53-
dependent transactivation from individual REs derived from human target genes [34].  
Variation in gene regulation by p53 has led to the postulation of the master gene of diversity 
concept [26] which can be applied to many sequence-specific transcription factors. Using a 
piano analogy, the master regulatory gene, p53 is the hand that plays a chord on the keys of a 
piano, the downstream target genes. The chord is the accumulation of biological responses 
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regulated and is dependent on both the genes regulated and strength of regulation.  
Functional mutations in the hand can alter the “selection of keys” by altering binding, 
spectrum of REs recognized, and/or the intensity of regulation [26]. 
 
Regulation and activation of p53 protein 
The p53 protein is a 393 amino acid modular protein comprised of two N-terminal 
transactivation domains (residues 1-73), a proline rich domain (PXXP, residues 63-97), a 
core DNA binding domain (DBD) (residues 94 - 292), a tetramerization domain (residues 
324-355) and a C-terminal regulatory domain (residues 360 – 393) [35, 36].  Within the cell, 
p53 is constitutively expressed, but the protein is kept at low concentrations (estimated at 
~1000 molecules/cell [37]) through several negative regulators, the most classic of which is 
the auto-inhibitory feedback loop formed with one of its own target genes, MDM2 (mouse 
double minute or the human homolog, HDM2).  The MDM2 protein inhibits p53-dependent 
transactivation by regulating p53 protein through two mechanisms.  First, it can bind to the 
amino terminal transactivation domain of p53 (residues 18-23) to inhibit interactions between 
p53 and the basal transcriptional machinery or transcriptional cofactors [38-40].  Second, it 
can function as a ring finger E3-ubiquitin ligase to ubiquitinate p53 on its C-terminal lysines 
which targets p53 for proteasome degradation [41-44]. 
Recently, MDMX (HDMX/MDM4 in humans), a ring finger protein related to 
MDM2 but lacking the E3 ligase activity, has been identified as an additional negative 
regulator of p53.  Similar to MDM2, MDMX represses p53-dependent transcription through 
binding the N-terminus transactivation domain of p53.  Under “non-stressed” conditions, 
MDMX forms heterodimers with MDM2 which prevents MDM2 from targeting itself for 
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auto-ubiquitination thus increasing MDM2 dependent degradation of p53 [45-48].  Several 
additional E3 ligases (i.e., COP1 and Pirh2) and de-ubiquitinating proteins (i.e., HAUSP) 
have also been implicated as having a role in regulating p53 protein levels [49, 50]. 
Following DNA damage or cellular stress, a cascade of signaling pathways induce 
post-translational modifications in p53 which have been postulated to contribute to the 
stabilization of the protein.  For example, phosphorylation of p53 at Ser15 by DNA-PK was 
proposed to directly interfere with interactions between p53 and MDM2 [51, 52].  
Phosphorylation of Ser15, Ser20 and Thr18 has also been proposed to decrease p53-MDM2 
interactions indirectly by enhancing p53 interactions with co-activators such as the histone 
acetyl transferases, p300 and CBP [53].  Additional post-translational modifications in the C-
terminal of the protein, such as Ser392 phosphorylation were found to contribute to shifting 
the tetramer-monomer equilibrium towards the tetramer formation which is necessary for p53 
transcriptional activity [37, 54].  
However, several studies have shown that mutations which render a residue unable to 
be modified, such as Ser20Ala do not necessarily prevent accumulation of the p53 protein 
[55].  Current research has implied the rapid degradation of MDM2 following damage or 
stress may play as imperative a role in p53 activation as modifications in p53 itself.  
Following damage, phosphorylation of MDM2 at Ser395 by ATM was shown to abolish the 
direct interactions with p53 [56-58].  Furthermore, phosphorylation of MDM2 has been 
postulated to impede the MDMX-MDM2 interactions which results in the E3 ligase 
specificity of MDM2 being drawn away from p53 and toward itself and MDMX [46].  
These findings have sparked ongoing debates as to whether post-translational 
modifications in p53 contribute to the activation of the protein or whether they dictate 
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promoter selection to specify or fine tune p53-dependent regulation and consequently a 
particular biological response [58].  Currently, there are approximately 40 upstream effectors 
identified which function to post-translationally modify p53 at over 30 residues (primarily in 
the N-terminal transactivation domains and C-terminal) [59].  The concept that specific post-
translational modifications in p53 impact its ability to differentially regulate target genes has 
been coined the “barcode hypothesis” [33].  For instance, one specific barcode which occurs 
after p53 stabilization at high doses of DNA damage is the phosphorylation of Ser46.  This 
post-translational modification has been shown to specifically enhance p53 binding to and 
activation of the apoptotic associated target, p53AIP1; mutagenesis of the residue mitigated 
transactivation from p53AIP1, but not other REs including p21, MDM2, p53R2 and Noxa 
[33, 60].  
In addition to the post-translational modifications, co-factors, small molecules, and/or 
other interacting binding proteins have been shown to influence the promoter selectivity of 
p53 to elicit specific biological responses.  ASPP1 and ASPP2 (apoptosis stimulating protein 
of p53) as well as p53 family members p63 and p73 have been shown to enhance p53 
binding toward some apoptotic REs, such as Bax [61, 62]. Whereas, HZF (hematopoietic 
zinc-finger) binds the p53 DBD to augment p53 binding toward REs associated with cell 
cycle arrest, such as p21 and 14-3-3σ [63].  Other proteins have been identified which 
channel or recruit p53 to selected downstream targets.  For example, BRCA1 has been shown 
to direct p53 to genes involved in cell cycle arrest and DNA repair, but not apoptosis [64]. 
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p53 interaction with its consensus RE  
The consensus sequence which p53 binds consists of two decamer half-sites 
[RRRCWWGYYY (0-13)n RRRCWWGYYY], where R = purine, Y = pyrimidine, W=A/T, 
and which can be spaced by up to 13 nucleotides apart [28-30].  Unlike for other 
transcription factor binding sites, such as NFκB, high evolutionary conservation between 
species is not observed for the p53 response element sequence [65].  The p53 consensus is 
highly degenerate where variation in sequence is tolerated at most positions with the 
exception of the conserved C and G at positions 4 and 7, respectively [26].  Interestingly, 
single nucleotide polymorphisms, or SNPs within the promoter RE sequences have been 
found to include or exclude sequences from the p53 transcriptional network [66]. 
  Each decamer is comprised of two inverted quarter sites arranged in a head-to-head 
fashion.  p53 cooperatively binds to the consensus site as a dimer of dimers, or tetramer 
protein where the two core DBDs of a dimer bind to consecutive quarter-sites (Figure 
1.3)[67-73].  Upon binding to the RE, p53 induces a conformational change in the DNA by 
bending the RE.  The degree of the angle is dependent upon the particular sequence of the 
RE, where REs with a stronger affinity toward p53 are associated with larger bending angles 
[71, 74].  Interestingly, various proteins such as HMG have been found to augment p53 
binding to REs by inducing bends in the DNA [75].  
While tetramerization is not a requirement for sequence-specific binding by the DBD 
[76], it is required for efficient transactivation from the consensus sequence [77-80].  
Arrangement of the quarter sites in a head-to-head orientation is essential for binding which 
results in transactivation.  p53 can bind to a RE sequence comprised of quarter sites arranged 
in a tail-to-tail fashion.  Yet, while the tail-to-tail RE functions similar to head-to-head REs 
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in competitive binding assays, WT p53 was not able to transactivate from these sites [81].  
These findings suggest in addition to sequence, the orientation of binding elements can also 
influence p53 dependent transactivation. 
Previous in vitro studies proposed modification of the C-terminal domain (i.e., 
phosphorylation of Ser392 [35]) was required to alter a “latent” p53 to an “active” p53 in 
order to disrupt its negative effect on transactivation and stimulate p53 sequence-specific 
binding [16, 22, 82].  However, recent structural studies revealed the conformation of p53 
was similar in both the latent and active states [73, 83].  While the C-terminal of p53 was 
previously believed to inhibit p53 binding, its non-sequence specific, structure-based DNA 
interactions, which are highly dependent on the DNA topology, are now postulated to 
facilitate p53 sliding on DNA as proposed by a linear diffusion based search for REs [76, 84-
87].  
Additionally, in vitro chromatin assembly and in vivo ChIP studies show p53 can bind 
to promoters prior to its induction or modification [59, 73, 88, 89].  Such active binding has 
favored the concept of a “selective context model” over a “selective binding model” [33].  In 
the selective context model, expression of a downstream target is reliant not on p53 binding 
per se, but on gene-specific requirements for transactivation.  Thus, individual targets must 
overcome specific hurdles in the transcription process or “filters” which may require more or 
less transcriptional coregulators for activity [33].   Such filters may be reliant on whether or 
not the promoter region is accessible to the general transcriptional machinery.  In the case 
where the promoter is not accessible, p53 binding can increase the promoter accessibility 
through recruitment of chromatin remodeling factors, histone acetyltransferases and/or 
methyltransferases [35].  If the promoter is accessible, p53 has been shown to facilitate pre-
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initiation complexes by interacting with mediator complexes or recruiting basal transcription 
factors.  In addition, p53 had been demonstrated to play a role in reinitiating paused 
polymerases [35].  Thus, downstream target genes such as p21 which have a pre-initiation 
complex, as well as a paused RNAP II at the promoter may require the recruitment of a 
smaller amount of transcription cofactors to overcome any “filter” than a RE which is lacking 
RNAP II.  Importantly, the availability of the cofactors required to overcome such filters may 
be cell-type or stimuli-specific.   
 
p53 structure 
Although structures for the individual domains of the protein have been solved 
independently the exact structure of the p53 tetramer and how two dimer proteins interact in 
terms of protein-protein and protein-DNA interactions remains controversial.  The highly 
disordered segments of the N- and C- termini which flank the structured core DNA binding 
and tetramerization domains, as well as the intrinsic instability of the protein has impeded the 
ability to form crystals of a p53 tetramer binding to a full-length p53 consensus sequence 
[83].  
The basic structure of the core DNA binding domain (DBD) was derived from a 
crystal structure solved by Cho et al., which had three p53 core domain monomers bound to a 
consensus half-site [90].  The p53 DBD was shown to consist of a β-sandwich which 
provides a scaffold for two large β-loops (L2 and L3) and a loop-sheet-helix motif which 
compose the DNA binding surface [90, 91].  The loop-sheet-helix motif binds to the major 
groove of targeted DNA through several residues, whereas the L3 loop interacts with the 
minor groove of DNA through Arg248. The L3 loop is structurally supported by the L2 loop; 
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both the L2 and L3 loops are coordinated by a zinc ion (contacted by residues Cys176, 
His179, Cys238 and Cys242) which is required for the stabilization of the protein, as well as, 
the sequence-specific DNA binding [92].  
 Recently, Kitayner et al., solved the crystal structure of the WT p53 DBD bound to 
three dodecamer sequences (consensus decamer half-sites separated by a 2 nt spacer)(Figure 
1.3) [73].  While the overall structure was similar to that solved by Cho et al., intriguingly, 
the DNA-protein interface was found to vary with the specific sequence encountered.  For 
example, residue K120 contacts the second purine of the response element sequence; 
however the nature of the contact is dependent upon the specific base present [73, 93].   
The DNA binding domain is linked to the tetramerization domain through ~35 
flexible amino acids [68].  The tetramerization domain of p53 is composed of a β-strand 
(amino acids 326-333) and an α-helix (amino acids 335-354) that form a “V-shape” structure 
through a hinge region, or tight turn at residue 334.  In the simplest terms, two monomers 
form dimeric proteins through interactions between the α-helices and β-strands, where the 
two β-strands from opposite monomers form an anti-parallel β-sheet.  The dimers then 
associate through hydrophobic interactions between the anti-parallel α-helices to form 
tetramers [67, 68, 70, 94-97].   
Regardless of the exact nature of the protein binding, tetrameric p53 has displayed a 
great capacity to bind many RE variants to differentially regulate the activity of downstream 
targets.  However, all binding is not equivalent nor will all binding result in transactivation.  
The overall goal of this study is to further contribute to the understanding of how p53 
functions as a sequence-specific transcription factor by further defining the “rules of p53 
transactivation”.  Through manipulation of the DNA sequence p53 encounters, it is possible 
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to address what constitutes a functional response element and how organization of the 
binding motif influences transactivation.  Understanding the interaction of p53 with various 
RE sequences under conditions which render all other factors (such as chromatin and 
transcriptional cofactors) essentially neutral may elucidate how different p53-DNA 
interactions alter the potential of p53-dependent transactivation and possibly dictate the 
remaining factors required for efficient transactivation.  Furthermore, analysis of the impact 
of p53 mutations upon transactivation will help to elucidate the role of p53 as a master 
regulator and how aberrations within its network contribute to carcinogenesis [32].   
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 Figure 1.1 
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Figure 1.1 The tumor suppressor p53 is a master regulatory gene.  As a sequence-specific 
transcription factor, p53 directly controls the regulation of many target genes within its 
transcriptional network to elicit a variety of biological responses.  In response to intra- and 
extra-celluar stresses (including: DNA damaging agents, oncogenic stimuli, hypoxia, cell 
adhesion, altered ribosome pools, redox stress), the p53 protein is stabilized, activated and 
post-translationally modified where it binds as a homotetramer, or dimer of dimers, at a 
consensus site composed of two palindromic decamers [28-30]. This sequence is degenerate 
where alteration from the consensus may affect the ability of the p53 DBD to interact with REs 
thus altering expression of regulated genes.   
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Figure 1.2 
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Figure 1.2 Phenotypic diversity within the p53 transcriptional network.  As a sequence 
specific transcription factor, p53 does not interact with each response element in an 
equivalent fashion [32].  Rather, differential regulation of target genes within the p53 
transcriptional network occurs as a result of a variety of factors including cell type, post-
translational modifications, co-factor availability, target sequence and stress inducing stimuli.  
As a result, the activity of some downstream target genes can be strongly activated, whereas 
others may be weakly activated or attenuated.  Such control of gene expression within the 
network allows for a large spectrum of p53-dependent biological responses. 
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Figure 1.3 
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Figure 1.3 p53 binds cooperatively to response element sequences as a dimer of dimers.   
(A) Kitayner at al. solved the crystal structures of p53 core DNA binding domains (residues 
94-293) bound to three dodecamer sequences (comprised of consensus decamers spaced by 2 
nucleotides) [73].  The exact nature of the p53-DNA interactions was dependent upon the RE 
sequence.  Dimers (formed by monomers A-B or C-D) bound to consecutive ¼-sites.  This 
figure has been reproduced from Kitayner et. al [73].  (B)  Tidow et al., recently solved a 3D 
model of the quarternary structure of human p53 bound to a RE using core DNA binding 
domains containing four stabilizing mutations (M133L/V203A/N239Y/N268D) and a 
combination of small-angle x-ray scattering (SAXS), nuclear magnetic resonance 
spectroscopy (NMR) and electron microscopy (EM)  [83].  The results were in agreement 
with the Kitayner et al. crystal structures. Depicted is a cartoon model of the p53 tetramer 
bound to a RE modified from Shakked 2007 [98].  p53 binds in a cooperative fashion as a 
dimer of dimers closing upon a RE (grey tube; arrows indicate ¼-site), where the core DNA 
binding domains (grey and blue ovals)  and tetramerization domains (grey and blue 
rectangles) are on opposite sides of the DNA and linked through an unstructured regions of 
the protein (dashed line) [98].  The N-terminal domain in the full-length protein protruded, or 
extended from the core binding domain in a flexible fashion.  The C-terminal domains were 
located in the central region of the protein surrounding the tetramerization domain [83].  This 
model would be consistent with the ability of p53 ability to interact with other proteins or to 
be post-translationally modified.  
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CHAPTER 2 
ISOGENOMIC IN VIVO DIPLOID YEAST SYSTEM TO ANALYZE 
TRANSACTIVATION CAPACITY OF THE MASTER REGULATOR p53 
Abstract 
As a sequence-specific master regulatory gene, p53 controls the differential 
expression of target genes within its extensive transcriptional network.  In response to 
cellular stress and DNA damage, p53 directly regulates genes involved in apoptosis, cell 
cycle, angiogenesis and DNA repair from promoter response elements (REs).  However, 
the mechanisms of regulation from the various promoter REs targeted by p53 remain 
unclear, particularly the relationship between p53 binding to target RE sequence and 
transactivation.  To specifically address the role of RE sequence variation in transactivation 
by WT and mutant p53 proteins at various levels of p53 expression, we developed an in 
vivo yeast-based reporter system.  The chromosomal position for all of the human derived 
REs was identical and the number of p53 molecules/cell could be varied over a hundred-
fold using an integrated GAL1::p53 construct that is sensitive to levels of galactose in the 
medium.  Evaluation of transactivation capacity was based on colony or enzyme based 
color reporters. Both reporters exploit a “rheostatable” promoter system for p53 expression 
and utilize the “delitto perfetto” in vivo mutagenesis approach for rapid inclusion of target 
REs upstream of a reporter and the development of mutant p53s.  This system expands a 
plasmid-based haploid yeast system previously developed in the Resnnick lab to 
systematically evaluate the contribution of RE sequence and p53 expression level towards 
p53 differential transactivation.  
Consistent with our previous findings, transactivation by WT p53 differs between 
REs where small differences in the 20 to 30 bp target RE sequence can contribute 
significantly to levels of transactivation.  Regardless of “strength of binding” or biological 
role, the initial induction of transactivation occurs at comparable levels of p53 expression 
 24
for all REs except from a novel sequence Con-A, described in chapter 5, which displays 
high levels of transactivation at low levels of p53 expression. These results challenge 
current notions that the ability of p53 to transactivate from various REs is simply due to 
differences in RE binding affinities.  Our results suggest that differences in binding affinity 
for the various REs and on-rates may not be the principal driver of p53 transactivation 
specificity.  Therefore, the role of sequence in p53 transactivation must be addressed using 
in vivo systems, not simply with in vitro binding measurements. 
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Introduction  
Yeast as a model system to study p53 
 With its ease of genetic manipulation and cost effective measures as a research 
tool, the budding yeast Saccharomyces cerevisiae has become a prominent model system to 
study various human diseases [1].  Fundamental aspects of cancer including, but not limited 
to DNA replication [2], cell cycle checkpoints [3], nuclear trafficking [4] and mechanisms 
of drug resistance [5] have been addressed in this smaller eukaryotic in vivo test tube, 
sometimes referred to as an “honorary mammal” due to its conservation of genes, signaling 
and cellular pathways [6, 7].               
Prior to the identification of the p53 consensus sequence, Schärer and Iggo 
capitalized on the finding that a p53::GAL4 fusion protein could function as a DNA binding 
transactivator in mammalian cells [8] to develop a transcription assay for human p53 in 
yeast [9].   The assay utilized a gap repair technique which allowed a linear p53 cDNA 
fragment (WT or mutant p53) to fill a gapped plasmid containing flanking regions of the 
p53 gene by homologous recombination.  This resulted in the generation of a p53 
expression plasmid where p53 was under the control of the inducible GAL1 promoter 
(repressed under glucose; activated in 2% galactose).  Transactivation was assessed by β-
galactosidase activity on X-gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside) 
plates where β-gal activity was dependent on the ability of the heterologous p53, which is 
not found in yeast, to drive the expression of a lacZ reporter.  The lacZ reporter was under 
the control of the minimal iso-1-cytochrome C (CYC1) promoter which had its upstream 
activating sequence (UAS) replaced by a 33 base pair sequence that p53 was previously 
shown to bind [10].  Binding of p53 to the DNA sequence that resulted in lacZ expression 
 26
stimulated production of the β-galactosidase enzyme which in turn hydrolyzed X-gal into 
galactose and 4-chloro-3-brom-indigo. 
Two important findings arose from this study.  First, human p53 (and murine p53) 
could utilize the conserved transcriptional machinery in yeast, where transactivation of a 
reporter was found to be dependent on the orientation and number of copies of the binding 
site used.  Second, yeast could be used as a tool to assess the function of p53 and 
discriminate between alleles that could support transactivation from those that were 
deficient, or temperature-sensitive for transactivation.  In addition, this study also 
demonstrated immuno-reactivity methodologies, which screened for p53 mutations based 
on the ability of the protein to bind conformation sensitive p53 antibodies, could not predict 
allele functionality.  Schärer and Iggo showed some p53 mutants that were 
indistinguishable from WT p53 in terms of antibody binding were transcriptionally 
inactive.  In contrast, mutants, such as E285K which preferentially recognized epitopes 
associated with altered protein conformation (i.e., PAb240) were partially active for 
transactivation [9].   
 
Analysis of tumor associated p53 mutations in yeast 
With the discovery that p53 could utilize the conserved transcriptional machinery in 
yeast, efforts were expanded in this model system to study additional aspects of p53’s role 
as a transcription factor including the following: classification of cancer-associated alleles, 
second-site suppressors, temperature sensitivity, dominant-negative and gain-of-function 
activity, chemotherapeutic or small molecule reactivity, and structure-function analysis 
[11-14].  These studies provide isogenic conditions that are not often obtainable in 
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mammalian systems, to determine p53 functional status from specific binding elements 
through various reporters which were either integrated into the genome or plasmid-based.   
The FASAY assay or functional analysis of separated alleles in yeast provides a 
means to screen tumor samples for p53 mutations that alter the transcriptional activity in 
comparison to WT p53 [15].  The first FASAY assay was originally developed as a colony 
growth assay [15].  RT-PCR products converted from potential carrier mRNA were used to 
fill a gapped plasmid resulting in placement of the p53 cDNA under the constitutively 
expressed ADH1 promoter;the plasmid could be selected for with the LEU2 marker. [Note: 
p53 expression levels were moderate from the ADH1   levels in comparison to GAL1 and 
did not induce growth suppression as observed with expression from GAL1 [16, 17]].  Use 
of a centromeric yeast plasmid ensured the colonies contained plasmids derived from one 
replication event such that a single allele of the p53 gene was analyzed for functionality.  
Transforming the p53 expression vector along with a reporter plasmid containing the HIS3 
gene expressed under a p53-responsive promoter (the ribosomal gene cluster, RGC RE 
upstream of the CYC1 minimal promoter) and selectable marker (TRP1) allowed for the 
functionality of p53 alleles to be determined through histidine prototrophy. Thus, only p53 
alleles which were capable of transactivating from the target binding element provided 
proficient growth on His- plates, where inactive mutant alleles would not proliferate. 
Flaman et al., further modified the yeast functional assay to screen for the presence 
of somatic or germline p53 mutations in tumor samples, blood samples, and cell lines [18].  
Similar to Ishioka et al. [15], the approach utilized unpurified RT-PCR products from 
tumor or cell line p53 mRNA samples in a gap repair assay to construct a p53 expression 
plasmid.  However, the functional status of p53 was assessed with a phenotypic assay 
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based on colony pigmentation.  Placement of 3 copies of the RGC p53 RE upstream of the 
CYC1 promoter resulted in transcription of ADE2 driven by the interaction of p53 with the 
REs.  Transcription of the ADE2 gene [encoding phosphoribosylamino-imidazole-
caroxylase [19]] resulted in large, white colonies.  Whereas, mutations in p53 that 
abrogated the protein’s ability to transactivate from the RGC REs rendered the ADE2 gene 
inactive.  This resulted in small, red colonies on plates with low, growth-limiting levels of 
adenine [200 ug/mL] due to the disruption in adenine biosynthesis (Figure 2.3) [19].  
Interestingly, the color assay could also identify partial function or temperature-sensitive 
mutations which generated pink colonies, for example the mutants V272L and H214R.  
Results from these yeast screens on a p53 mutant’s functional status were consistent 
with those obtained from similar assays in mammalian cells [20].  Yet, the yeast system 
provided the opportunity to screen a larger number of p53 alleles for function within a 
simpler model.  Several limitations in the system occur in that mutations in the p53 
promoter are not detected nor are mutations which cause alternative splicing or those that 
occur in the 3’ or 5’ untranslated regions [12, 13].  Furthermore, these screens relied on the 
transcriptional activity from a single RE assuming functionality of p53 was an all-or-
nothing event where the ability of p53 to bind DNA in a sequence-specific fashion equated 
to transactivation, a key issue addressed in the present study.   
 
Differential transactivation from REs by WT and mutant p53 
Several yeast studies expanded the FASAY assays to analyze transactivation from 
multiple REs factoring in the possibility that a mutant p53’s transactivation potential may 
be influenced by the RE encountered.  These studies postulated that a fraction of p53 
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mutations may retain some function as a transcription factor towards a subset of REs and/or 
under particular conditions.   
Di Como and Prives analyzed WT p53 and 20 p53 mutants, including hotspot and 
non-hotspot residues, for transactivation activity towards 9 REs (p21, mdm2, GADD45, 
Cyclin G, Bax, IGF-BP3 Box A and Box B, RGC and a consensus sequence SCS [which 
we refer to as Con-A]) based on the HIS prototrophy growth assay [16].  Interestingly, 
transactivation activity for WT p53 (expressed from the ADH1 promoter) was dependent 
on both temperature and the RE, where p53 could transactivate from p21, SCS/Con-A, 
MDM2, GADD45 and cyclin G to induce normal growth rates, from RGC and Bax to 
induce reduced growth rates, but could not transactivate from the IGF-BP3. Assessment of 
mutant transactivation revealed that some mutant p53s could transactivate target genes in a 
manner that was dependent on the RE and temperature.  Hotspot missense mutations lacked 
transactivation capability, whereas among non-hotspot mutations there was loss-of-function 
or retained function.  Importantly, this study showed several cases where transactivation 
was not equivalent to in vitro binding.  For example, two mutations (V143A and 
M160I/A161T) could transactivate from p21 in vivo, but in EMSA assays could not bind 
the RE in the presence of the RE alone or in the presence of several p53 antibodies which 
were thought to modify p53 to enhance its ability to bind target sequences.  In addition, 
C277Y was found to bind, but not transactivate from the SCS or RGC REs.  These 
observations were unexpected since the prevailing view was that strength of transactivation 
would reflect the strength of p53 affinity in vitro to a specific DNA sequence.    
The hypothesis that partial function mutations would be able to transactivate from 
REs with a high affinity for p53 but not a low affinity  was drawn from the observation that 
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the R175P  mutation could activate p21 to induce G1 cell cycle arrest, but not Bax 
associated apoptosis in vivo mammalian cells [21, 22].  Flaman et al., explored this finding  
by analyzing the ability of 51 p53 missense mutations to transactivate from p21, bax or 4 
consecutive bax REs and stimulate the ADE2 reporter in yeast [23].  Thirty-nine of the 
mutations were loss-of-function mutations that were unable to transactivate from any of the 
REs examined (i.e., V272L, R249S and C277Y).  However, similar to the phenotype 
determined for R175P, 8/51 mutations were able to transactivate from the p21 RE, but not 
Bax to produce white pigmented colonies with the ADE2 reporter (i.e., K120R, R181H and 
R283H).  In addition, 4 mutations were able to transactivate from p21 and multiple copies 
of the Bax RE, but not a single copy of the Bax RE (i.e., R175C, R175L and R181L).  
 To determine if the loss of or change in transactivation activity was explained by 
loss of binding to the REs, Flaman et al. performed bandshift analysis on WT p53 and 
several of the contact (C277Y and R283H) and conformation (R181L and V272L) mutant 
proteins [23].  Interestingly, R181L and R283H bound to the p21 probe to levels 
comparable to WT p53, whereas V272L and C277Y displayed reduced levels of binding.  
Examination of binding to the Bax probe revealed that all the mutations had reduced levels 
of binding in comparison to WT p53 with the exception of C277Y which had lost its ability 
to bind the Bax sequence in vitro.  While the authors reasoned the loss of transactivation by 
the mutations from the Bax RE, but not p21 RE was caused by a lower affinity for the 
DNA sequence, the finding that binding was not completely lost, but merely abated by the 
mutant proteins suggests that binding alone may not be sufficient for transactivation by 
p53. 
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Campomenosi et al. continued to analyze mutations for selective or discriminant 
transactivation capacities from the p21, Bax and PIG3 REs with the ADE2 assay [24].  A 
screen of 77 mutations revealed 12 p53 missense mutations that could transactivate from 
the p21 RE, but not Bax or PIG3.  Four additional mutations were found to be able to 
transactivate from the p21 RE comparable to WT p53, but transactivated from either the 
Bax or PIG3 REs to reduced levels.  Unexpectedly, this screen found mutations outside of 
the DNA binding domain resulted in discrimination towards target REs (S99Y, S99F) or 
cause loss-of-transactivation function (R337G and Q354E) suggesting residues in the 
transactivation domain or tetramerization domain also influenced the p53 tertiary 
configuration necessary for adequate interactions with DNA and/or other proteins.  Finally, 
four BRCA associated p53 missense mutations (T150I, G199R, R202S and S215C) were 
found to be indistinguishable from WT p53 in their transactivation capacity. 
 
Rheostatable promoter for controlled, inducible expression  
While yeast systems could discriminate between alleles that were active or inactive 
for function, the overexpression of p53 did not allow for a discrepancy between silent or 
subtle, altered-function mutations as in the case of the BRCA-associated p53 mutations.  In 
such studies, p53 was often overexpressed from either constitutively active (i.e. ADH1), or 
inducible promoters (i.e., GAL1) which may not always recapitulate physiologically 
relevant conditions (Figure 2.1)[25].  The Resnick lab has contributed to the study of 
sequence-specific transcription factors from specific target sequences by developing an 
isogenic plasmid-based haploid yeast system which utilizes a rheostatable rather than 
highly expressing promoter [26].  The rheostatable promoter allows for the functional 
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assessment of a sequence-specific transcription factor at various protein concentrations 
from a single copy of a target RE upstream of a reporter (Figure 2.2) [26-28] providing the 
opportunity to address the responsiveness of REs to wild type and mutant p53 proteins.  
This can be viewed as an in vivo opportunity to better address biochemical properties of the 
two factors.     
In the case of the p53 tumor suppressor, the p53 coding sequence is placed under 
the control of the GAL1 promoter, which provides for inducible control of p53 expression 
through variation in the amount of galactose in the medium.  Transcription of the p53 
cDNA is dependent on activation of the GAL1 promoter by GAL4 [29, 30].  Gal4 binds to 
an upstream activation sequence (UAS) of GAL1.  In the absence of galactose, Gal80 
interacts with Gal4 inhibiting its ability to function as an activator although it may bind the 
UAS.  Addition of galactose leads to Gal3 inhibition of the Gal80/Gal4 interaction, 
allowing Gal4 to stimulate the activation of its target genes through association with the 
SAGA(Spt/Ada/Gcn5/acetyltransferase) complex and subsequent recruitment of the TBP 
(TATA-binding protein)  and RNA polymerase II.  Glucose prevents GAL1 expression 
through a catabolite repression mechanism [25]  
Importantly, it should be noted that complete repression of the GAL1 promoter 
through GAL4 is not entirely achievable.  Evidence of “leakiness” from the GAL1 promoter 
becomes apparent when attempted inducible promoter fusions between GAL1 and a 
particular gene of interest is toxic to the yeast cells even under “repressed”,  or non-
inducing conditions.  For example, attempts to fuse GAL1 with the bacterial DNA 
endonuclease genes, PvuII or EcoRV result in cell death even when glucose is 
supplemented within the media.  The toxicity in these examples is postulated to be due to 
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the inefficient repair of the blunt end, double strand breaks each enzyme creates.  Lewis et 
al., demonstrated the basal levels of expression can be attenuated without compromising 
the ability to strongly induce the GAL1 promoter and gene of interest when particular 
mutations are introduced within the UAS that Gal4 binds [31]. 
The rheostatable, plasmid-based haploid yeast system was utilized to systematically 
evaluate the contribution of RE sequence and p53 expression level towards p53 differential 
transactivation.  In addition, it was employed to address the consequences of mutations and 
SNPs on the ability of p53 to function as a transcription factor [26, 27].  Twenty-six REs 
(22 biological targets and 4 consensus sequences) were ranked for transactivation capacity 
based on the ADE2 phenotypic color reporter assay (Figure 2.3). The assay was 
subsequently modified to place ADE2 under the control of the minimal CYC1 promoter and 
RE of choice at its natural loci on chromosome XV.   
Transcriptional capacities of the REs were determined based on the minimal 
relative amount of p53 required for a phenotypic change in pigmentation which ranged 
from red to pink to white depending on the extent of transactivation.  This assessment 
revealed, under isogenic conditions that both the sequence and level of p53 protein 
contributed to transactivation, where greater than a 1,000 fold difference at various protein 
concentrations was observed between REs.  The REs which were classified by 
transactivation capacity as strong binders (i.e., p21-5’ and P53R2), modest inducers (i.e., 
NOXA and PA26) or poor transactivators (i.e., CFOS and PIG3) did not group according to 
biological functions.  Furthermore, a correlation between functional rank and statistical 
prediction of binding energy of the REs was not observed.  Importantly, the central core 
sequence in each decamer was determined to greatly affect the ability of WT p53 to 
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transactivate from a RE.  These observations suggested that an intrinsic property of the core 
sequence “CATG” was required for strong levels of transactivation.  (Binding studies 
agreed with this finding suggesting the flexibility of the CATG sequence increases the 
affinity of p53 towards an element [32].)  Altering the CATG in the core to CTAG 
dramatically reduced levels of transactivation by 20-fold.  Finally, the rheostatable 
promoter was used to unmask subtle transactivational differences between WT p53 and 
several p53 missense mutations associated with breast cancer which had previously been 
determined to be equivalent to WT in transactivation capacity under conditions of high 
expression (including the T150I, G199R, R202S and S215C mutations discussed 
above)[24].  Subsequent studies on p53 transactivation capacity utilizing the rheostatable 
promoter revealed that variation in the p53 transcriptional network result from a matrix of 
factors including p53 expression level, target binding sequence and mutations.  These 
findings culminated in the view that p53 is a “master regulatory gene of genetic diversity” 
[27].   
In order to further expand the understanding of p53’s role as a transcription factor 
and to analyze how sequence and protein alterations contribute to the variability observed 
within the p53 transcriptional network, we have modified the rheostatable system to 
develop an integrated diploid yeast system.  This system allows for a more sophisticated 
and sensitive evaluation of the contribution of RE sequence, binding motifs and p53 
expression on functionality and regulation within the p53 transcriptional network.  
Furthermore, the system allows for a rapid assessment of the consequences of mutations 
towards many REs in the p53 transcriptional network at various levels of expression.   
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Results 
Isogenomic system to address p53 transactivation from REs in diploid yeast 
While many factors may determine the ability of p53 to differentially transactivate 
individual genes in human cells including stress stimuli, post-translational modifications, 
and transcriptional co-factors, the yeast system addresses the potential for wild type and 
mutant p53 to bind and transactivate from various response elements derived from human 
genes when placed in a constant chromatin environment.  We have expanded the 
rheostatable plasmid-based haploid yeast system to one based in diploid yeast to further 
assess the transactivation capacities of p53 (WT or mutant) (Figure 2.4).  This system 
allows a single copy of a p53 variant to be rapidly assessed for transactivation capabilities 
from many REs simply by taking advantage of the yeast mating types.    
Two panels of modified S. cerevisiae strains were generated. The first was a set of 
p53 host strains in which p53 (WT or mutant) is directed by a “rheostatable” GAL1 
promoter that allows for controlled, over 200-fold, inducible expression of p53 in yeast 
depending on the carbon source in the media (Figure 2.6). Importantly, similar to p53 
protein accumulation in mammalian cells following stress [33],  expression from the GAL1 
promoter in yeast displays a graded transcriptional response such that there is a range of 
activity from the promoter as opposed to a binary, or on/off response [34-36].  Biggar and 
Crabtree [34] demonstrated through fluorescence-activated cell sorting (FACS) 
experiments that expression of green fluorescent protein from a GAL1-GFP reporter within 
a population of cells generated a single fluorescent peak where the intensity of the peak 
was dependent upon the concentration of galactose supplemented in the media.  Thus, 
increases in galactose will result in a homogeneous response where the vast majority of 
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cells in the population respond (and within our system expressing an induced amount of 
p53) rather than merely increasing the percentage of cells within the population expressing 
the maximal level of protein.  
The second set of strains of opposite mating type contained promoter REs upstream 
of the minimal CYC1 promoter and either the ADE2 color reporter or the firefly luciferase 
reporter [26].  To facilitate the construction of a large number of p53 mutants and REs at 
chromosomally located target loci we employed the delitto perfetto system for in vivo 
mutagenesis. Delitto perfetto utilizes oligonucleotides and targeted homologous 
recombination to rapidly generate S. cerevisiae yeast strains with specific genetic 
alterations [37-39]. 
Mating of the reporter and p53 host strains results in isogenic, diploid yeast that 
enable the rapid assessment of the transactivation potential for WT or mutant p53 proteins 
towards many individual REs in the p53 transcriptional network [27].  Importantly, all the 
conditions in the cells are constant, i.e., isogenomic , where the only variables between 
strains are the RE sequence, WT or mutant p53 and level of expression.  The rheostatable 
GAL1 promoter allows for controlled, over 100-fold, inducible expression of p53 in the 
diploid yeast (Figure 2.6 A and B).  A rough estimate of the number of p53 molecules in 
each cell ranges from ~250 -500 at basal levels of expression to over 30,000 at 0.024% 
galactose (Figure 2.6 C).   
The ADE2 reporter provided a qualitative assay to determine transactivation 
potential through the appearance of pigmentation in the stationary cells of colonies over 
several days (Figure 2.3).  It was used to differentiate WT p53 tranasctivation potential 
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from REs, as well as to assess mutant p53 transactivation potential in comparison to WT 
p53 and other mutants at variable levels of expression (Figure 2.7). 
The luciferase reporter provided a quantitative estimate of transactivation capacity 
of WT p53 from the various REs in cultures of logarithmically growing cells (Figure 2.3).  
An example of quantitative assessment of transactivation capacity of p53 over a range of 
expression is shown for p53-induced transactivation from the p21-5’ RE in vivo (Figure 
2.8). Functional assessment with the luciferase reporter assay provided an indication of the 
kinetics   of transactivation with a basal level of transactivation at 0.00% galactose (2% 
raffinose), initial induction of transactivation (between 0.004 – 0.008% galactose) and 
maximal level of transactivation (between 0.016% - 0.024% galactose).  The p53 protein 
appeared stable suggesting variation in measured maximal levels of transativation between 
RE was due to intrinsic properties of the RE and not a decay in protein (Figure 2.9). 
 
Transcriptional assessement of toxic mutants to validate the diploid system 
 Previous findings have shown that high expression of p53 in Saccharomyces cerevisiae 
and Schizosacchromyces pombe can result in growth suppression [16, 17, 40].  Within 
haploid budding yeast, the induced expression of WT p53 from the GAL1 promoter at 2% 
galactose resulted in decreased colony size in comparison to cells lacking p53 expression  
[17].  p53 mutants (V143A or R273H) also resulted in a growth inhibitory phenotype when 
expressed at high levels, but to a reduced degree (dependent upon the specific mutation) in 
comparison to WT p53.  Highly induced levels of WT p53 increased doubling time from 
4.4 to 11.6 hours, whereas no variation was observed under non-induced (2% raffinose) or 
repressed (2% glucose) conditions.  While p53 and its family members did not evolve until 
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the existence of multicellular organisms it was predicted that p53 could interact with the 
evolutionarily conserved protein complexes involved in cell cycle progression to produce 
this phenotype [17].  Analysis of p53 phosphorylation status by  labeling the cells with 32P 
followed by immunoprecipitation revealed p53 was phosphorylated in yeast [17].  
However, mutation analysis of the phorphorylated sites showed that differential 
phosphorylation (by endogenous or exogenous cell cycle dependent kinases) did not play a 
direct role in the growth suppressive phenotype [17]. 
These findings led to a screen for mutations that would exacerbate the growth 
suppressive phenotype at moderate to low levels of p53 expression [41].  Interestingly, 
several mutations, including V122A, C277R and G279R, exhibited novel phenotypes. They 
were toxic at modest levels of expression.  However, at lower levels of expression there 
was enhanced activity, termed super-transactivation, towards some REs, but a reduction or 
loss of transactivation activity towards, resulting in an overall altered spectrum of p53 
transactivation. None of the mutants were loss-of-function. 
In order to validate the integrated diploid system, three toxic mutations (V122A, 
C277R and C279R) and one super-transactivating mutation (S121F) (described below) 
were assessed for transactivation capacity towards 6 REs (p21-5’, P53R2, GADD45, 14-3-
3σ, CYCLIN G, AIP1) at various p53 expression levels with the ADE2 color assay.  
Overall, as shown in Table 2.3, there was general agreement between the haploid and 
diploid yeast systems in the functional assessments.  Similar to previous results in the 
haploid system, within the diploid system all the mutations displayed super-transactivation 
from the p21-5’ RE which was defined as an enhanced activity from the RE in comparison 
to WT p53 for at least one level of expression analyzed.  [It should be noted that the diploid 
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system required a slightly greater amount of p53 induction to generate a response.  For 
example, WT p53 yAFM-p21-5’ colonies were nearly white on glucose plates in the 
haploid system [26], however white pigmentation was not completely acquired in the 
diploid cells until ~0.004 – 0.008% galactose.]   While the S121F mutation consistently 
exhibited an enhanced activity from all the REs in comparison to WT p53, the toxic 
mutations exhibited an altered spectrum of regulation towards the remaining REs.  For 
example, the C279L had lost its ability to transactivate from the cyclin G and AIP1 
response elements, but had a reduced ability to transactivate from the REs of  P53R2 and 
14-3-3σ.  Two transactivation discrepancies were found between the systems for the 
V122A transactivation from 14-3-3σ and C277R transactivation from AIP1.  The V122A 
was considered equivalent to WT p53 in its transactivation capacity from 14-3-3σ in the 
diploid system, whereas it showed a slight reduction in relative transactivation within the 
haploid system.  With the C277R transactivation from AIP1, the haploid system showed a 
loss in transactivation capacity whereas the diploid system scored the C277R as  reduced 
transactivation capacity with colonies remaining pink even at maximum p53 expression. 
Finally, a growth inhibition phenotype was observed with all the toxic mutations at 
approximately 0.032 – 0.064% galactose which was consistent with the haploid results. 
 
Transactivation capacity of WT p53 from biological REs   
The quantitative luciferase assay was used to evaluate the strength and kinetics of 
transactivation for WT p53 from 23 biologically relevant, canonical REs and 3 consensus 
REs at increasing levels of induction (0 - 0.032% galactose) (Figure 2.10).  The consistency 
between biological and experimental repeats in the luciferase assay allowed for 
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comparisons to be drawn between the REs using WT p53 transactivation from the p21-5’ 
RE as a common reference.  Relative transactivation capacities for the various REs were 
ranked according to the average strength of transactivation (calculated as the relative light 
units/ug protein) at maximal induction levels (0.020-0.032% galactose) (Table 2.2).  
Maximal levels of transactivation ranged from strong (98 -115%), moderate (50 – 77%), 
weak (20 – 42%), extremely weak (5-16%) to nonfunctional (below 5%).   
Consistent with functional assessments in the haploid yeast system, p53 displayed 
high levels of activity from the Con-A, p21-5’ and P53R2 REs.  Synergistic transactivation 
from Bax A + B and MDM2 P2, (which were comprised of two adjacent weak REs), 
equated to or exceeded the levels of transactivation from the strong REs, respectively.  
Several REs (p48, zac1 and msh2) from which p53 was not able to alter the colony 
pigmentation at 2% galactose when assessed with the ADE2 color assay in diploid yeast 
were excluded from analysis with the luciferase assay.  No significant difference in 
transactivation by WT p53 was observed between the well-known Arg or Pro 
polymorphisms at codon 72 with the color assay in diploid cells (data not shown), thus 
transactivation as measured with the luciferase reporter was only assessed for the Pro 
allele.    
 
Discussion 
Isogenomic system to address p53 transactivation from many REs in diploid yeast 
Yeast has been extensively used as an in vivo test tube to assess the potential role 
that target sequence plays in p53 transactivation. Such yeast-based assays provide the 
opportunity to analyze p53 [25, 27] transactivation capacities towards p53 response 
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elements (REs) derived from human genes.  A distinct advantage of yeast is the opportunity 
to rapidly modify in vivo either the target REs or to create mutant p53 coding sequences 
utilizing a highly efficient recombination-based system, known as delitto-perfetto [Italian 
for “perfect murder”] that targets desired changes with oligonucleotides [37-39].  The 
newly developed diploid yeast approach extends previous work in the Resnick lab with a 
plasmid-based haploid yeast system in order to capitalize upon the opportunity to 
conveniently merge a large number of integrated (single copy) p53 mutants with 
assessment of transactivation capabilities at many response elements simply through 
mating of strains.  Not only can the rheostatable, diploid yeast system differentiate between 
functional and nonfunctional REs, it can also estimate weak to strong functionality at 
different levels of p53 expression.  
 In addition, the rheostatable promoter provides the ability to address subtle mutant 
defects at low levels of p53 protein.  We examined four p53 mutants associated with a toxic 
or super-transactivating phenotype in order to compare the integrated diploid yeast system 
with the haploid plasmid based system.  Consistent with previous data, the four mutations 
showed altered-function towards the six REs examined, confirming the diploid yeast 
system can be used to differentiate transactivation potentials of altered function missense 
mutations.  The results in yeast have proven useful in guiding studies with highly expressed 
WT and mutant p53 towards potential target REs in human cells and evaluations of direct 
DNA binding [42]. 
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Small changes in sequence can lead to dramatic differences in transactivation 
Transactivation capacities of WT p53 towards a subset of biological REs were 
assessed in the diploid yeast system, where sequence specific differences in transactivation 
can be resolved with the luciferase assay. Consistent with previous findings in the haploid 
plasmid-based system [26, 27], transactivation by WT p53 differed considerably between 
the 26 REs.  Small changes in sequence were shown to dramatically affect functionality in 
terms of maximal levels of transactivation from a given binding element (Figure 2.10).  
Variation in level of p53 expression amplified these differences.  Although there is 
considerable difference in the transactivation ability towards the various REs, level of p53 
at which transcription is first detected is comparable for all REs (0.008% -0.012%) 
regardless of the biological role of the RE-associated genes.     
 
p53 transactivation does not appear to follow a simple binding model 
Differential modulation of transactivation has been postulated to arise due to the 
differences in p53 binding affinity towards various DNA sequences.  To compare the in 
vivo transactivation (which is an endpoint of binding) with reported in vitro binding 
measurements, an empirical value of 0-5 derived from the maximal transactivation levels 
obtained with the luciferase assay, was assigned to each RE (Table 2.2).  These values 
which represent relative strength of transactivation were compared with published binding 
affinities of a tetrameric p53 construct (residues 94-360 of the DNA binding domain and 
oligomerization domain) towards various REs [32] (Figure 2.12).  The binding affinities 
were derived by fluorescence anisotropy which measures p53 binding to recognition 
elements based on the polarization of emitted light from a fluorescently labeled oligo 
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bound by p53 that is rotating in solution in comparison to a free, unbound oligo.  The Kd 
value represents the concentration of p53 dimerized protein required for 50% of the DNA 
oligos to be bound.  (Dimer concentrations were used in the study because under the 
experimental conditions, tetramerization of p53 did not occur until binding.  Binding of the 
dimers to REs was reported to be co-operative with the Hill coefficients measured between 
1.7 – 1.8 for all REs, where total co-operativity displays a Hill constant of 2.0 [32].)  
Importantly, our system based of transactivation assays reflects variation in binding with 
increasing p53 expression, whereas, the in vitro measurements determine binding with 
increased p53 expression.  A simple binding model would suggest that REs that yield a 
larger Kd should require more p53 expression to initially induce transactivation.  As protein 
concentrations increase, the values for weak binders would asymptotically reach those for 
stong binders. The transactivation patterns obtained from the luciferase assays (Figures 
2.10 and 2.11), which show the amount of p53 required to initially induce transactivation 
was comparable for all REs, regardless of the Kd value, suggests that functional 
transactivation by p53 at REs is not simply explained by in vitro binding properties. The in 
vivo and in vitro properties differ further in that transactivation from weak REs do not 
reach the levels found for REs transactivated as levels of p53 increase.  
Importantly, as demonstrated in Figure 2.11, we found that while the reported in vitro 
binding abilities of some REs were comparable, large differences in in vivo transactivation 
capacity could be observed.  For example, cyclin G and GADD45 have binding constants 
measured at 7.7 ± 1.6 and 7.7 ± 1.2, respectively, yet p53 transactivates moderately from 
cyclin G but weakly from GADD45.  Additionally, the range of the dissociation constants 
overlap for three strong binders, p21-5’, P53R2, and PCNA (4.9 ± 0.6 nM, 5.7 ± 0.8 nM 
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and 6.6 ±1.4 nM, respectively).  If transactivation simply reflects in vitro binding, the 
maximal transactivation obtained should be comparable for these REs with similar Kds.  
P21 and P53R2 bind at similar rates in vitro and have similar “kinetics” of transactivation 
in vivo in response to increased p53.  However, while PCNA has comparable binding in 
vitro to p21-5’ and P53R2, it transactivates to a very different level in vivo (Figure 2.10B).  
This difference may be due to the lack of the flexible CATG at the junction of quarter sites 
in the RE sequence of PCNA.  Conversely, several REs were shown to have similar levels 
of transactivation, but were significantly different in binding affinities.   Figure 2.11 shows 
p53 transactivates from PCNA and p53AIP1 to similar weak levels where the binding 
constants for each are 6.5 and 11 nM, respectively. 
From comparisons between in vitro binding and in vivo transactivation, levels of 
transactivation are not predictable without direct assessment of function in vivo under 
conditions where p53 levels of expression can be varied. This implies that factors other 
than just sequence and sequence organization can have a large influence on transactivation 
by p53 in a manner that is distinguishable from simple DNA binding, even under 
identical/isogenomic conditions in the cell.   A semi-in vitro system has recently been 
developed (Nourreddin et al, submitted; described in Chapter 3) that provides opportunities 
to address the additional factors influencing in vitro binding.  This system has already been 
employed to address impact of spacers in REs (see Chapter 3). While not part of the present 
study, the yeast based system will provide the opportunity to address the mechanisms by 
which varying just the sequence can have such a strong effect on transactivation.    
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Conclusions 
The sequence of target REs, level of expression and alterations in protein can 
greatly impact the p53 master regulatory network in a way that is not predicted by simple 
DNA binding.  The integrated diploid yeast system has been developed as a tool to address 
a matrix of factors which contribute towards the variability and different levels of 
regulation within the p53 transcriptional network under isogenomic conditions.  Key issues 
that have been addressed with this system include: (i) what constitutes a functional RE for 
transactivation, (ii) how do changes in the RE sequence affect transactivation, (iii) the 
importance of p53 level on transactivation and (iv) the relationship between in vitro 
binding and in vivo transactivation.   
Furthermore, this system can also be used to characterize p53 functional mutations 
associated with disease to determine the impact on spectrum and intensity of 
transactivation and to address mechanisms.  Using the yeast-based system, p53 mutations 
were classified into groups according to their retained transactivation capacities at various 
levels of p53 expression.  In contrast to in vitro biochemical assays, the yeast assay has the 
advantage of comparing p53 variants in a constant chromatin environment--under identical, 
isogenomic conditions--for activity towards individual REs.  Functional analysis of p53 
missense mutations associated with disease may have diagnostic value and may also be 
used as a predictor of tumor behavior in response to chemotherapeutic agents. Previous 
results obtained with yeast functional assays appear predictive of whether a mutation will 
also have a biological impact in mammalian cells [25, 42].  Although the yeast-based 
functional assay is a powerful screening tool, assays in mammalian cells are needed to fully 
characterize the impact of p53 mutation. Additional promoter elements and transcriptional 
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cofactors in mammalian cells, beyond just RE sequence, are expected to influence p53 
mediated transactivation.  Importantly, the present results describe the potential role that 
RE sequence may play in the p53 master regulatory network with normal and mutant p53 
under conditions where the level of p53 can be varied. 
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Figure 2.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Yeast as an in vivo test tube to determine mammalian p53 transactivation 
capacity. Traditional yeast assays have determined p53 functional status under conditions 
where p53 cDNA is constitutively expressed at moderate to high levels from a selectable, 
low copy number expression vector or integrated promoter, such as ADH1.  The 
constitutively expressed p53 can interact with individual RE sequences (derive from p53 
regulated human genes) that have replaced the upstream activating sequences of a minimal 
promoter (ie, cytochrome C) that regulates the expression of a reporter (ie., HIS3, URA3, 
ADE2, beta-galactosidase, green fluorescent protein (GFP), firefly luciferase gene).  
Transactivation of the reporter gene is dependent on p53 and is a direct readout of p53 
interaction with the specific RE sequence.  Multiple yeast strains containing different RE 
sequences can be used to assess how specific deviations from the degenerate consensus 
sequence affect p53 transactivation, as well as provide functional status in terms of the 
transactivation capacity of mutant p53. (Reproduced from Menendez et al., 2007 Oncogene 
26:2191-2201)  [25]. 
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Figure 2.2 
 
 
 
 
 
 
Figure 2.2 Rheostatable promoter to address p53 transactivation potentials.  
The rheostatable promoter allows for the highly controlled regulation of p53 protein 
expression under the GAL1, 10 promoter.  Under conditions where glucose is contained in 
the media, the GAL1, 10 promoter is repressed.  Raffinose provides a basal level of 
expression, where the GAL1, 10 promoter is de-repressed but not induced.  Increases in 
levels of galactose in the media as the carbon source correlates with increasing p53 
expression that can vary over a 100-fold range.  The controlled expression of p53 with the 
rheostatable promoter allows for analysis of transactivation by p53 from individual REs at 
various expression levels.  This system may allow for a further understanding of how p53 
functions as a transcription factor from specific RE sequences, especially at low levels of 
expression.  In addition, the sensitivity of the system which provides for the expression of 
p53 at various low levels of expression can be used to unmask subtle phenotypic 
differences in transactivation capacities of mutant p53 proteins that remain undetected in 
traditional functional assays that utilize transient over-expression of p53. (Reproduced from 
Menendez et al., 2007 Oncogene 26:2191-2201)  [25].  
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Figure 2.3 A 
 
 
 
 
 
 
 
 
 
 
Figure 2.3A Qualitative plate color assay.  The ADE2 phenotypic color assay determines 
the ability of p53 variants to transactivate from specific REs in stationary cells through the 
accumulation of pigment. The ability of p53 to interact with REs upstream of the ADE2 
gene is assessed on plates containing a minimal amount of adenine.  Colony pigmentation 
is dependent on the ability of p53 to transactivate from a specific RE sequence.  If p53 (WT 
or mutant) is capable of strongly transactivating from a RE, colonies are large in size and 
white, whereas if p53 is not able to transactivate from a RE, colonies are smaller and red.  
Traditional functional assays with high levels of p53 expression are limited to establishing 
whether a p53 protein (WT or mutant) has the ability to transactivate from a RE (either red 
or white colonies) and cannot assess the intensity of this interaction.  Inducible expression 
of p53 under the rheostatable GAL 1, 10 promoter enables p53 transactivation capacity to 
be assessed at variable levels of protein expression.  Therefore, the range of pigmentation 
(pink to white) correlates with the extent of p53 induction from a particular RE.  (Reprinted 
from Menendez et al., 2007 Oncogene 26:2191-2201)  [25].   
 
 
 
 
 
 
 
 
Induce p53 with increasing amounts of galactoseA.
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Figure 2.3 B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3B Quantitative luciferase assay.  The quantitative luciferase assay is used to 
address in vivo the contribution of sequence towards the ability of wt or mutant p53 to 
transactivate from specific REs. The quantitative luciferase assay can be used to follow the 
variation in transactivation for wild type (WT) and mutant (mut) p53 over a range of p53 
expression levels, from basal to high levels, in logarithmically growing cells. 
Transactivation by wt p53 can be shown to differ considerably between REs based on the 
small changes in RE sequence with the quantitative assay (i.e., RE1 verse RE2).  
Furthermore, the affect of specific mutations on the ability of p53 to transactivate from 
distinct REs can be directly compared to wild type p53 and other mutations with this 
sensitive assay.  (Reproduced from Menendez et al., 2007 Oncogene 26:2191-2201)  [25]. 
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Figure 2.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Isogenomic diploid yeast system to investigate transcriptional capacity of 
p53 towards many REs at various p53 levels.  Transactivation capacities of p53 (WT or 
mutant) from cognate REs were determined using diploid strains derived from haploids 
where p53 and reporters with upstream REs were integrated into different chromosomal 
loci. Two panels of haploid  strains were generated. The first was a set of p53-host strains 
in which p53 (WT or mutant) was controlled by a “rheostatable” GAL1 promoter (blue 
cells). The rheostatable promoter (previously described in, [41]) allows for controlled, 
inducible expression of p53. The second set contained promoter REs upstream of the 
minimal CYC1 promoter and either the ADE2 color reporter (REP) or the firefly luciferase 
reporter (tan-colored cells) [43].  Mating of the REP and p53-host strains results in isogenic 
diploid yeast that provide for rapid assessment of the transactivation potential for WT or 
mutant p53 proteins towards many individual REs in the p53 transcriptional network [27]. 
Strains are referred to as “isogenomic” because they only differ by RE sequence or single 
base mutations in p53. 
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Figure 2.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Delitto perfetto site-directed in vivo mutagenesis system.  To insert the 
different putative p53 response elements (REs) upstream of the ADE2 and luciferase 
reporters and generate specific p53 missense mutations of interest, the delitto perfetto site-
specific in vivo oligonucleotide mutagenesis system was used [39].  Delitto perfetto is a 
two step process for rapid genome modification that is dependent on homologous 
recombination and Rad52.  The first step is the integration of a COunterselectable REporter 
(CORE) cassette within the genome through homologous recombination.  Two master 
reporter strains, yAFM-ICORE and yLFM-ICORE, and were constructed following the 
protocol previously described [26].  In addition, as depicted above, the ICORE was placed 
at 9 locations in the p53 cDNA, yAT-iGAL::p53 (Table 2.1).  ICORE is a modification of 
the CORE (counter selectable reporter) cassette [39] and contains, in addition to the 
counter-selectable KLURA3 and the reporter KanMX4, the I-SceI endonuclease gene under 
control of the GAL1 promoter and one copy of its unique 18-nt recognition site. Integration 
of the CORE can be selected for with URA3+ and G418 (geneticin) resistance and verified 
with PCR.  Step 2 entails replacement of CORE through a standard lithium acetate (LiAc) 
transformation with Integrative Recombinant Oligonucleotides (IROs).  To create DNA 
modifications the ICORE was replaced with oligonucleotides containing the desired p53 
RE (see Table 2.2) or p53 mutation of interest according to the Delitto Perfetto protocol 
[39].  Induction of I-SceI on galactose leads to the generation of a single DNA double-
strand break at the ICORE site, resulting in a dramatically increased homologous DNA 
CORE
CORE
wt p53 cDNAGAL
GAL
GAL  ISceI kanMX4   KLURA3
?=PCR primers
wt p53 cDNAGAL
ICORE
STEP 1
*
GAL *
GAL CORE
*
GAL CORE
STEP 2
targeting by oligonucleotides along with coincident loss of the ICORE.  Replacement of the 
CORE cassette is confirmed with selection on 5-FOA plates against URA3+ (URA3 
converts 5-FOA to fluorodeoxyuridine, which is toxic to yeast cells) and G418 sensitivity.  
Direct sequencing verifies introduction of the correct RE or mutation of interest.  
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Table 2.1 
 
 
 
 
Table 2.1 ICORE insertion sites in p53 cDNA and window of modification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Delitto perfetto used to generate a panel of 9 isogenic p53 host S. cerevisiae strains--where 
each contains the p53 cDNA controlled by the inducible (“rheostatable”) GAL1 promoter, 
integrated in a chromosomal locus, plus a CORE (COunterselectable marker and REporter 
marker) cassette inserted at various positions in the p53 cDNA.  The cassette allows a 150 
bp window for site-directed modification around the CORE with the site-directed 
mutagenesis system (Table 2.1).  The p53 mutants under tight regulatory control are 
created with oligonucleotides that contain the desired mutation and replace the specific 
CORE cassette through homologous recombination to generate a full length mutant p53 
cDNA.   
a CORE-I-SceI cassettes are strategically inserted along the p53 cDNA to allow for 
modification throughout the large DNA region.  Indicated are the amino acids flanking the 
inserted CORE.  
b CORE cassettes allow for a window of modification of approximately 100 nucleotides, or 
as shown 30 amino acids in either direction.     
 
CORE Integrated sitea odification windowb I M
C 133 -134 118 - 149 
D 163 -164 148 - 179 
E 193 -194 178 - 209 
F 223 – 224 208 - 239 
G 253 – 254 238 - 269 
A 283 – 284 268 - 299 
B 313 – 314 298 - 329 
C1 335 – 336 320 - 351 
C2 373 – 374 358 – 389 
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Table 2.2 
 
 
Table 2.2 Response element sequence, strength and rank of transactivation capacity. 
 
Listed are the REs examined for transactivation potential by WT p53 with the quantitative 
luciferase assay along with the associated target gene and biological function.  (A= 
apoptosis, C = cell cycle response, D = DNA damage recognition and repair, O = other 
including p53 stability and regulation, agiogenesis, and consensus elements)   
Transactivation capacity is presented as strength of transactivation, percent of maximal 
transactivation and scale.  Maximal induction was calculated as the average relative light 
units/ ug protein measured at 0.020% - 0.032% galactose.  Percent of transactivation was 
relative to WT p53 transactivation from the p21-5’ RE.  Maximal transactivation was 
converted to an arbitrary scale value of 0 – 5 to represent strength of transactivation, where 
0 is nonfunctional, 2 is weak transactivation and 5 is strong transactivation.  Sequences of 
the RE are broken into decamer half-sites.  Nucleotides that deviate from the consensus RE 
are shown in red lower case letters and blue indicates an insertion into the central sequence 
of a half-site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Response Gene
 Element  Name Strength % scale Half-site spacer Half-site
 p21-5' RRRCWWGYYY N RRRCWWGYYY
MDM2 RE1+RE2O MDM2 strong 115 5 GGtCAAGTTg GGACAcGTCC
GAGCTAagTC c tGACATGTCT
P53R2D RRM2B strong 102 5 tGACATGCCC AGGCATGTCT
p21-5'C CDKN1A strong 100 5 cAACATGTTg GGACATGTTC
CON AO strong 100 5 GGGCATGTCC GGGCATGTCC
BAX A+BA BAX strong 98 5 tcACAAGTTa g AGACAAGCCT
AGACAAGCCT GGGCgTGggC
PA26C SENS1 moderate 77 4 GGACAAGTCT cAACAAGTTC
CYCLIN GC CCNG1 moderate 72 3.5 AGGCTTGCCC GGGCAgGTCT
MMP2A  collagenase (IV) moderate 70 3.5 AGACAAGCCT GAACTTGTCT
PUMA BS2A BBC3 moderate 68 3.5 ctGCAAGTCC tGACTTGTCC
CON BO moderate 58 3 GGGCTAGTCC GGGCTAGTCC
CON CO moderate 50 3 GGGCAAGTCT GGGCAAGTCT
GADD45D GADD45A weak 42 2.5 GAACATGTCT AAGCATGCTg
MDM2 RE1O MDM2 weak 34 2 GGtCAAGTTg GGACAcGTCC
PCNAD PCNA weak 34 2 GAACAAGTCC GGGCATaTgT
NOXAA PMAIP1 weak 28 1.5 AGGCTTGCCC cGGCAAGTTg
P53AIP1A P53AIP1 weak 26 1.5 tctCTTGCCC GGGCTTGTCg
14-3-3σ SITE 2C stratifin  weak 20 1 tAGCATTAGCCC AGACATGTCC
PIDDA PIDD very weak 16.5 1 AGGCcTGCCT gcgtgctg GGACATGTCT
MDM2 RE2O MDM2 very weak 16 1 GAGCTAagTC c tGACATGTCT
APAF1A APAF1 extremely weak 6.5 1 AGACATGTCT ggagaccctagga cGACAAGCCC
14-3-3σ SITE 1C stratifin extremely weak 6 0.5 AGGCATGTgC cAcCATGCCC
P21-3'C CDKN1A extremely weak 5 0.5 GAAgAAGaCT GGGCATGTCT
LIPHGO SCGB1D2 extremely weak 5 0.5 GGtCTTGTTT AGACTTGCTC
BAX BA BAX nonfunctional 3 0.25 AGACAAGCCT GGGCgTGggC
BAX AA BAX nonfunctional 0.75 0.25 tcACAAGTTa g AGACAAGCCT
RAD51D RAD51 nonfunctional 0.5 0 AAACTcGCgC agg ATCAAGCTCT
Transactivation Sequence
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Figure 2.6 
 
 
 
Figure 2.6 Inducible expression of p53 under the rheostatable GAL1 promoter. (A) 
The GAL1 promoter allows for controlled expression of p53 depending on the level of 
galactose in the media.  Raffinose was added to provide a basal level of expression, 
derepressed from the GAL1 promoter. Presented is a Western blot analysis of p53 
expression 24 hours post-inoculation with raffinose or raffinose plus increasing amounts of 
galactose (.004-.032%). Increases in galactose from 0 – 0.032% correlated with an increase 
in p53 over a 100-fold range. The p53 protein was detected with DO-1 and pAb1801 
antibodies. The asterisk (*) depicts a longer exposure to reveal protein at basal and lower 
galactose levels. GAPDH, identified by immunodetection provided a standard loading 
control.  (B) Low level expression of p53 under the rheostatable GAL1 promoter.  With 
glucose supplemented in the media, the GAL1 promoter is repressed. Presented is a 
Western blot analysis of p53 expression 24 hours post-inoculation with 2% glucose (G), 
2% raffinose (R) or 2% raffinose plus increasing amounts of galactose (.002-.008%). The 
p53 protein was detected with DO-1 and pAb1801 antibodies.  Immunodetection with 
GAPDH was used as a standard loading control. To determine the relative protein 
concentrations at repressed “G” glucose added, basal and low galactose levels, pixel values 
were measured from autoradiographs of increasing exposure lengths (from 1- 15 minutes). 
The ratio of measured pixel values were calculated between samples and compared 
between exposure lengths to derive the relative differences in p53 expression between 
media containing glucose (2%), raffinose (2%) or raffinose (2%) plus increasing 
concentrations of galactose (data not shown).  A 3-fold induction of p53 expression was 
observed between samples containing glucose vs. raffinose, as well as between raffinose 
and raffinose + 0.004% galactose. There was a further 2-fold induction between the 
0.004% galactose and 0.006% galactose samples and a 3-fold difference between the 
0.006% and 0.008% galactose samples. This totaled a relative increase in p53 expression of 
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54-fold between repressed conditions and induction at 0.008% galactose and an 18-fold 
between basal level expression and induction at 0.008% galactose.  (C) Estimation of the 
number of p53 molecules per cell at increased expression.  The diploid yeast strain 
containing GAL1::WT p53 crossed with the p21-5’ RE-luciferase reporter was grown 
overnight in complete medium, diluted, washed and inoculated into selective medium 
containing either raffinose or raffinose plus 0.008% or 0.024% galactose for 24 hours.  A 
small sample of the overnight culture was aliquoted to estimate the concentration of 
cells/mL with a hemocytometer.  Protein lysates were obtained and analyzed by Western 
analysis in comparison to known amounts of purified p53 protein (20, 30 and 40 ng) (BD 
Biosciences Pharmingen, San Diego, CA).  Depicted is an estimate of the number of p53 
molecules per cell calculated from the estimated total protein/cell and ng p53/cell. 
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Figure 2.7 
 
 
 
Figure 2.7 Differential transactivation capacities of WT and mutant p53 towards REs 
at variable expression observed with the phenotypic color assay.  The ADE2 reporter 
provides a qualitative assay to determine transactivation potential through the accumulation 
of colony pigmentation in stationary cells over several days.  WT or mutant p53 cDNA is 
expressed from the GAL1 promoter at variable levels dependent on the amount of galactose 
supplemented in the media.  The color assay can be used to differentiate WT p53 
tranasctivation potential from distinct REs at comparable expression (A), or to distinguish 
mutant p53 transactivation potential in comparison to WT p53 and other mutants at 
variable levels of expression (B).   
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Figure 2.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8 Quantitative assessment of p53-induced transactivation from the p21-5’ RE 
in vivo.  The diploid yeast strain containing GAL1::WT p53 crossed with the p21-5’ RE-
luciferase REP was grown overnight in complete medium, diluted, washed and inoculated 
into selective medium containing either raffinose or raffinose plus increasing galactose (0 – 
0.032%) for 24 hours. Protein lysates were obtained and a luciferase assay was used to 
determine the transactivation capacity of p53 from the p21-5 RE’. The strength of 
transactivation was calculated as relative light units/ug protein. Circled are the basal, 
linear-increase, and plateau phases of the transactivation response as a function of galactose 
concentration and are referred to as basal, moderate and high levels of p53 expression. 
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Figure 2.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9  p53 protein stability following a glucose pulse.  To determine the stability of 
p53 within the diploid system, the half-life of p53 was followed after addition of glucose, 
which represses the GAL1 promoter, to the media.  WT p53 crossed to the p21-5’ RE::luc 
was grown overnight in YPDA complete media, diluted and grown in synthetic media 
supplemented with 2% raffinose plus 0.024% galactose overnight with vigorous shaking at 
30°C.  Eighteen hours after inoculation into induction media, 2% glucose was added to the 
cultures.  Samples were harvested at the time points indicated and levels of p53 protein 
were assessed by Western analysis after adjusting to common overall protein levels.  
Induction of p53 was stable within the inducing media, where p53 levels remained elevated 
until approximately 4 hours after the addition of glucose when a decrease in protein levels 
was observed.   The two lower bands appear to be product of protein degradation. 
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Table 2.3 
 
 
 
 
Table 2.3 Toxic and super transactivating mutations display altered function in the 
haploid and diploid rheostatable systems. 
 
 
 
Relative transactivation capacities were assessed with the ADE2 color assay in the diploid 
(2n) integrated rheostatable system and compared to data previously obtained in the 
haploid (1n) plasmid-based system [27, 41].  Transactivation capacities were determined to 
be equal (=) to WT p53, lost (L) or increased (↑) or decreased (↓) in comparison to WT p53 
at one or more expression level analyzed. 
MUTANT V122A C277R C279R S121F 
 2n 1n 2n 1n 2n 1n 2n 1n 
P21-5’ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ 
P53R2 = = ↓ ↓ ↓ ↓ ↑ ↑ 
GADD45 ↑ ↑ ↓ ↓ ↑ ↑ ↑ ↑ 
14-3-3σ = ↓ = = ↓ ↓ ↑ ↑ 
CYCLIN G ↓ ↓ L L L L ↑ ↑ 
AIP1 ↓ ↓ ↓ L L L ↑ ↑ 
 TOXIC SUPERTRANS 
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Figure 2.10 
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Figure 2.10 Sequence specific differences in WT p5 transactivation capacity from REs 
does not correlate to the biological function of the target gene.  The quantitative luciferase 
assay was used to resolve sequence specific differences in transactivation by WT p53.  
Isogenomic diploid yeast strains were grown in increasing concentrations of galactose (0 – 
0.032%) to induce p53 protein.  The ability of WT p53 to transactivate from RE sequences was 
measured by a luciferase assay 24 hours after inoculation into the galactose supplemented 
media.  Induction from each RE was compared relative to the ability of p53 to transactivate 
from the p21-5’ RE (as quantified in Table 2.2).  Presented is the mean and standard error of 
measurement (SEM) of 8 independent repeats graphed with REs of similar biological function.  
WT p53 transactivates from p53 target REs to various degrees, where small differences in 
sequence can contribute significantly to levels of transactivation.  Regardless of transactivation 
capacity or biological role, the initial induction of transactivation occurs at comparable levels 
of p53 expression for all REs.   
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Figure 2.11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11  In vivo transactivation vs. in vitro binding.  We have asked whether the 
ability of p53 to transactivate from target RE sequences in vivo simply reflects its ability to 
bind to DNA based on in vitro assays or whether there are additional intrinsic factors that 
contribution to in vivo transactivation.   The “kinetics” of transactivation from several REs 
(scored as 0-5) was compared to the dissociation constants (1/KD) recently determined 
using fluorescence anisotropy [32].  While there seems to be a general trend in strong 
transactivators having smaller KD values, the in vivo transactivation data for the different 
REs under isogenomic conditions argue that differential transactivation by WT p53 is not 
simply due to the variation in p53 binding affinities.  In spite of comparable p53 binding in 
vitro, transactivation in vivo can vary dramatically under isogenic conditions (i.e., cyclin G 
vs. Gadd45).  Furthermore, functional assays show WT p53 transactivates to similar levels 
from REs despite differences in binding affinities (i.e., MDM RE1 vs PCNA).   
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Abstract 
Sequence-specific binding by the human p53 master regulator is critical to its 
tumor suppressor activity in response to environmental stresses. p53 binds as a tetramer to 
two decameric half-sites separated by 0–13 nucleotides (nt), originally defined by the 
consensus RRRCWWGYYY (n= 0-13) RRRCWWGYYY. To better understand the role of 
sequence, organization and level of p53 on transactivation at target response elements (REs) 
by wild type (WT) and mutant p53, we deconstructed the functional p53 canonical consensus 
sequence using budding yeast and human cell systems.  Contrary to early reports on binding 
in vitro, small increases in distance between decamer half-sites greatly reduces p53 
transactivation, as demonstrated for the natural TIGER RE.  This was confirmed with human 
cell extracts using a newly developed, semi-in vitro microsphere binding assay. These results 
contrast with the synergistic increase in transactivation from a pair of weak, full-site REs in 
the MDM2 promoter that are separated by an evolutionary conserved 17 bp spacer. 
Surprisingly, there can be substantial transactivation at noncanonical ½- (a single decamer) 
and ¾-sites, some of which were originally classified as biologically-relevant canonical 
consensus sequences including PIDD and Apaf-1. p53 family members p63 and p73 yielded 
similar results. Efficient transactivation from noncanonical elements requires tetrameric p53, 
and the presence of the carboxy terminal, non-specific DNA binding domain enhanced 
transactivation from noncanonical sequences. Our findings demonstrate that RE sequence, 
organization and level of p53 can strongly impact p53-mediated transactivation, thereby 
changing the view of what constitutes a functional p53 target. Importantly, inclusion of ½- 
and ¾-site REs greatly expands the p53 master regulatory network.  
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Introduction 
The tumor suppressor p53 (OMIM no. 191170) is a sequence-specific master 
regulatory gene that controls an extensive transcriptional network providing for genome 
integrity in response to cellular and environmental stresses or damage [1-3]. p53 
differentially regulates the expression of target genes, as well as microRNAs associated with 
cell cycle control, apoptosis, DNA repair, angiogenesis, senescence and carbon metabolism 
[4, 5]. A variety of factors such as stress and cell-type dependent, post-translation 
modifications and transcriptional co-factors can influence p53-induced transcriptional 
changes [6-8]. Paramount to p53 transcriptional function is the direct interaction between p53 
and its targeted DNA sequence. The nature of this interaction could per se determine 
transactivation capacity, as well as influence p53-mediated biological processes [9]. Such 
activities are often altered during human cancer development as highlighted by the frequent 
appearance of p53 missense mutations in its sequence-specific DNA binding domain [10, 11] 
which can abrogate or alter p53 transactivational activity that result in changes in biological 
responses, such as the balance between apoptosis and survival in response to DNA damage. 
[3, 10, 12-15]. 
Through in vitro studies, a consensus p53 DNA binding sequence has been derived 
comprising a motif of two decamers (half-sites) RRRCWWGYYY (n) RRRCWWGYYY, 
(where R=purine, W= A or T, Y= pyrimidine and n is 0-13 bases) where each decamer is 
composed of two adjacent p53 monomer binding sites (quarter-sites) in inverted orientation 
[16-18]. p53 binds cooperatively to the consensus RE as a dimer of dimers, where a tetramer 
is the accepted functional unit required for full transcriptional activity [19-26]. Most 
functional response elements (REs) identified in association with p53 target genes depart 
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from this consensus, where base changes are tolerated at each position with the exception of 
the C and G at positions 4 and 7 in each half-site [27, 28]. 
Recent crystal structures show that the interactions between p53 and DNA are 
influenced by the base pairs present in the RE sequence [29] while binding assays in solution 
established a wide range of dissociation constants among natural p53 REs [23].  Functional 
studies in model systems demonstrate that the RE sequence and amount of p53 expression can 
dramatically influence the level to which p53 can transactivate from a specific RE [3, 30].  
However, results of those various approaches do not fully overlap and it is still not well-
understood how the loose consensus, in terms of base variation and spacer length between 
half-sites affects p53 binding to DNA, or how differential binding relates to transactivation 
specificity [31-33]. 
More recently, several studies have refined the accepted, or canonical p53 consensus 
binding sequence based on presumed unbiased chromosome- or genome-wide in vivo binding 
assays using chromatin immunoprecipitation (ChIP) [34-37].  However, the findings may be 
skewed towards stronger p53 interacting sequences or influenced by the agent used to induce 
p53 protein, as well as the human cell lines examined. While ChIP provided a powerful tool 
for identifying sequences that p53 could bind and the results pointed to a refined p53 
consensus with more restrictive sequence features [34], these assays could not address the 
strength of p53 binding. Furthermore, the experimental approach failed to retrieve known 
p53 binding sites, indicating that the technique could miss interactions between p53 and 
weaker response elements which might include noncanonical sites that do not match the 
accepted consensus motif. 
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Bioinformatics studies to identify p53 REs are guided by identified sequences. Based 
on the consensus sequence, computational algorithms have exploited the base pair 
composition of known p53 REs to determine binding probabilities of p53 towards sequences 
and generate position-weight matrices (PWM) or “logos” [38, 39]. While such algorithms 
may guide the identification of p53 binding sites in the genome, they cannot assess the 
strength of p53 binding to these sequences. The ability of p53 to bind (and presumably 
transactivate from) a sequence is often related to compliance with the canonical consensus 
sequence where each position in the motif is assumed to be equivalent and mutually 
exclusive in terms of affecting p53 binding [40]. However, PWM values appear not to be a 
good predictor of p53 transactivation [30].  
While the canonical consensus sequence has guided studies of the p53 network, an 
additional layer of complexity was identified recently suggesting that the canonical motif is 
not limited to two decamers in human cells. p53 dependent-transactivation was detected in 
association with a decamer half-site created by a single nucleotide polymorphism (SNP) in 
the promoter of the Flt-1 gene (the vascular endothelial growth factor (VEGF) receptor-1 
gene) [41]. These results showing that p53 can function from a noncanonical consensus 
sequence imply that the number of potential p53 target sites within the genome may be much 
greater than anticipated. Current methods that identify and/or define putative p53 REs would 
overlook such noncanonical binding elements. 
Stimulated by the observation of a transcriptionally active p53 half-site, as well as by 
the finding that even a single nucleotide change can greatly impact transactivation potential 
of a RE [42, 43], we have systematically deconstructed the canonical p53 RE sequence to 
address the requirements for a functional p53 binding site. Utilizing in vivo systems we 
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developed in the budding yeast Saccharomyces cerevisiae (see chapter 2), the transactivation 
potential of p53 was first examined from p53 canonical consensus REs containing base 
changes and/or variations in organization of binding motifs (i.e., multiple REs and various 
spacer lengths) and then assessed transactivation from ½- and ¾-site REs, which we refer to 
as noncanonical REs.  For these noncanonical REs the surrounding sequence does not 
resemble a p53 binding sequence and the motif itself would not be recognized within 
standard descriptions of a p53 canonical consensus sequence. Within the yeast system, we 
have addressed not only the ability of p53 to function from specific target sequences (i.e., 
on/off), but also the extent of transactivation from these sites at variable levels of expression. 
These studies have been extended to transactivation capacity and p53 promoter occupancy in 
a human cell system, and the in vivo functionality evaluations were compared with results 
obtained in a recently developed semi-in vitro binding assay using human cell nuclear 
extracts. Several structural mutants were examined to assess the p53 structural requirements 
for transactivation from noncanonical REs.  Overall, the findings expand our understanding, 
as well as the anticipated size of the human p53 master regulatory network.   
 
Results 
Increases in distance between weak, full-site REs can lead to synergistic transactivation 
A common feature of many p53 target genes, including p21, PUMA, BAX, and 
DDB2 (p48), is the presence of multiple p53 binding sites [44-50]. The distance between 
binding sites is variable and can even be overlapping.  The Mdm2 gene, which targets p53 for 
degradation by the ubiquitination pathway through a negative feedback loop, is an example 
of a p53 target gene that contains two promoters. The upstream promoter is constitutively 
 75
active and does not rely on p53 for transactivation, whereas the second is in the first intron 
and is p53-dependent [51, 52]. The second promoter contains two full-site p53 REs separated 
by 17 nucleotides (nt). Using our diploid yeast-based p53 rheostatable system, we 
investigated the interaction between these two REs and the impact of this spacer by changing 
the distance between the murine MDM2 REs.  
The induction from the individual MDM2 REs at high p53 expression was much 
weaker than observed with the strong p21-5’ RE (Figure 3.1A):  ~33% (RE1) and ~18% 
(RE2) relative to p21-5’ RE. However, transactivation from the natural MDM2, containing 
the 17 base spacer, was much higher than the sum of the individual REs, reaching the p21-5’ 
RE levels. The synergy was apparent at both moderate and high p53 levels. To determine the 
impact that a spacer may play for full-site REs, the distance was reduced to either 10 or 5 nt.  
As shown in Figure 3.1B, decreasing the separation to 10 nt had little effect. However, a 
decrease to 5 nt resulted in a substantial reduction in transactivation suggesting that 
synergistic interactions are lost as full REs become closely spaced, although transactivation 
from the two sites  remain additive. 
 
Increase in spacer between half-sites decreases p53 transactivation 
While weak full-site REs can interact synergistically when separated by 17 bases, 
previous studies have indicated that spacers between decamer half-sites of the canonical 
consensus RE can alter the ability of p53 to transactivate from a RE [18, 53, 54]. We 
systematically investigated the role that spacers may play on p53 transactivation using the 
yeast-based rheostatable promoter and a system based on expression following transfection 
into human cells. Addition of a one-base spacer between the p21-5’ half-sites resulted in a 
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dramatic 60% decrease in p53 transactivation (Figure 3.2A) in yeast. Addition of a second 
nucleotide further decreased p53 transactivation to approximately 25% of transactivation at 
high p53 expression. Importantly, at lower p53 levels transactivation was essentially 
abolished, demonstrating that the impact of spacer is markedly affected by p53 expression 
level. Further increases in spacer resulted in decreased transactivation and at 5 nt there was 
almost no detectable luciferase activity at high p53 expression levels. Similar findings were 
observed in a plasmid-based haploid yeast system when p53 transactivation was measured 
from p21-5’ REs containing a spacer of 0, 2, 5, or 10 nt (Supplemental Figure 3.1A) [3, 28, 
30]. Thus, the length of spacer sequence between decamer half-sites combined with level of 
p53, greatly influences the ability of p53 to transactivate from the p21-5’ sequence. 
Interestingly, transactivation by the p53 family members p63β and p73β was also 
compromised when p21-5’ RE contained spacers (Supplemental Figure 3.1B); a 2 nt spacer 
essentially abolished transactivation. 
To determine the effect of spacers upon weak target REs in the p53 transcriptional 
network, transactivation was assessed from the RE of the human apopotosis gene Noxa [55] 
with and without a 5 nt spacer between the decamer half-sites. In comparison to the p21-5’ 
RE, transactivation from the Noxa RE was ~30% of the levels of p21-5’ at high p53 
expression (Figure 3.2A). This was comparable to p53 transactivation from the p21-5’ RE 
containing a spacer of 1 or 2 bases. A spacer of 5 bases between the Noxa half-sites 
abolished p53 responsiveness (also found with the haploid yeast system; Supplemental 
Figure 3.1A). 
 Finally, we wanted to establish the impact that naturally occurring spacers in REs might 
have on transactivation. TIGAR (TP53 induced glycolysis and apoptosis regulator) contains a 
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p53 target RE with a two-base spacer between decamers. This gene reduces levels of 
glycolysis, decreases free reactive oxygen species and attenuates the apoptotic response [56-
58]. Interestingly, the natural TIGAR RE is one of the few examples in the genome where the 
binding element matches the canonical p53 consensus sequence precisely (i.e., no 
mismatches). However, p53 could only induce transactivation from this sequence to ~ 20% 
of the levels with the p21-5’ RE, which does not precisely match the consensus p53 sequence 
(Figure 3.2A). When the spacer was removed, p53 could transactivate from TIGAR to levels 
comparable to the p21-5’ RE. Similar results were obtained with the haploid yeast system 
(Supplemental Figure 3.1A).  
The impact of spacers on the ability of p53 to function from a RE was also assessed 
in human cells under conditions of high p53 expression. Luciferase reporter vectors 
containing the p21-5’ RE with spacers of increasing length were generated in the vector 
pGL3 promoter (pGL3-P). The ability to transactivate from transfected p21-5’ REs was 
assessed in p53 null SaOS2 cells (derived from a human osteosarcoma line) that were 
transfected with a cytomegalovirus (CMV) based p53 expression plasmid [59]. Consistent 
with the results observed in yeast, p53-dependent transactivation decreased with increasing 
spacer length between decamer half-sites. As shown in Figure 3.2B, expression of WT p53 
resulted in an ~35-fold induction of transcription from the natural p21-5’ RE as compared to 
transfection with a p53 deficient plasmid, whereas transactivation from the p21-5’ RE 
containing a one- or two-base spacer resulted in a 45% and 67% reduction in relative 
luciferase activity, respectively. Similar to the situation in yeast, additional nucleotides 
resulted in >90% net reduction in transactivation. It is interesting that within the three 
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systems--haploid and diploid yeast and human cells--transactivation from a RE with a spacer 
of 10 bases was slightly increased in comparison to a RE with a 5 base spacer. 
 
Spacers between half-sites impact p53 binding in vivo and in vitro 
To determine if the difference in p53-dependent transactivation from REs containing 
spacers is simply due to a reduction in p53 promoter binding, we investigated in vivo 
occupancy using chromatin immunoprecipitation (ChIP) assays and in vitro binding using a 
newly developed microsphere binding assay (Noureddine et al., submitted). ChIP assays 
were performed on the luciferase reporter plasmids containing the p21-5’ RE with spacers of 
varying lengths which had been transfected into SaOS2 cells along with the p53-expressing 
plasmid. As shown in Figure 3.2C, a one nt spacer decreased occupancy at the p21-5’ RE by 
two-fold. Further increases in spacer length reduced p53 occupancy. No occupancy was 
observed in mock-transfected cells. Thus, the pattern of occupancy by p53 mirrored that for 
transactivation. Consistent with the transactivation results, p53 occupancy at the p21-5’ RE 
with a spacer of 10 nucleotides was slightly increased in comparison with a spacer of 5 
nucleotides (0.6% vs 0.4%). 
To further characterize the impact of spacer on p53 interactions with a RE, we 
utilized a fluorescent microsphere binding assay to evaluate sequence-specific p53-DNA 
binding interactions (Noureddine et al., submitted). Briefly, this assay addresses p53 binding 
to individual beads with specific RE test sequences, where each bead “type” (i.e., beads with 
specific REs) is identified with a unique double stranded oligonucleotide 24-nt “tag” 
sequence. Several bead types are then multiplexed in a binding assay and analyzed using 
Luminex technology to determine the amount of p53 bound to each bead type. We generated 
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a series of oligos with the p21-5’ RE sequence of interest that contained various spacer 
lengths flanked by non-specific DNA. Each of these RE sequences was conjugated to beads. 
The bead types were combined and incubated for 60 minutes with nuclear cell extracts 
obtained from human lymphoblastoid cell lines that were either not induced or induced for 
p53 expression with doxorubicin (Dox). The level of p53 expression was approximately 15-
fold greater in extracts from Dox-treated versus nontreated cells (data not shown). The p53 
interaction with each bead type (i.e., each p21-5’ RE variant) was determined after 
incubation with p53 antibodies and secondary antibodies conjugated with phycoerythrin.  
As displayed in Figure 3.2D, the mean relative binding of p53 to the p21-5’ RE with a 
spacer of 1 nucleotide (0.83 ± 0.09) was comparable to that for the p21-5’ RE (1.0 ± 0.11) 
with no spacer. However, p53 binding to the p21-5’ REs was affected when the spacer 
between half-sites was ≥2 nucleotides, with a dramatic decrease at > 4 nucleotides. The 
sequence of the spacer used to increase the distance between the decamer half-sites had no 
apparent effect on binding activity (data not shown). Furthermore, p53 did not bind to the 
negative control (NC) sequence which had the p21-5’ RE replaced with a scrambled 
sequence. Interestingly, p53 displayed the same residual binding to the individual half-sites 
of the p21-5’ RE [p21-5’ left (L) and right (R)] as it did towards REs containing a spacer of 4 
nucleotides or more (0.06 and 0.08, respectively).  
 
p53 can transactivate from half-site REs in yeast and human cells 
Since a low level of binding or transactivation was observed with widely separated 
decamers, we investigated p53 binding and transactivation from single decamer sequences in 
the yeast diploid and human cell systems. Transactivation was barely detectable from the left 
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or right decamers of the p21-5’ RE (Figure 3.3A). However, two additional complete 
consensus half-sites, designated Con G and Con D, were able to support transactivation at a 
level corresponding to 2.4% and ~10%, respectively, of that from the full p21-5’ RE. 
Importantly, transactivation was only observed at high levels of p53 expression. By way of 
comparison, transactivation from the con D half-site was comparable to levels obtained from 
the low-responding 14-3-3σ RE. 
 To assess the ability of p53 to transactivate from decamer half-sites in a mammalian 
system, luciferase reporter vectors containing the p21-5’ RE half-sites were transiently 
transfected with or without a vector containing p53 under the CMV promoter into p53 null 
SaOS2 cells [59]. As shown in Figure 3.3B (also see Figure 3.2B), WT p53 induced 
transactivation from the full p21-5’ RE was 35-fold greater than with an empty pGL3-P 
vector. However, there was clear induction from the left and right half-sites, 4- and 6-fold, 
respectively. These results correlated well with the relative p53 occupancy assessed by ChIP: 
4% for the full RE, 0.4% for the left decamer and 0.9% for the right decamer and agree with 
the previous findings in Menendez et al. [60] that p53 can function from a half-site RE. 
Based on these findings, the p53 transcriptional network may incorporate more downstream 
targets than previously predicted. 
 
p53 transactivation from decamer half-sites is sequence-dependent 
The sequence requirements for p53-dependent transactivation were examined further, 
utilizing a plasmid-based haploid yeast system with rheostatable p53 expression (previously 
used to assess transactivation capacity of canonical full-site REs; see Materials and Methods 
and [30]). Similar to results from mammalian cells, p53 was able to weakly transactivate 
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from p21-5’ half-site REs at a level that was ~1% of the levels of transactivation from the 
p21-5’ full-site RE (Figure 3.3C). This result differed somewhat from that of the diploid 
yeast system where transactivation from the p21-5’ half-site REs was <0.5% of the 
transactivation from the full-length p21-5’ RE (Figure 3.3A). Transactivation from Con D 
was greater than p53 transactivation from either of the p21-5’ half-sites and Con D was 
greater than Con G in both systems. 
We also examined the impact of changes in the WW of the core CWWG (W = A or 
T). The 3 bases on either side consisted of GGG and TCC which had been shown to enhance 
binding at full-site REs [33] (Figure 3.3C). Decamers required the central CATG motif at the 
junction of the monomer binding sites for modest levels of transactivation, ~7% of the levels 
from the p21-5’ RE (Figure 3.3C). Altering the motif from CATG to CAAG or CTTG 
decreased transactivation another 2- to 3-fold whereas changing this motif to CTAG nearly 
eliminated transactivation. 
Transactivation was also assessed with various combinations of sequences 
surrounding the CATG core domain. As shown in Figure 3.3C, transactivation with the 
GGG/CCC flanking sequence was comparable to the GGG/TCC sequence tested with the 
CWWG motifs. However, transactivation was reduced when other alterations were made. For 
example, a change in flanking sequence to GGG/CTC or GGA/CTC resulted in almost no 
transactivation.  
 
p53 functionality from noncanonical, ¾-site REs in yeast 
We also addressed the ability of p53 to transactivate from ¾-site REs. A consensus 
binding site was created for each of the two possible configurations of a ¾-site RE. The first, 
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designated Con J, consists of a ¼-site directly adjacent to a ½-site, whereas the second, 
designated Con K, contains a 5 base spacer between the ¼-site and the ½-site. 
Transactivation in the diploid yeast system from the Con J and Con K ¾-site REs was 25% 
and 18%, respectively, of the full p21-5’ RE level (Figure 3.4A), at high p53 expression 
(0.024% galactose). This was substantially more than observed for half-site REs. Similar 
findings were observed in the haploid yeast system (Supplemental Figure 3.2A). Further 
evaluation of the sequence requirements for p53 transactivation from ¾-sites with the haploid 
yeast system showed p53 could transactivate from a ¾-site RE containing a CTTG core 
(Supplemental Figure 3.2B). Transactivation was also effected by surrounding flanking 
sequences. 
 
Canonical REs containing spacers may actually be noncanonical ¾-site REs 
In our examination of full-site RE sequences containing spacers, several REs 
contradicted our finding that large spacers between decamer half-sites abolish p53 
transactivation. For example, the PIDD RE (p53 induced protein with death domain) [61] 
which promotes apoptosis has an 8 nt spacer in its RE. Contrary to our expectation, high 
expression of WT p53 resulted in ~20% of the level of transactivation from the p21 5’ RE. 
As expected, removal of the 8 nt spacer between the decamer half-sites increased the levels 
of p53 transactivation (Figure 3.4B). 
Examination of the PIDD RE sequence suggested that rather than functioning from a 
canonical full-site RE, p53 might transactivate from a noncanonical ¾-site RE. The canonical 
PIDD element was first separated into two noncanonical ¾-site REs (designated PIDD ¾ A 
and PIDD ¾ B), both of which utilized the “spacer” sequence as part of the binding element. 
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The noncanonical REs were comprised of a ¼-site directly adjacent to a ½-site, but differed 
in the central CWWG motif in the half-site and number of mismatches from the consensus 
binding sequence. Transactivation assays revealed p53 could function from the PIDD ¾ A 
sequence to levels equivalent to the canonical PIDD RE containing the 8 nt spacer at high 
expression (Figure 3.4B). In contrast, WT p53 could not transactivate from the PIDD ¾ B 
RE. These findings showed that the PIDD RE was neither a true canonical consensus RE nor 
an exception to the “spacer” rule, but rather a noncanonical ¾-site RE which can support p53 
transactivation. 
The results of the PIDD RE sequence analysis suggested that other known p53 REs 
previously identified as canonical full-site REs are actually ¾-site REs. Based on an 
empirically derived set of RE rules previously established in our lab to predict p53 
transactivation capacity [14, 30, 62], several established p53 target REs were re-examined to 
determine if their responsiveness to p53 was actually due to the presence of a noncanonical 
¾-site RE instead of a full-site RE. As shown in Figure 3.4C, the REs of p21-3’, PCNA, 14-
3-3σ (site 2) and Apaf-1 REs were actually comprised of a genuine ¾-site binding element 
(containing a ½ -site directly adjacent to a ¼ -site) followed by an additional sequence that 
vastly deviated from a consensus ¼ -site. Luciferase assays in the diploid yeast strains 
revealed that p53 transactivation from these sites was clearly reduced in comparison to 
transactivation of p21-5’ RE (Figure 3.4C), but comparable to the levels of transactivation 
from the consensus ¾-site REs, Con J and Con K (see Figure 3.4A). These results are 
consistent with p53 transactivation capacities towards the p21-3’, PCNA, and Apaf-1 REs 
assessed with the haploid yeast system in a recent study focused on examining conservation 
of RE sequence and conservation of RE functionality [62]. 
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Structural requirements for p53 transactivation from ½- and ¾- site REs 
We examined several p53 mutations that could address the structural requirements for 
transactivation from noncanonical REs (½- and ¾-site REs) in comparison to canonical REs 
(weak and strong full-sites). The following REs were examined:  ½-site REs (con G, con B, 
p21-5’ left, and p21-5’ right), ¾-site REs (con J and con K), as well as weak (TIGAR and 
Gadd45) and strong (p21-5’ and TIGAR-spacer) full-site REs. Mutations in the 
oligomerization domain were analyzed for transactivation capacity to determine the extent to 
which the tetramerization of p53 facilitated functionality from noncanonical REs. Also 
examined were N-terminal transactivation domain and C-terminal regulatory domain 
mutants. The results are summarized in Table 3.1 and presented relative to transactivation 
from the p21-5’ RE. The variation in transactivation by the p53 mutants towards the REs was 
not due to differences in levels of expressed p53 protein (Supplemental Figure 3.3). 
The Arg337 residue is located on the surface of the tetramerization domain and plays 
a role in tetramer stabilization through a salt bridge with Asp352 on the opposite monomer 
[63-67]. The mutations R337C and R337H, associated with Li-Fraumeni-like syndrome 
(LFL) and adrenal cortical carcinoma (ACC), respectively, appear to compromise the ability 
to form tetramers. The impact of the R337C mutation (previously described as a partial 
function mutation) on p53 functionality has been postulated to arise by a change in 
thermodynamic stability, shifting the equilibrium from the tetramer to dimer and/or 
monomeric states [68, 69].   The R337H mutation is considered to have a subtle functional 
effect causing a pH dependent effect on folding [63, 68, 70-73] (Storici and Resnick, 
unpublished data). 
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In agreement with previous findings by Lomax et al.[68], R337C was found to be an 
altered function mutation in the diploid yeast and SaOS2 cell systems, significantly 
diminishing transactivation from both canonical and noncanonical REs. Transactivation from 
the strong, full-site REs was reduced to less than 25% of the levels of WT p53 (“+” in Table 
3.1), whereas transactivation from the weaker full-sites and the ¾-site REs was barely 
detectable (“+/-”  in Table 1) with no transactivation from the ½-site REs. 
Similar to previous results [68], the p53 R337H mutant could transactivate from the 
p21-5’ RE to levels comparable to WT p53 in the haploid yeast system. However, although 
R337H could function from the p21-5’ RE in the diploid yeast and SaOS2 cell transactivation 
assays, the level was reduced in comparison to WT p53. Similar results were found for 
transactivation from the weaker full-site REs and ¾-site REs. The differences between WT 
and mutant p53 were not as clear for the ½-site REs. 
L344 is one of five residues that comprise the hydrophobic core of the α-helices 
which form the interface for p53 dimer-dimer interactions [64, 66, 67, 74, 75]. The mutation 
L344A prevents tetramer formation although stable dimers are formed [66, 74, 76, 77]. The 
missense mutation L344P disrupts the helix [68, 78-80] and is associated with Li-Fraumeni 
syndrome (LFS). This alteration prevents dimer formation resulting in monomeric p53 
protein [68, 69, 80-83]. Within the haploid and diploid yeast systems, the L344A protein had 
reduced transactivation activity towards the strong canonical full-site REs and noncanonical 
¾-site REs (Table 3.1) and no activity towards half-sites. However, the L344A protein was 
capable of transactivating to low levels from the p21-5’ half-site REs within mammalian 
cells. Similar results were seen in SaOS2 cells with an N345S dimer mutation, where 
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transactivation was measurable, but significantly reduced in comparison to WT p53 
transactivation (data not shown). 
Consistent with previous findings showing L344P is a loss-of-binding mutation, the 
monomeric p53 L344P was not able to transactivate from the full-site, ¾-site, or ½-site REs 
tested within the 2n yeast or SaOS2 cells (Table 3.1) [68, 69, 80-83].  Similarly, the germline 
mutation L330H, which is predicted to form only monomers through destabilizing the β-
strand of the tetramerization domain [74, 81, 84], was also inactive for transactivation from 
the p21-5’ full-site RE and half-site REs in the mammalian system (data not shown). 
Finally, deletion of the tetramerization domain (Δ325-357) or a terminal truncation 
(331 stop: similar to the p53β isoform) resulted in complete loss of transactivation from any 
of the binding sequences examined, including full-site REs, in the yeast or SaOS2 cell 
systems (data not shown). These results were in agreement with previous findings that the 
tetramerization region is necessary for p53 binding to and transactivation from a RE [77, 85]. 
 Previously, we reported that the terminal deletion Δ368 resulted in reduced 
transactivation capacity towards full-site REs when assessed with a yeast ADE2 reporter 
plate assay (on plates) in haploid yeast [30]. Those studies have been extended to address its 
ability to transactivate from full-, ¾- and ½-site REs. We found that removal of the C-
terminal tail resulted in at most a modest transactivation from the noncanonical and canonical 
REs (Table 3.1). The inhibition varied with the strength of the RE sequence, as well as with 
level of p53 expression (data not shown) for all REs. Thus, in comparing WT to mutant, the 
C-terminal domain of p53 appears in several cases to actually enhance rather than repress 
transactivation from canonical, as well as noncanonical REs. 
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Finally, we also examined a deletion in the N terminal domain, Δ1-39, to assess if 
transactivation from ¾- and ½-site REs was differentially affected. The mutation resulted in 
<25% residual transactivation from the full-site REs (strong: p21-5’ and TIGAR – spacer; 
moderate: GADD45) at low expression in the haploid yeast system (data not shown). At the 
high expression levels required to examine noncanonical REs (0.128% galactose), 
transactivation was also reduced from ¾-site REs (con J and con K) and a ½-site RE (con G) 
suggesting that the canonical and noncanonical REs are similarly affected by defects in the 
transactivation domain. 
 
Discussion 
Given the role for p53 in assuring genome stability, it is important to understand how 
this master regulator functions as a sequence-specific transcription factor. The interactions of 
p53 bound to DNA, as well as the mechanisms by which WT or mutant p53 can transactivate 
to different extents from the many variants of the consensus motif are not completely 
understood. In this work, we have developed a matrix of factors influencing transactivation 
that include WT and mutants, sequence and motif, and DNA binding. We have established 
that p53 can function from many noncanonical ½- and ¾-site REs that are common to the 
genome. Importantly, functionality of a sequence is not directly predictable by relation to the 
consensus sequence. 
 
Spacers can have opposite effects on transactivation 
Previous studies have shown that widely-separated full-size REs associated with the 
same p53 target gene, such as the muscle creatine kinase (MCK), can interact to 
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synergistically transactivate the associated target gene [86]. The mechanism has been 
suggested to involve looping out of the intervening DNA so that multiple p53 tetramers can 
“stack” and concentrate the basal transcription machinery [86, 87]. While this mechanism of 
transactivation may hold for REs separated up to 3 kb, the synergy was proposed to be lost 
when the distance was less than 25 bases due to steric hindrance [86], an arrangement that 
holds for several p53 target genes including MDM2. We found that p53 could function 
synergistically from the two weak MDM2 REs separated by a 17 and 10 nt spacer, but 
further reduction to 5 nt resulted in additivity. 
Interestingly, the length of the spacer between the two REs within the promoter of 
Mdm2 has been conserved between mouse and human although the sequence of the spacer is 
50% diverged. In the haploid yeast system, p53 was found to function similarly from the 
human and murine MDM2 REs in terms of synergistic transactivation [62]. Given the 
divergence in the sequence of the spacer, it is unlikely that an additional transcription factor 
binding site would be found in the 17 nucleotides that would allow a second transcription 
factor to interact cooperatively with p53 to induce the observed synergistic transactivation 
from the two REs. Instead, there may be a functional conservation that assures the level of 
p53-mediated transactivation. This is supported by sequence analysis across 14 species, 
corresponding to at least 70 million years of evolution, where 12 had maintained the 17 
nucleotide spacer (with varying degrees of sequence divergence) between RE1 and RE2 
(including chimp, rat, rabbit, dog, elephant, armadillo and hedgehog), while opossum and bat 
had a one nucleotide indel [88, 89]. From this preliminary search, it appears that the spacer 
sequence is under stabilizing selection such that variations in the length of the spacer which 
would affect the ability of p53 to synergistically function from these sites were not observed. 
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Interestingly, a similar phenomenon, is observed in the DNA sequences within and between 
(but not flanking) cis-regulatory elements of the otx, delta, wnt8, and brachyury genes where 
insertions or deletions of random sequence do not occur as assessed by a comparison 
between the orthologous cis-regulatory regions and flanking sequences of the sea urchins, 
Strongylocentrotus purpuratus and Lytechinus variegatus [90]. We are currently 
investigating whether functional conservation of spacer length as a mechanism for regulating 
p53 functionality holds with other closely-spaced full-sized p53 REs. 
The impact of the spacer between full-sites acts opposite to that of a spacer between 
half-sites. In previous studies, it was proposed that REs had a “rotational specificity” where 
spacers between half-sites could abrogate p53-dependent transactivation if they were on 
opposing faces of the DNA helix, but had little impact on transactivation when the half-sites 
were on the same face [18, 53, 54]. Recently, in electrophoretic mobility shift binding assays 
(EMSA), a 2 nt spacer did not significantly alter p53 affinity (Kd) towards a consensus RE 
[29]. Furthermore, in a 3D model derived through cryoelectron microscopy of full length 
p53, where p53 dimers are proposed to form through interactions of alpha-helices on the N- 
and C-termini rather than alpha helices on the C-termini, the best fit RE sequence had a 
spacer length of 6 nucleotides [91]. These in vitro findings imply if p53 transactivation is 
primarily dependent on the ability of p53 to bind target REs, a small spacer would not affect 
p53-dependent transactivation. 
The effect of spacer upon transactivation from a RE at varying levels of p53 was first 
analyzed with the WAF1/Cip1 p21-5’ RE.  The present results are in agreement with an 
earlier report showing that increases in spacer length of 4 or 14 bases between half-sites 
decreases p53 transactivation in yeast [18]. However, there is no evidence for rotational 
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specificity influencing transactivation. This is the first demonstration that a spacer of 1 or 2 
nt between half-sites can dramatically affect the ability of p53 to transactivate from a RE.  
Importantly, the impact of spacer on the ability of p53 to transactivate from a RE is greatly 
influenced by the intrinsic potential transactivation strength of the RE, as shown for NOXA, 
as well as level of p53 expression. We also established with the haploid yeast system that a 
spacer had a similar negative effect on the ability of p53 family members, p63β and p73β, to 
transactivate from a RE. 
The biological importance of spacer as a means for affecting response to p53 was 
clearly demonstrated for the TIGAR RE. We propose that unlike the implications from the 
established consensus RE, a spacer between half-sites in natural elements serve to modulate 
the levels to which p53 can regulate the associated target gene and may play an important 
mechanistic role in the evolution of RE responsiveness to p53. In the case of TIGAR, the 
opportunity to address evolutionary implications is limited due to the apparent recent 
emergence of the putative p53 binding site in the primate lineage, however, the orthologous 
TIGAR RE in Pan troglodytes (chimpanzee), and Macaca mulatta (rhesus monkey) also 
contain a 2 nt spacer [88, 92]. 
 
Binding vs. transactivation 
Several modes of binding have been postulated for p53 to a RE containing a spacer 
that include shifting of the tetramer on the DNA to compensate for the reduced protein-
protein interactions, bending and/or kinking of the DNA within the spacer and/or RE and 
rotational motions of p53 to accommodate supercoiling of the spacer sequence [24, 27]. In 
any of these, binding would modify either the conformation of the p53 tetramer and/or the 
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DNA sequence itself in a fashion that is not predictable from current structural studies. While 
functional studies demonstrate that the RE sequence can dramatically influence the level to 
which p53 can transactivate from a specific RE [3], the relationship between in vitro binding 
and efficiency of in vivo transactivation had not been established prior to this study. 
We utilized a novel fluorescent microsphere, semi-in vitro binding assay to determine 
the effect of spacer upon p53 binding. Recently, we demonstrated a good correspondence 
between binding and in vivo transactivation for several human p53 target REs (Noureddine et 
al., submitted). While differences were observed between the in vivo and in vitro assays for 
p53 binding to the p21-5’ RE containing a single nucleotide spacer, increasing the length of a 
spacer between the decamer half-sites beyond one nucleotide had a large impact on the 
ability of p53 to bind in the semi-in vitro assays, contrary to reports with pure components 
[22, 23].  Interestingly, p53 binding to a RE with a ≥3 nt spacer was nearly equivalent to 
binding to the individual p21-5’ half-site REs, suggesting that p53 may recognize each 
decamer sequence as a distinct binding motif once a spacer increases beyond a certain length. 
These findings strongly argue that the 0-13 nucleotide spacer in the established p53 
consensus sequence, which is based on interactions between purified protein and REs, should 
be reduced to no more than a few bases. It appears that factors present in nuclear extracts or 
cells limit the ability of p53 to recognize REs with spacers between half sites. It will be 
interesting to identify these putative spacer-discriminating factor(s). 
 
p53 functionality from ½-site and ¾-site  REs  
The observations that p53 can function, as defined by binding and transactivation, 
from consensus half-site REs in yeast and from the p21-5’ half-site REs in mammalian cells 
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indicate the p53 transcriptional network is comprised of many more downstream targets than 
previously predicted. Transactivation from half-sites is strongly dependent upon the targeted 
sequence and level of p53 expression. Similar to full-site REs [30], the central binding motif 
at the monomer junction (i.e., CATG) had the greatest impact upon the ability of p53 to 
function from half-sites. The difference between the yeast and mammalian systems in 
functionality from the half-sites indicates that additional co-factors in human cells may assist 
in p53 interactions with weaker binding sequences. Tetrameric p53 can bind full-site and 
half-site binding elements in vitro, but the p53 bound to a half-site had a much higher 
disassociation rate in vitro as indicated through “trap” assays that had measured dissociation 
of p53 from a labeled RE sequence [22]. 
Given the higher probability of a decamer sequence occurring in the genome 
compared to a 20 base sequence, it will be interesting to determine the number of functional 
p53 half-site REs in the human genome which is composed of ~3 billion base pairs. In a 
preliminary genomics screen, we have identified over 1,400 “perfect” p53 half-sites 
containing a CATG core motif in the genome within 2 kb of a transcriptional start site.  
However, the question remains as to which of these sites will have a relevant biological 
function in p53-dependent stress responses or whether the sequences are merely “noise” 
within the genome.    
Half-sites could serve many roles in the genome. For example, a collection of half-
sites could affect chromatin accessibility to transcriptional machinery (i.e., loosening the 
chromatin or recruiting and sequestering chromatin modifiers). Such sites might function in 
the proposed opening of the genome to make it more available for repair [93]. On the other 
hand, half-sites might also serve to titrate p53.  Additionally, p53 half-sites may play a role in 
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bringing together different transcriptional networks as described for a SNP in the FLT1 
promoter [41, 60]. Subsequent studies of the Flt-1 half-site have shown that p53 bound to the 
T-SNP can cooperate with estrogen receptor (ER), also bound to a half-site of its own 
consensus sequence, to synergistically transactivate from the Flt1-T promoter [60].  Such co-
regulation may be advantageous for precise fine-tuning of p53-regulated responses and may 
make activity from the noncanonical ½-site REs more dependent on availability of 
cooperating transcription factors or additional cofactors and on levels of nuclear p53.  
Within yeast, p53 was able to transactivate from noncanonical consensus ¾-site REs 
containing a ¼-site adjacent to a ½-site or a ¼ -site separated from a ½-site by a 5 nt spacer. 
The lack of a significant difference between the transactivation from both ¾-site REs imply 
that p53 encounters the ¾-site RE as a tetramer protein. Transactivation from ¾-site REs was 
moderate relative to full-sites. Furthermore, the hierarchy of transactivation, in terms of the 
level to which p53 could bind and transactivate in vivo, was comparable to earlier in vitro 
studies that measured p53 binding efficiencies towards ½ -sites, ¾ -sites and full-site 
sequences with competitive gel retardation assays [53]. The impact of a ¾-site was revealed 
in our study of the RE for the PIDD gene where p53 transactivation was substantial even 
though the RE contained a spacer greater than 3 nt. Transactivation assays revealed the 
responsiveness of the originally described PIDD RE was actually due to a noncanonical ¾-
site RE. Transactivation from the PIDD ¾ A RE, but not the PIDD ¾ B reinforces the 
requirement for a strong core element for functionality and that a functional RE cannot 
contain greater than 3 mismatches within a half-site. There are likely to be many functional 
¾-site REs in the genome, among which are sequences that were originally considered as 
canonical, full-site REs containing >2 nt spacers.  Furthermore, as recently pointed out in our 
 94
functional conservation analysis of p53 REs from several species, there are clear examples of 
weaker, apparently  noncanonical ¾-site REs, such as p21-3’ and APAF1 being conserved in 
evolution [62]. 
While this report is the first to systematically evaluate p53 function from 
noncanonical ½- and ¾-site REs, there are other reports of a transcription factor binding to 
noncanonical binding sites within the genome. Johnson et al. [94], recently mapped the in 
vivo interactome for the transcription factor neuron-restrictor silencing factor (NRSF) using a 
large scale ChIP analysis and found that NRSF bound to noncanonical half-site binding 
motifs. A variety of approaches such as ChIPSeq or FAIRE, formaldehyde-assisted isolation 
of regulatory elements, may be able to reveal interactions at noncanonical sites under 
different stress conditions and in various cell types [95, 96] to better understand the 
dimensions of the p53 master regulatory universe.     
 
Transactivation from ½-site and ¾-site REs require tetrameric p53 
Having established WT p53 interacts with sequences that do not fully conform to the 
canonical p53 binding sequence, a panel of p53 mutants was analyzed to determine what 
structural features of p53 play a role in transactivation from ½- and ¾-site REs versus full-
site REs. Together, the mutations suggest that common functional aspects of p53 are required 
for the ability of p53 to function from full, ¾-, and ½-site REs. In general, the observed 
transactivation of oligomerization mutations towards full-site REs was in agreement with 
previous reports of mutants able to form tetramers or dimers retaining transactivation towards 
strong REs, while monomeric proteins were inactive [83]. 
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Having established WT p53 interacts with noncanonical sequences, a panel of p53 
mutations was analyzed to determine what structural features of p53 play a role in 
transactivation from ½-site and ¾-site REs versus full-site REs.  The observed 
transactivation of oligomerization mutations towards full-site REs has confirmed previous 
reports of mutants able to form tetramers or dimers retaining transactivation towards strong 
REs, while monomeric proteins were inactive [83]. Together, the mutations suggest that 
common functional aspects of p53 are required for the ability of p53 to function from full, ¾, 
and ½-site REs. 
The DNA binding domain of p53 has been shown in vitro to bind DNA in the absence 
of the oligomerization domain and that dimeric p53 can bind to half-sites  in a cooperative 
fashion independent of tetramerization [22, 97]. While able to transactivate at a low level 
from strong full-site REs and ¾-site REs, the L344A dimerization mutation was unable to 
transactivate from the weak full-site REs or consensus half-site REs in yeast. In agreement 
with these findings, Waterman et al. previously showed that the L344A protein could bind in 
vitro to oligonucleotides containing an optimal consensus binding site and/or half-site, but 
not to an oligonucleotide containing a suboptimal full-site [77]. 
The impact of the dimer mutation L344A, as well as N345S, was less severe in 
mammalian cells. Similarly, a designed dimer mutant (Met340Gln/Leu344Arg) was capable 
of transactivating from a p21 full-size RE within SaOS2 cells to half the level of WT p53 
suggesting a direct correlation between the oligomeric state and transactivation activity [69]. 
While L344A dimeric proteins may bind to the sites in a cooperative fashion, tetramerization 
which is a necessity for efficient transactivation may be required to stabilize the binding and 
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reduce the off-rate of p53 from the DNA in yeast. It is possible that other factors in SaOS2 
cells may contribute to this stabilization accounting for the difference between the systems. 
Since altered tetramer proteins and dimers exhibited a reduced ability to transactivate 
from noncanonical REs, transactivation is not simply an additive process determined by the 
number of available pentamer sequences. It is possible that binding and transactivation in 
vivo, but not binding alone, may require a conformational change of the p53 protein that is 
only obtainable with a tetrameric protein. Several transcription factors have displayed such a 
characteristic including the heat shock protein which can bind chromatin weakly as 
monomer, but is not sufficiently active to cause a biological response until after it is induced 
and forms a trimer [98, 99]. Furthermore, in the case of a half-site, where there is not a 
sequence to which the second p53 dimer can bind, tetramerization may assure the second 
dimer is in the vicinity of the p53 binding element in order to interact with other factors 
required for transactivation. 
The finding that the p53 Δ368 mutation reduced transactivation from both canonical 
and noncanonical REs agrees with studies showing that p53 does not require modification of 
the C-terminal to engage its target binding sites [31, 32]. Furthermore, these results indicate 
that the C-terminal is not absolutely essential for function from canonical or noncanonical 
sites, but may play a role in regulating the level of transactivation. 
The deletion of the first N-terminal transactivation domain (TAD) which mimics a 
naturally occurring alternatively spliced form of p53 that is differentially expressed in breast 
tumors, had a more severe impact upon transactivation than previously reported with the 
qualitative ADE2 color reporter (data not shown) [30, 100]. The results may reflect the 
greater quantitative assessment of transactivation with the luciferase assay. Nevertheless, 
 97
both assays revealed that the decreased opportunity to interact with the transcriptional 
machinery through the loss of the transactivation domain strongly affects p53 transactivation 
from both canonical and noncanonical REs. 
 
Conclusions and Implications 
Through deconstructing the canonical consensus sequence and assessing 
functionality, as determined by binding and transactivation within three in vivo model 
systems and a semi-in vitro binding assay, it has been possible to refine the requirements for 
functional p53 binding elements. The organization and arrangement of binding motifs, as 
well as the level of p53 expression, have a large impact on the ability of p53 to transactivate 
from a RE sequence. It is interesting that p53 may not function from reported canonical 
consensus REs yet functions from noncanonical REs that are common to the human genome. 
Half-sites and spacers between full-sites may provide additional levels of regulation in p53 
transcriptional network. Truly functional REs may be restricted to decamers separated by <3 
nucleotides. When the spacer increases beyond 3 nucleotides, we suggest p53 recognizes the 
half-sites as separate binding entities. 
The ability of p53 to function from noncanonical decamer half-sites introduces a new 
realm of target sequences and genes into the p53 transcriptional network and expands the 
universe of p53 regulated genes. Noncanonical sequences might provide p53 responsiveness 
at high levels of expression or in combination with other transcription factors, as for the case 
of the Flt-1 gene [60]. As discussed in the “piano model” for transactivation from a broad 
range of REs [14], variation in the level of p53, as well as various mutants can markedly 
affect the spectrum of p53 responses. Determining the relationship between expression levels 
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and responsiveness at canonical and noncanonical target sequences is important in 
understanding how p53 implements cellular fate in response to stress, such as cell cycle 
arrest or apoptosis. It is also important for addressing the consequences of p53 alterations, 
particularly those mutations that retain transactivation capabilities, as well tailoring 
individual therapies. 
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Figure 3.1 Weak REs can function synergistically when separated by a spacer. (A) 
To ascertain if p53 functions from the two full-site REs of MDM2 independently or if the 
REs interact, p53 transactivation from the isolated REs, as well as the natural MDM2 RE 
containing a 17 nucleotide spacer were evaluated. Isogenomic diploid yeast strains 
containing the p21-5’ and MDM2 REs, as indicated, were grown in increasing 
concentrations of galactose to induce p53 protein to basal, moderate and high levels of 
expression. The ability of wt p53 to transactivate from RE sequences was measured by a 
luciferase assay 24 hours after inoculation into the galactose supplemented media. 
Induction from each RE was compared relative to the ability of p53 to transactivate from 
the p21-5’ RE at 0.024% galactose and is depicted as the mean and standard error of 
measurement (SEM) of 6 independent experiments. The average light units/ug protein 
from p21-5’ at 0.024% galactose was 2.1 million. Solid arrows over the sequences 
indicate a ¼-binding site. 
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Figure 3.1B 
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(B) Impact of reducing the spacer to 10 and 5 nucleotides. The average light units/ug 
protein for p21-5’ at 0.024% galactose was 2,800,000. 
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Figure 3.2A 
 
 
Nucleotides in spacer
0* 1 2 3 4 5 10
In
du
ct
io
n 
re
la
tiv
e 
to
 m
ax
im
um
 p
21
-5
’
0.2
0.4
0.8
1.0
0.6
0* 5 0 2*
AGGCTTGCCC  cGGCAAGTTg Noxa
TigarAGACATGTCC  AGACTTGTCT
cAACATGTTg GGACATGTTC p21-5’
ac
1.2
p21-5’ Noxa Tigar
% galactose
0
0.008 
0.024 
In
du
ct
io
n 
re
la
tiv
e 
to
 m
ax
im
um
 p
21
-5
’
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Spacer decreases p53 transactivation, promoter occupancy and binding 
in yeast and mammalian cells and in vitro (A) Transactivation in yeast. The ability of 
p53 to transactivate from REs containing spacers of variable nucleotide length sequences 
was measured 24 hours after p53 induction with a quantitative luciferase assay. Induction 
from each RE at various p53 expression levels were compared to the induction from the 
p21-5’ RE at 0.024% galactose. The average light units/ug protein for WT p53 towards 
p21-5’ at 0.024% galactose for a minimum of 6 biological repeats was 1.26 million. 
*indicates the number of nucleotides in the spacer of the natural RE. Solid arrows 
identify a ¼-binding site. 
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Figure 3.2B 
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(B) Human SaOS2 cells were transfected with p21-5’::luciferase reporter constructs 
containing spacers of increasing length between decamer half-sites in the presence (solid 
bars) or absence (open bars) of the high expressing pCMV-p53wt vector. At 48 hours 
post transfection, induction of the luciferase reporter was assessed. Relative luciferase 
activity was compared to the pGL3-P plasmid lacking the p53 RE (mock) and is 
represented by the average and standard deviations of three independent experiments, 
each containing three replicates. 
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Figure 3.2C 
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(C) Occupancy of p53 at p21-5’ REs in human cells. The p21-5’ promoter constructs 
containing the increasing spacers between half-sites were co-transfected with p53 into 
SaOS2 cells (as described in (B)). Twenty-four hours later, ChIP analysis was performed. 
Presented are the average and standard deviation from 4 independent experiments (left). 
PCR products of the Input DNA (input) and ChIP DNA (p53, IgG, or no antibody, Ab) 
are shown (right). The “M” corresponds to a pGL3-P plasmid control lacking the p53 RE. 
No bands were observed above the 600 bp markers. 
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Figure 3.2D 
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(D) In vitro fluorescent microsphere binding assay to evaluate sequence-specific p53-
DNA binding interactions (see Materials and Methods). Fluorescent microspheres 
bearing double stranded DNA fragments were multiplexed and incubated in the presence 
of nuclear extracts from non-treated (NT) or Doxo-treated (0.6ug/mL [1mM] 
Doxorubicin for 18 hours at 37˚C) lymphoblastoid cells. The DNA fragments contained 
the p21-5’ RE, p21-5’ RE with spacers of increasing length (0-15), p21-5’ half-site RE 
(left or right), or a scramble sequence.  
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Figure 3.3A 
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Figure 3.3 Half-sites function as noncanonical REs for transactivation in a sequence-
dependent manner in yeast and human cells. (A) Transactivation from decamer REs in 
the diploid yeast was quantified with a luciferase assay. Protein lysates were obtained 24 
hours post inoculation into galactose supplemented media. The average light units/ug 
protein for wt p53 towards p21-5’ at 0.024% galactose for six biological repeats was 1.8 
million. Solid arrows indicate ¼-binding sites. Comparisons were made with 
transactivation from the p21-5’ full site at high protein levels. 
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Figure 3.3B 
 
 
 
Mock
R
el
at
iv
e 
lu
ci
fe
ra
se
ac
tiv
ity
SaOS2
10
20
30
40
0
p21-5’
leftfull right
Response element 
INPUT
p53 ChIP
No Ab
%
 IP D
N
A
p53 occupancy
1
2
3
4
0
5
transactivation
IgG
R
el
at
iv
e 
lu
ci
fe
ra
se
ac
tiv
ity
%
 IP D
N
A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) Transactivation in human SaOS2 cells. The cells were co-transfected with WT p53 
along with either the full, left or right half-sites of the p21-5’ RE containing reporter 
construct. Transactivation was assessed with the luciferase assay 48 hours later. Relative 
luciferase activity was compared to a mock transfection containing the promoter-less 
pGL3 plasmid. Presented are the averages and standard deviations of 3 independent 
experiments that were each done in triplicate. PCR products of the input DNA (input) and 
ChIP DNA (p53, IgG or no antibody, Ab) are shown (right). Input and ChIP PCR 
products for the mock and p21-5’ full-site are shown in Figure 3C. No bands were 
observed above the 600 bp markers. 
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Figure 3.3C 
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(C) Sequence dependence of p53 transactivation from decamer half-sites. The extent to 
which p53 transactivation from half-sites is sequence dependent at high expression levels 
(2% galactose) was determined with a plasmid-based haploid yeast system [30]. Relative 
light units/ug protein from ½-sites were compared to transactivation from the yLFM 
strain containing the p21-5; full-site RE. The average light units/ug protein from p21-5’ 
at 2% galactose was 2.9 million. 
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Figure 3.4A 
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Figure 3.4 A ¾-site can function as a noncanonical RE in p53 transactivation. 
(A) Transactivation was assessed from ¾ REs Con J and Con K. The ability of WT p53 
to transactivate was measured with the diploid yeast luciferase assay 24 hours post 
inoculation into the galactose-supplemented media. Induction from each RE was 
compared relative to the ability of p53 to transactivate from the p21-5’ RE at 0.024% 
galactose and is depicted as the mean and SEM of 6 independent experiments. The 
average light units/ug protein from p21-5’ at 0.024% galactose was 2.1 million. Solid 
arrows indicate a ¼-binding site.   
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Figure 3.4B 
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(B) p53 functions from a  ¾-site RE in the PIDD RE. Removal of the natural 8 bp spacer 
increased transactivation as expected; however, p53 was also able to transactivate from 
the natural PIDD RE containing the spacer. To determine the true functional p53 binding 
element, the canonical PIDD RE was broken into two noncanonical sites, ¾ PIDD-A and 
¾ PIDD-B, which incorporated the spacer sequence into the RE and assessed for 
transactivation capacity with the luciferase assay. Solid arrows indicate ¼-binding site; 
dashed arrows indicate putative ¼-binding sites. 
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Figure 3.4C 
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(C) Analysis of p53 transactivation from various p53 targets in the genome,that may be 
functioning ¾-sites. Shown are the identified p53 target sequences for p21-3’, PCNA, 14-
3-3σ site 2 and APAF1 with the noncanonical ¾-site RE contained in these sites 
(identified by solid arrows).  
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Table 3.1 
 
 
Table 3.1 Transactivation capacity of WT and mutant p53 towards canonical and 
noncanonical REs. 
 
 SYSTEM p53 ALLELE: RE
tetramer          altered  tetramer      dimer  monomer terminal Δ
WT R337C R337H L344A L344P Δ368
FULL RE:
1n +++ +++   +/- a +/- a +++
2n +++ + +   +/- b - ++           p21-5'
mammalian +++ + ++            ++ d - ++
1n +++ ++           Tigar
2n +++ + + +/- - +++              no spacer
1n + +/-           Tigar
2n + +/- +/- - - +/-        natural
1n ++ +           Gadd45
2n ++ +/- +/- - - +
3/4 RE:
1n ++ + + - +           Con J
2n ++ +/- +/- +/- - +
1n ++ + + - +/-           Con K
2n + +/- +/- +/- - +
1/2 RE:
1n  +/- - - +/-           Con G
2n +/- - +/- - - +/-
1n +/- - - -           Con B
2n +/- - +/- - - +/-
mammalian +   [y +/-] - +/- +/- -           p21-5' left
mammalian +   [y +/-] - +/- +/- -           p21-5' right
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WT p53 and several structural mutations were examined in three in vivo systems (haploid 
[1n] and diploid [2n] yeast and human SaOS2 cells) for transactivation from REs 
representing full, ¾-sites and ½-sites. The ability of the p53, WT or mutant, to 
transactivate from a RE was measured with a luciferase assay and compared to the ability 
of WT p53 to transactivate from the p21-5’ RE at 0.008% and 0.024% galactose in 1n 
and 2n yeast, respectively,  or compared to the pGL3 plasmid lacking the promoter REs 
in human cells. Relative transactivation by a p53 variant in comparison to WT p53 
towards the p21-5’ RE is represented by +++ (75-100%), ++ (25-75%), + (7.5-25%), +/- 
detectable but weak response, or - (no detectable response). The R337C and R337H 
mutations are compromised for their ability to form tetramers (the equilibrium between 
dimers and tetramers is altered in comparison to WT p53) [80]. The L344A and L344P 
mutations result in p53 protein being present as a dimer and monomer, respectively. The 
 112
Δ368 mutation deletes the C-terminal basic domain required for structure-specific and 
non-sequence specific binding but has no effect on dimer or tetramer formation. “a” 
corresponds to significantly higher response at high galactose concentrations (0.128 and 
2%). “b” indicates that the mutant was capable of transactivation from RE in an ADE2 
plate assay at high galactose concentrations.  “d” indicates that the dimer mutation N345S 
was also analyzed in the mammalian system and yielded the same results as L344A. 
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Supplemental Figure 3.1A 
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Supplemental Figure 3.1 Increase in spacer decreases transactivation by p53 family 
members. (A) The plasmid-based haploid yeast system [30] was utilized to determine the 
extent to which p53 transactivation was impacted by a spacer between decamer half-sites. 
Transactivation was measured as relative light units/ug protein at 0.008% and 0.128% 
galactose and compared to WT p53 transactivation from the p21-5’ RE. Depicted are the 
average light units/ug protein and standard deviations from 3 biological repeats. The 
average light units/ug protein for WT p53 towards p21-5’ at 0.128% galactose was 2.9 
million. 
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Supplemental Figure 3.1B 
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(B) The transactivation capacity of p63β and p73β from the p21-5’ RE containing 
spacers of 0, 2, 5 and 10 nt  was measured to determine the affect of spacers on 
transactivation by p53 family members. Transactivation was measured at moderate and 
high levels of p53 expression.  
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Supplemental Figure 3.2A 
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Supplemental Figure 3.2 Transactivation from noncanonical ¾-site REs in haploid 
yeast. (A) The ability of p53 to transactivate from the consensus ¾-site REs, Con J and 
Con K were determined in the haploid yeast system, as described in Inga et al. [30]. The 
ability of WT p53 to transactivate from the ¾-site REs was measured 24 hours post 
inoculation into the galactose-supplemented media by a luciferase assay. The ability of 
WT p53 to transactivate from each ¾-site RE was compared to the ability of WT p53 to 
transactivate from the p21-5’ RE at 0.128% galactose. Transactivation is depicted as the 
light units/ug protein and presented as the mean and standard deviation of 3 independent 
experiments. The average light units/ug protein from p21-5’ at 0.128% galactose was 2.9 
million. Solid arrows indicate a ¼-binding site. 
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Supplemental Figure 3.2B 
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 (B) Sequence dependence of p53 transactivation from ¾-site REs. The plasmid-based 
haploid yeast system [30] was utilized to determine the sequence requirements for 
transactivation from noncanonical ¾-site REs at high expression levels (0.128% 
galactose). The central core “CWWG” motif was altered from CATG to CTTG and 
flanking regions were changed as described. Transactivation from 3/4-site REs was 
measured with a luciferase assay and calculated as light units/ug protein.  
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Supplemental Figure 3.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 3.3 Mutant p53 expression. To exclude the possibility that 
variation in transactivation capacity towards the canonical and noncanonical REs by 
mutant p53 was due to variable protein levels, the relative expression of p53 mutants was 
compared to WT p53.  Western analysis was performed 24 hours following transient 
transfection of mock, WT p53 or mutant p53 pCMV plasmid vectors into SaOS2 cells.  
Thirty-five ug of total protein was run on 4-12% BisTris NuPAGE as described in the 
Materials and Methods. Staining of the gel with SimplyBlue SafeStain (Invitrogen) for 
total loading protein was performed to discriminate possible overlap of protein between 
the loading control actin and the truncated p53 protein Q331stop which run at 
comparable distances.   
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Abstract 
Mutations in the master regulator p53 that alter transactivation function could result 
in changes in the strength of gene activation or spectra of genes regulated, thereby leading to 
dramatic phenotypic changes and diversification of cell response.  Mutations in p53 are 
associated with ~25% of sporadic breast cancers, a rate lower than the frequency in other 
cancers, such as lung and colorectal carcinomas.  However, p53 mutations occur at much 
higher frequencies in BRCA1/2 germline-associated and in familial breast cancers (especially 
in the autosomal dominant Li-Fraumeni syndrome, LFS).  We have determined functional 
fingerprints of breast cancer related p53 mutants particularly those associated with LFS 
families and BRCA1/2 related cancers.  The ability of p53, wild type and mutants, to 
transactivate from 11 human target REs has been assessed at variable expression levels with 
an in vivo, isogenomic yeast model system that allows for the rapid analysis of p53 function 
using a qualitative and a quantitative reporter.  Among 50 missense mutants, 29 were 
classified as loss-of-function p53 mutations.  The remaining 21 (42%) retained 
transactivation towards at least one RE.  Interestingly, at high levels of p53, 12 of the 21 
mutants that retain function appear similar to WT in their transactivation capacity.  However, 
when the levels of these p53 mutants were reduced, subtle transactivation defects were 
revealed.  Our results demonstrate that altered function p53 missense mutations can occur in 
breast cancers although the transcriptional effects associated with some of these mutations 
are often subtle.  Understanding the consequences of altered function mutations on the p53 
transcriptional network will help elucidate how specific mutations contribute to the 
development, penetrance, and phenotype of breast cancers, as well as the response to  
chemotherapeutic agents.
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Introduction 
The tumor suppressor p53 is a master regulatory gene that regulates the differential 
expression of target genes in a sequence-specific manner in response to cellular and 
environmental insults [1-5].  Cell cycle regulation, apoptosis, angiogenesis, replication and 
repair are processes interconnected within the p53 transcriptional network.  p53 exerts itself 
as a transcription factor by binding as a homotetramer, or dimer of dimers, to a consensus 
response element (RE) sequence comprised of two decamer half-sites.  These decamer half-
sites [RRRCWWGYYY]2 (where R= purine; W= A/T; Y=pyrimidine) vary between 
downstream target genes and can be separated by up to 2 nucleotides for efficient 
transactivation ( Jordan et al, submitted).  Activation of a downstream target is dependent on 
a matrix of factors including cell type, stimuli, post-translational modifications and 
transcriptional co-factors [6].  
The importance of p53 as a tumor suppressor and sequence-specific transcription 
factor in human cells is highlighted by the occurrence of p53 mutations in the majority of 
cancers [7].  Interestingly, p53 is unique in comparison to other transcription factors in that 
over 75% of mutations that occur in this tumor suppressor are single amino acid changes 
which result in missense mutations [8]. These missense mutations predominantly occur in the 
DNA binding domain of the protein (>80%) [8].  At the molecular level, p53 mutations 
found in cancers, including breast cancer, are usually associated with loss of the ability to 
maintain proper cell cycle checkpoints, suppress transformation caused by oncogenes, induce 
apoptosis and maintain the integrity of the genome [1, 9]. 
Specific mutations in p53 are known to denature the native protein or abrogate its 
ability to bind DNA thus completely abolishing its function.  Such mutations are thought to 
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provide a selective advantage within cancerous cells by forming a hetero-tetramer with WT 
p53 thus providing the opportunity for either dominant-negative or gain-of-function effects 
[10-12].  However, recent studies have demonstrated that other p53 missense mutations 
retain their ability to function as a sequence-specific transcription factor towards some 
downstream targets such that the ability to regulate cellular responses is mitigated but not 
completely lost [4, 13, 14], sometimes resulting in a change-of-spectrum of genes regulated 
rather than a simple modulation. These findings have led to a “master gene of diversity” 
concept which draws an analogy between sequence-specific transcription factors, in this case 
p53, and a hand playing the keys of a piano, the downstream target genes [4, 5].  The chord is 
the accumulation of biological responses regulated and is dependent on both the genes 
regulated and strength of regulation.  Functional mutations in the hand (i.e., p53) can alter 
transactivation functions by altering binding, strength of activation, and/or spectrum of genes 
regulated which may lead to changes in the transcriptional network.  
To date, functional p53 mutations have been identified as super-transactivating, 
change-in-spectrum and those that proportionately modulate the levels of transactivation 
downward.  For example, mutant p53 with altered function may be capable of regulating 
genes containing a strong RE, such as p21, but unable to regulate those with a weak RE, such 
as Bax.  This is consistent with the observation of mutant p53s that still induce cell cycle 
arrest, yet lose the ability to activate apoptosis [15-19].  In addition, p53 mutations may alter 
the active binding sites of potential transcriptional cofactors, thus diminishing the potential 
maximal level of transcriptional response.  Modifications in the transcriptional network may 
result in cellular responses that impact genome stability, repair, replication, and programmed 
cell death.  Varying patterns of cellular responses, including apoptosis and survival have 
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been elicited in human cells as a consequence of distinct altered function p53 mutations [20].  
Furthermore, the aberrant biological consequences of the specific altered function mutations 
seemed to be influenced by the specific cell type and activating stimuli.  
Mutations in p53 are associated with approximately 25% of sporadic cases of breast 
cancer, a rate lower than the frequency in other sporadic cancers, such as lung and colorectal 
carcinomas.  However, p53 mutations occur at much higher frequencies in BRCA1/2 
germline-associated [21, 22] and in familial breast cancers (especially in the autosomal 
dominant Li-Fraumeni syndrome, LFS) [23-26]  where family members are predisposed to 
early onset cancers.  BRCA1/2 and p53 are involved in maintaining genome stability by 
controlling aspects of homologous recombination and repair, centrosome regulation, cell 
cycle checkpoints and transcription [27]  where loss of either increases the occurrence of 
carcinogenesis [28, 29].  Interestingly, a significant increase in the frequency of sporadic p53 
mutations occurs with an inherited mutation in BRCA1, possibly due to a decreased 
efficiency to repair damage [22, 30, 31]. BRCA1-associated cancers have an altered 
spectrum of p53 mutations which may reflect changes in mutagenesis and/or selection for the 
acquired mutations [22].  While BRCA1 mutations are largely absent in somatic breast 
tumors, silencing of the gene through hypermethylation has been reported in sporadic cases 
[32]. Such epigenetic changes have been reported to associate with estrogen receptor 
negative (ER-) tumors and occur concomitantly with p53 mutations [32]. In addition, a recent  
hierarchical clustering analysis of immuno-histochemistry profiling has established that 
degrees of genomic instability correlate with specific subtypes of breast cancers, where the 
basal subtype had the highest number of genomic aberrations in both sporadic and familiar 
BRCA-associated cases [33-35].   
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Li-Fraumeni and Li-Fraumeni-like (LFL) germline disorders--which often harbor a 
p53 mutation--display an array of early onset, tissue specific tumors of which breast tumors 
are most frequently observed [8, 36].  The specific p53 mutation carried in the germline, 
particularly structural-based mutations, may influence the tumor type and penetrance of the 
disease [36-39].  Recent studies have determined the severity of a particular inherited p53 
missense mutation on its ability to function as a sequence specific transcription factor 
correlates with clinical manifestations [8, 40].  Partial deficiency alleles are associated with 
less severe family history, lower number of tumors, later onset of disease in comparison to 
severe deficiency (loss-of-function) alleles and higher risk of breast tumors.  Similar findings 
were observed with somatic p53 mutations associated with breast cancers; however, it was 
postulated that the majority of these missense mutations were devoid of transcriptional 
function and contributed to a clinical phenotype through a dominant-negative effect [41].    
At the clinical level, p53 mutations in breast cancer have been associated with poor 
prognosis, earlier on-set, increased aggressiveness of tumors, aneuploidy, and adverse 
responses to chemotherapeutic treatments [42, 43].  Studies which classify breast cancers 
based on gene expression profiling have shown p53 mutations are more frequent in the 
hormone receptor-negative subtypes such as the HER2+/ER- [human epidermal growth 
factor-2 positive/estrogen receptor negative] and the basal-like subtypes [ER-, PR- 
(progesterone receptor), HER2-, cytokeratin 5/6+, and/or HER1+] [44-47].  Based on a 
recent population based study, these subtypes were prevalent among African American 
and/or premenopausal women and correlated with a more aggressive disease and shortened 
survival, irrespective of lymph node status [46].  Regardless of subtype, p53 status (WT or 
mutant) also displays a signature expression profile in breast tumors which is a prognostic 
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indicator of patient survival, where WT p53 associates with a more favorable outcome [44, 
48, 49].   
Based on previous findings that several p53 missense mutations associated with 
breast cancers display subtle transactivation defects when examined in mammalian cell-based 
or yeast functional assays [50, 51], many other reported mutations are likely to retain 
function. However, functional consequences of mutations may not be predicted simply by 
assessments of conservation, topology, or structural models. Using functionality assays based 
in the budding yeast Saccharomyces cerevisiae, it is possible to assess the transcriptional 
capacities of p53 mutants towards various promoters.  We have employed a newly developed 
diploid yeast model system to analyze the functional consequences of p53 missense 
mutations found in breast cancers on gene activation endpoints in the p53 transcriptional 
network at various levels of p53 expression (Jordan et al., submitted).  Transactivation 
capacities of WT and mutant p53 have been determined using a qualitative and a quantitative 
reporter to establish a functional fingerprint for each mutant towards a subset of human REs 
that are representative of p53-dependent cellular responses.  Using a “rheostatable” promoter, 
we have ascertained functional discrepancies between WT and mutant p53 transactivation at 
variable expression levels.  We have determined that p53 missense mutations found in 
sporadic and familial breast cancers can retain function and the alterations in transactivation 
are often subtle where differences can be exaggerated by changes in p53 levels. 
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Results 
Functional fingerprinting of p53 missense mutations associated with breast cancers 
Budding yeast, which lack endogenous p53, have been used previously as an in vivo 
test tube to analyze directly interactions between p53 and REs elements in a cellular 
environment [4, 5].  Recently, we developed a diploid yeast model system to address the 
contribution of RE sequence, organization and level of p53 upon p53-mediated 
transactivation (Jordan et al. submitted). We have utilized this system, described in Figure 
2.4, to assess the consequences of p53 missense mutations found in breast cancers upon 
transactivation and ultimately clinical manifestations.     
We sought to define how specific p53 missense mutations interfere with p53 function 
by assessing the ability of mutant p53 to transactivate from a panel of REs associated with 
p53-dependent downstream target genes. The 50 mutations associated with breast cancer 
examined were chosen based upon the following criteria: 1) appear in Li-Fraumeni syndrome 
(LFS), Li-Fraumeni-like syndrome (LFL), or familial history (FH) cancers; 2) present in the 
L2 loop, L3 loop or zinc binding region of the protein; 3) associated with familial BRCA1/2 
cancers; 4) multiple amino acid changes at the same codon; and/or 5) identified in patients 
undergoing neoadjuvant treatment for locally advanced breast tumors (Table 4.1).  Within 
criteria group 5, p53 mutational analysis was performed on untreated breast cancer tissues 
obtained from women participating in two clinical-translational trials, a single institution 
study from the University of North Carolina – Lineberger Comprehensive Cancer Center 
(UNC-LCCC 9819), and a multiinstitutional cooperative group trial sponsored by the 
National Cancer Institute (CALGB 150007). Both trials involved acquisition of breast cancer 
tissue before treatment with neoadjuvant anthracycline-based chemotherapy in order to 
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correlate biomarkers with response to primary chemotherapy.  (These studies were approved 
by the institutional review boards of the University of North Carolina at Chapel Hill and 
participating institutions through the Cancer and Leukemia Group B (CALGB).  All study 
subjects gave written informed consent to participate in the clinical trial and the correlative 
science studies.) 
 Twenty-one missense mutations identified in patients participating in these trials 
(referred to as neoadjuvant treatment) are assessed within the present study for functional 
status and later will be correlated to therapeutic responses to determine if transactivational 
activity can be used as a prognostic tool for implementing treatment.  Forty-nine of the fifty 
p53 missense mutations are listed in the International Agency for Research on Cancer 
(IARC) p53 mutation database as being detected in somatic breast tumors or identified as a 
germline mutation in LFS, LFL, or FH families (Table  4.1) [8].  The single mutation not 
reported in the IARC database, M246A, was identified in a patient participating in the multi-
institutional prospective trial (see group 5); p53 status in the neoadjuvant treatment patients 
(group 5) was confirmed by single-stranded conformational polymorphism analysis (SSCP) 
and validated with direct sequencing [52].  
The ADE2 plate color assay was used to determine functional fingerprints for WT 
and the p53 missense mutations based on their ability to transactivate from 11 different REs 
at variable levels of protein expression (Figure 4.1 and Supplemental Figure S4.1).  The REs 
analyzed are associated with known p53 target genes involved in cell cycle, DNA repair, 
apoptosis, angiogenesis, and p53 regulation (Supplementary Table S4.1).  Transcription of 
ADE2 is dependent on the ability of p53 (WT or mutant) to interact with and transactivate 
using the specific RE sequence upstream of the reporter and the minimal CYC1 promoter.  
 135
The ADE2 color assay scores p53 transactivation capacity from a RE based on colony 
pigmentation which ranges from red (none) to pink (weak to moderate) to white (strong) 
depending on the extent of ADE2 transcription. The level of p53 expression was controlled 
by replica plating strains onto plates containing rich media, raffinose (2%) plus various 
amounts of galactose (0 – 0.128%) in the presence of low levels of adenine (5mg/L).  
Mutations were classified as loss-of-function if they were unable to transactivate from a 
single RE at any protein concentration.  Mutations were categorized as functional if they 
were equivalent to WT p53 in transactivation capacity or altered function if the allele 
retained the ability to function from a RE(s), but deviated from WT p53 in transactivation 
capacity from several REs at any level of p53 expression.  
Among the 50 missense p53 mutations, 29 were classified as loss-of-function due to 
their inability to transactivate from a single RE (Table 4.1).  The remaining 21 (42%) 
mutations were able to function from at least one biological RE.  Among the 21 functional 
mutations, 9 were clearly altered in transactivation capacity at high levels of expression 
(0.128% galactose) (Supplemental Figure S4.1) and displayed a change-in-spectrum as 
exemplified by reduced or absence of transactivation from the 14-3-3σ and PCNA REs by 
P151A and R283P, respectively, in Figure 4.1. Of the 9 mutations, 3 (Y220C, M237I and 
P278A) retained the ability to transactivate from only the strongest REs, p21-5’and P53R2 
(and, in the case of P278A, MDM2 which contains 2 full-site REs) (Supplemetal Figure 
S4.1).   
 At high levels of p53, the remaining 12 of the 21 mutants (L130V, A138V, C141W, 
P151H, R174K, R174W, P190L, H214R, R267Q, V272L, E285K, and R337H) looked 
similar to WT in their transactivation capacity (L130V in Figure 4.1 and Supplemental 
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Figure S4.1).  Transactivation from three biological replicates was either indistinguishable 
from WT p53 or nearly identical with the exception of 1 or 2 REs at 0.128% galactose.  
However, when the levels of p53 were reduced, subtle transactivation defects were revealed 
that further differentiated 6 of the 12 mutants (underlined) from WT p53 at 3 or more REs.  
Similar to previous studies [4], the variation from WT p53 at lower levels of expression 
consisted of both reduced and enhanced transactivation capacities from specific REs.  The 
remaining 6 mutants that appeared similar to WT p53 at high levels of expression remained 
similar to WT p53 in transactivation capacity at low levels of expression with the exception 
of subtle variation at 1 or 2 REs.  For example, A138V was only observed to be slightly 
reduced in transactivation compared to WT p53 towards PCNA at 0.008% galactose 
(Supplemental Figure S4.1).  The 9 missense p53 mutants that were identified as change-in-
spectrum at higher levels of expression also displayed aberrant transactivation patterns at 
lower p53 expression albeit to a greater extent.  Consistent with previous results [4, 52], the 
change-in-spectrum mutation T125R suppressed growth at low expression levels in the 
diploid yeast (0.032-0.064% galactose).    
 
Luciferase assays confirm transcriptional anomalies 
The functional status of the 21 p53 missense mutations that retained function was 
examined with a luciferase assay that provides the opportunity to quantitate transactivation 
from REs in late log phase growing cells. This is illustrated by transactivation from the p21-
5’ RE over a range of WT p53 levels (Figure 4.2; see also Figure 2.7).   
Assessment of the altered function mutants with the luciferase assay showed variable 
degrees of functionality from the p21-5’ RE, where the maximal level of transactivation was 
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dependent on the specific mutation.  Similar to the results with the plate assay, several 
mutations (i.e., R174W and R267Q) did not differ from WT p53 in their ability to 
transactivate from the p21-5’ RE at high expression levels.  However, decreasing the p53 
expression revealed a reduction in transactivation for several mutants in comparison to WT 
p53 (i.e., R267Q) (Figure 4.2).  Other mutations, such as L194P, displayed a decreased 
ability to transactivate from the p21-5’ RE in comparison to WT p53 at low and high levels 
of expression.  Several mutations that were similar to WT p53 in terms of maximal levels of 
transactivation from the strong p21-5’ RE showed an altered transactivation potential when 
assessed for transactivation from the weaker GADD45 RE (Figure 4.3).  For example, 
H214R showed an increased ability to transactivate from the RE in comparison to WT p53.  
Others such as A138V and R174W were indistinguishable from WT p53.   
The transactivation with increasing levels of p53 (i.e., increase galactose) was similar 
between the DNA binding domain mutations and WT p53 where the initial induction 
(between 0.004 – 0.008% galactose) and maximal levels of transactivation (plateauing 
between 0.016% - 0.024% galactose) occurred over the same range of p53 induction.  This 
was not observed for two mutations at the same codon in the tetramerization domain, R337C 
and R337H.  In the luciferase assay, R337H clearly altered transactivation from the p21-5’, 
14-3-3σ and GADD45 REs, requiring higher levels of p53 expression than WT to initiate 
transactivation, although maximal levels of transactivation appeared similar to WT p53 
(Figure 4.4).  The R337C mutation resulted in overall dampening of p53 transactivation.  The 
requirement for increased p53 levels necessary for initial transactivation by the tetrameric 
mutants appeared dependent on the strength of the RE.   
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Change-in-spectrum mutations which retained transactivation function from some 
REs, but were devoid of function from others, were also verified with the luciferase assays.  
As shown in Figure 4.5, Y220C was able to transactivate from the strong p21-5’ RE, but to 
reduced levels; the maximal level of transactivation was comparable to that for WT p53 
transactivating from the weaker 14-3-3σ RE.  The Y220C mutant was deficient in 
transactivation from the 14-3-3σ RE. 
Protein levels were analyzed at 0.024% galactose (within the range of expression 
where transactivation was shown to plateau in the luciferase assays) by Western analysis for 
the 21 mutations that retained function (Supplemental Figure S4.2).  Thirteen of the twenty-
one mutants displayed similar levels of protein in comparison to WT p53.  However, seven 
mutants (C141W, L194P, Y220C, M237I, P278A, 285K and R337C) displayed a significant 
reduction in expression compared to WT p53.  Although detectable amounts of p53 were 
present, the finding was puzzling since several of these mutants were shown to efficiently 
function from multiple REs in the ADE2 color assay.  Detection of the p53 protein with 
additional antibodies which recognized different epitopes was consistent with most of these 
mutants having reduced levels of protein in comparison to WT p53 (Suplemental Figure 
S4.3).  Detection of R337C protein increased with the use of the PAb420 and Ab-1 
antibodies suggesting there was an issue with the recognition of the epitope; additionally, an 
increased ratio of degraded protein was apparent relative to R337H.  Transactivation from the 
p21-5’ (assessed with the exact samples used in the Western blots) was significantly reduced 
for the L194P, Y220C, M237I and P278A mutants in comparison to WT p53 which reflected 
the decreased expression of protein (Suplemental Figure S4.3).  However, C141W and 
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E285K induced activity from the p21-5’ RE to ~26 and 38% of the levels of WT p53, 
respectively which remained disproportionate to the levels of protein expressed.  
 
Discussion 
Single amino acid changes can differentially impact transactivation at various targets 
and affect biological outcomes [20].  The specific changes may result in selective advantage 
of specific p53 mutations in certain tissue types or stages of neoplastic transformation as well 
as alter the responsiveness to or the efficacy of chemotherapeutic agents.   
We have used a diploid yeast system to analyze the potential transactivation capacity 
for a set of p53 missense mutations associated with breast cancers.  The 50 missense p53 
mutations examined represent approximately 18% of all somatic p53 mutations reported in 
the IARC p53 mutation database and 20% of all p53 missense mutations documented in 
breast tumors [8].  Among the 50 mutations analyzed, one mutation occurs at an acetylation 
site in a non-structured portion of the protein, 2 mutations are in the tetramerization domain 
and 47 of the mutations are distributed across the sequence-specific DNA binding domain 
(DBD).  Among the mutations, 12 have been associated with LFS, LFL, or FH syndromes, 5 
have been found within BRCA-associated tumors and 21 have been identified in locally 
advanced tumors of patients undergoing neoadjuvant treatment. 
 
Breast cancer associated mutations in the DBD can modulate p53 transactivation  
The DBD of p53 consists of a β-sandwich which provides a scaffold for two large β-
loops, L2 and L3 that are stabilized by a zinc ion and a loop-sheet-helix motif [53, 54].  
Mutations in the DBD have been postulated to affect the binding affinity of p53 towards REs 
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by abolishing DNA contacts, decreasing the thermodynamic stability of the protein, causing 
local distortions in the DNA binding surface, or enhancing the loss of the Zn ion [55, 56].  
Mutations in the L2/L3 loops are predicted to be highly destabilizing to the tertiary structure 
of p53 and/or cause chemical shifts which alter the DNA binding surface [8, 57, 58].    
Alterations in this region have been correlated with a progressive breast cancer that is often 
nonresponsive to chemotherapeutic treatments including doxorubicin, tamoxifen, and/or 
combined therapies of 5-flurouracil and mitomycin. [27, 59, 60].  Of the 47 DBD mutations 
analyzed for transactivation potential, 10 are in residues within the L2 loop, 16 are in the L3 
loop and 6 are zinc-binding residues.  All 6 mutations (C176F, H179R, C238F, C242F, 
C242S, C242Y) which interfere with the histidine or cysteine side chains involved in 
coordination of the Zn ion rendered the protein nonfunctional in terms of transactivation, 
reiterating the vital role of this molecule in site-specific DNA binding and stabilization of the 
p53 protein [55, 61].  Similarly, all the missense mutations analyzed in the L3 loop which 
binds the minor groove of DNA and partakes in the dimerization interface between core 
domains [56] were loss-of-function mutations with the exception of M237I.  M237I showed 
weak transactivation from the p21-5’ RE which was only slightly above the background 
levels of transactivation observed with a loss-of-function mutation and partial transactivation 
from the p21-5’ and P53R2 REs in the plate color assay (data not shown).  Among the 10 
mutations in the L2 loop, four mutations (R174K, R174W, P190L and L194P) retained 
function.   
Functional fingerprinting of the mutations shows single nucleotide changes occurring 
in breast cancer can markedly affect the ability of p53 to transactivate from REs.  For 
example, different missense mutations at the same residue affect p53 function differently as 
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for the case of L194R which results in loss-of-function whereas L194P results in altered 
function.  Importantly, each altered-function p53 missense mutation had a unique functional 
fingerprint (Supplemental Figure S4.1).  Overall, the majority of the change-in-spectrum 
mutations do not seem to be the result of a general reduction in transactivation (i.e, a 
proportional reduction in transactivation capacity from all REs).  Rather, the p53 mutants 
appear to impact the REs differentially where the variation in transactivation capacity is 
distinct to a specific RE. 
Differences in transactivation could not be attributed simply to protein stability since 
most of the p53 mutants were expressed at levels comparable to that for WT protein.  Of the 
six DBD mutations that had a reduced level of protein expression, the altered function 
Y220C and M237I mutants were severely compromised for transactivation capacity.  In 
agreement with these findings, previous reports which analyzed folding of WT and mutant 
core p53 proteins (residues 94 – 312) showed Y220C and M237I were thermodynamically 
unstable and were estimated to significantly decrease the percent of protein folded, as well as 
reduce the binding affinity towards the GADD45, p21, cyclin G and Bax REs relative to WT 
p53 [62].  However, C141W and E285K mutants which also expressed low levels of protein 
were only modestly compromised for transactivation capacity in comparison to WT p53.  
Based on the transactivation and protein expression results, there is no obvious explanation 
for the observation that these mutants can transactivate from the majority of the REs 
analyzed with such a compromised protein level and would suggest the mutants were more 
active than WT p53 based on unit of protein.  However, Schärer and Iggo published similar 
results concerning E285K where the levels of protein in the yeast were decreased in 
comparison to WT p53, yet when assessed for transactivation from a 33 base pair sequence at 
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29°C, E285K activity was ~75% of WT p53; this finding was attributed to protein instability 
[63].  It is possible, the reduced levels of protein may be due to an increased level of 
degradation within the cell due to conformation changes associated with temperature 
sensitive alleles; the Y220C, M237I, and E285K have been reported as temperature sensitive 
[62-65]. 
 
Tetramerization mutations that alter p53 transactivation  
 Although the majority of p53 missense mutations occur in the DNA binding domain, 
several missense mutations have been found in the tetramerization domain that are associated 
with germline syndromes and are found in sporadic breast tumors.  R337C is a partial 
function mutation associated with LFS [66].  R337H has been associated with pediatric cases 
of adrenocortical carcinoma (ACC); however, it may be a low penetrant LFS or LFL allele as 
well [25, 26, 67, 68] (also see chapter 3).  
  The functional fingerprints varied between the two mutations in that R337C had a 
greater impact on p53 transactivation from the various REs which may reflect a greater 
instability of the protein as depicted in the protein analysis (Supplemental Figure S4.1).  
Contrary to previous reports, the p53 missense mutation R337H was not a silent mutation but 
displayed altered function when examined in the ADE2 phenotypic assay (Supplemental 
Figure S4.1). At high expression levels, R337H looked identical to WT p53 in the color 
assay.  At low levels of p53 expression, R337H has a reduced ability to transactivate from 
REs in comparison to WT p53, presumably due to its reduced ability to form tetramers.  
Interestingly, the luciferase assay revealed a pattern of transactivation that was unique to 
R337H where higher levels of protein expression were required to detect transactivation.  
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This altered pattern of transactivation may be a manifestation of the novel features R337H 
which include a pH-dependent instability and a higher propensity to form amyloid-like fibrils 
[69, 70].  R337C clearly demonstrated an altered transactivation capacity which was distinct 
in comparison to WT p53 displaying an overall dampening effect on transactivation. 
 
Change-in-spectrum mutations can alter the selection of target REs 
Another yeast-based functional assay which uses an ADH1-p53 expression plasmid 
and high copy RE reporter plasmid system has been developed by Kato et al. [13].  
Functional analysis of all but one (M246A) of the 50 mutations examined in the present 
study is available on the IARC p53 mutation database [8].   There was less than 65% 
agreement in terms of overall transactivation functionality. Only 8/49 or 16% were identified 
as functional (6 partially functional; 2 functional) as compared to 21 mutations in the present 
study system (16 altered function; 5 functional) (Supplemental Table S4.2).  The large 
discrepancy between the two systems may be in part due to the method of classifying a 
mutation as retaining function.  In that study, functional classification was determined based 
on the median of 8 RE specific activities, expressed as % WT p53 activity for transactivation 
[8, 13].  In order for a mutation to be considered partially functional, the median for the 8 
REs had to be between 20 - 75% of WT activity, whereas the mutant was considered 
functional if the median was between 75 -140%.  In the present study, a mutant was 
considered at least partially functional if there was a level of expression for which there was 
transactivation from at least one of 11 REs, which may be why more mutants are described 
as retaining function in the present study. For example, we concluded the R337C was an 
altered function missense mutation whereas, Kato et al, classified it as a nonfunctional 
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mutation although it did display transactivation equating to at least 20% of WT activity for 3 
of the 8 REs analyzed (WAF1, MDM2 and P53R2).  Because of the wide range of p53 
expression, the present study also provides greater opportunity to identify change-of-
spectrum mutants, as well as subtle changes in transactivation.     
Our results suggest several downstream targets are eliminated from the p53 
transcriptional network under some biological conditions for several of the p53 mutants 
resulting in a change-in-spectrum of RE targets.  For example, R337C was not capable of 
transactivating from AIP1, 14-3-3σ or PCNA at moderate levels of expression (Supplemental 
Figure S4.1).  However, the observation that transactivation is retained under other 
conditions should not be overlooked because it suggests a priori that the mutant may be an 
ideal candidate for drug rescue [57].  For example, the Y220C mutation which lies in the 
periphery of the β-sandwich and plays a role in stabilizing its hydrophobic core [58] was 
found in the present study to be capable of transactivating from only the p21-5’ and P53R2 
target REs at higher levels of expression.  Recent crystal structures of the p53 core domain 
containing the Y220C mutation revealed that although the mutation was thermodynamically 
destabilizing, the overall conformation of the core remains intact [58].  The Y220C mutation 
results in a cavity or cleft in the protein away from the RE binding site which can be 
specifically targeted by a small molecule to rescue transcriptional function [56, 58]. 
 
Subtle variation in transactivation capacity of altered function missense mutations 
A particularly interesting observation in this study was that many of the altered 
function mutations when examined at higher levels of p53 expression looked similar to WT 
p53 in terms of transactivation capacity.  Importantly, these mutations would not have been 
 145
distinguished from WT p53 in typical yeast functional assays where p53 is expressed at high 
levels from a constitutive promoter.  By reducing the level of transcription with the 
rheostatable promoter, it was possible to unmask subtle transcriptional discrepancies.   These 
mutants might have unique properties in terms of biological consequences.  Possibly, the 
mutants function similarly to WT p53 for gene expression from target genes under high stress 
and chemotherapeutic conditions, but differently under conditions of low p53 expression.  
Other transcription factors could further modify the response.  It is also possible that these 
mutations are acquired early in tumor development and in combination with mutations in 
other genes contribute in an additive fashion to the complex cancer disease.  Also, mutations 
in p53 may be an underlying contributor to the genomic instability observed in BRCA1-
associated breast cancer cases and the functional status of individual p53 missense mutations 
may impact the degree of genetic imbalance.   
The functional relevance of p53 at low expression levels is beginning to be elucidated 
and highlights the need to understand mutants under conditions of low expression.  Espinosa 
et al. [71, 72] observed that p53 occupies some REs, (i.e., p21) prior to overall p53 
stabilization.  There is transcriptional initiation from these REs, but the transcriptional 
machinery stalls prior to elongation.  Such regulation may be required for a rapid response to 
cellular stress and may be lost in mutations that have an aberrant low level response.  The 
loss of transactivation function at low levels may promote an alternative mode of promoter 
selectivity and/or provide the opportunity for a competing transcription factor to bind 
promiscuously to p53 target elements.  Although mutations in p53 are often associated with 
nuclear accumulation of the protein, recent observations from the Lozano group have shown 
this is not necessarily the case in vivo [73].  These observations suggest a scenario can exist 
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within the cell where aberrant low level p53 response can affect a biological outcome.  Based 
on our transactivation analysis, interactions between the subtle p53 missense mutations and 
the MDM2 RE remain intact, suggesting this feedback regulatory loop can be initiated by the 
p53 mutants. 
 
Conclusion and Implications 
Given the heterogeneity of breast cancers, understanding the consequences of altered 
function mutations on the p53 transcriptional network will help elucidate how specific 
mutations predispose and/or contribute to the development, penetrance, and phenotype of 
breast cancers.  Our results demonstrate that altered function p53 missense mutations can 
occur in breast cancers.  Among 50 p53 mutations identified in breast cancers, 21 had altered 
function—not simply complete loss—towards at least one RE.  Although the transcriptional 
effects associated with these mutations are often subtle, by reducing the level of transcription 
with the rheostatable promoter, it is possible to address the retained functions of mutant p53 
and novel features in transcriptional networks.  Importantly, structure-based analysis of 
mutations in the DBD was not predictive of the in vivo transactivation capacity, where 
greater than 45% of the predictions based on computational geometry (which assessed 
residual score profiles derived from Delaunay tessellations) disagreed with the results of the 
transactivation assays (Supplemental Table S4.2)  [8, 74].  This finding emphasizes the need 
to address function of p53 mutations in vivo.  It is important to emphasize that the yeast-
based results indicate the potential for transactivation and that many factors can come into 
play in p53 mediated transactivation in human cells. 
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Results obtained with the yeast functional assay appear predictive of whether a 
mutation will also have a biological impact in mammalian cells [20]. While the yeast-based 
assay can predict the potential for specific p53 mutations to display altered function, assays 
in mammalian cells can ascertain the full impact of the functional mutations in the presence 
of p53 transcriptional cofactors and in the endogenous chromatin context of the RE.  
However, we propose that assessments of functional fingerprints for p53 missense mutations 
associated with breast cancer in yeast provide diagnostic value and with further study may 
also be used as a predictor of tumor behavior in response to chemotherapeutic agents.  This 
would be particularly relevant to the tailoring of individual therapies, especially when the 
treatment agents impact p53-dependent biological responses.   
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Table 4.1 
 
Table 4.1 p53 missense mutations associated with breast cancers: functional status, 
frequency, and features. 
 
IARC DATABASEb 
SOMATIC  
 
p53 
MUTATION 
 
FUNCTIONALa 
STATUS TOTAL BREAST 
GERMLINE 
FAMILIES 
 
FEATURESc 
T125R ALTERED 2 1 0  
L130V ALTERED 21 3 0 Neo. 
C135F LOSS 49 3 0  
C135Y LOSS 70 11 0 Neo. 
A138V FUNCTIONAL 48 7 0  
C141W ALTERED 14 1 0 Neo. 
P151A ALTERED 17 3 0 BRCA 
P151H FUNCTIONAL 35 4 0 Neo. 
G154S ALTERED 11 0 0 Neo. 
V173L LOSS 85 10 0 L2; Neo. 
R174K ALTERED 9 1 0 L2 
R174W FUNCTIONAL 14 2 0 L2 
C176F LOSS 181 7 0 L2-Zn 
H179R LOSS 139 16 0 L2-Zn; Neo. 
R181P LOSS 22 2 1 L2; LFS, LFL, FH 
S183L LOSS 3 1 0 L2 
P190L ALTERED 48 4 0 L2; BRCA 
L194P ALTERED 14 1 0 L2; BRCA 
L194R LOSS 55 9 0 L2 
H214R ALTERED 72 5 0 BRCA 
Y220C ALTERED 315 41 4 LFS, LFL, FH; Neo. 
M237I ALTERED 172 26 1 L3; LFS, LFL, FH 
C238F LOSS 38 5 0 L3-Zn; BRCA 
N239D LOSS 43 5 0 L3; Neo. 
N239T LOSS 9 2 0 L3 
S241C LOSS 33 4 0 L3 
C242F LOSS 86 7 0 L3-Zn 
C242S LOSS 32 5 0 L3-Zn 
C242Y LOSS 51 5 3 L3-Zn; LFS, LFL, FH; Neo. 
M243T LOSS 8 2 0 L3 
G244V LOSS 23 2 1 L3; LFS, LFL, FH 
G245S LOSS 396 35 18 L3; LFS, LFL, FH; Neo. 
M246A LOSS 0 0 0 L3; Neo. 
M246T LOSS 12 3 0 L3 
R248L LOSS 112 6 0 L3, Neo. 
R249G LOSS 43 7 0 L3 
R249S LOSS 374 14 0 L3, Neo. 
D259V LOSS 17 2 0 Neo. 
G266R LOSS 65 5 0 Neo. 
R267Q ALTERED 12 3 3 LFS, LFL, FH 
V272L FUNCTIONAL 47 1 1 LFS, LFL, FH 
R273C LOSS 611 28 9 LFS, LFL, FH; Neo. 
R273H LOSS 733 76 16 LFS, LFL, FH; Neo. 
P278A ALTERED 24 5 0 Neo. 
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D281E LOSS 48 3 0  
R283P ALTERED 34 3 0 Neo. 
E285K FUNCTIONAL 156 20 0 Neo. 
K305M LOSS 2 2 1  
R337C ALTERED 17 4 3 LFS, LFL, FH 
R337H ALTERED 2 0 69 LFS, LFL, FH; ACC 
 
aBased on transactivation capacity from 11 human p53 target REs assessed with the plate 
color assay and the luciferase assay.  
bNumber of reported allele specific mutations in the R12 release of the IARC p53 mutation 
database. Total number of somatic mutations reported 24,810; total number of missense 
mutations occurring in breast tumors 1984; total number of germline mutations reported is 
399; however, families may have multiple tumors in various tissues with the same mutation. 
cCriteria used to select the specific missense mutation for transcriptional analysis.  BRCA, 
associated with BRCA1/2 cancers; LFS, Li-Fraumeni syndrome; LFL, Li-Fraumeni-like 
syndrome; FH, familial history; L2, L2 loop; L3, L3 loop; Zn, zinc binding; neo., identified 
in patients undergoing neoadjuvant treatment for locally advanced breast tumors.    
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Figure 4.1 
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Figure 4.1 Functional fingerprints of mutant p53 reveal subtle transactivational 
differences.  The ADE2 plate color assay was used to assess the transactivation capacity of 
WT and mutant p53 towards 11 human target REs at various protein concentrations.  Single 
colony isolates of yeast strains containing the mutation and RE of interest were streaked onto 
YPDA plates containing glucose and high levels of adenine and grown at 30ºC.  The plates 
were then replica plated onto a series of plates containing synthetic media with low levels of 
adenine [5 mg/L ], 2% raffinose and various amounts galactose (0, 0.001, 0.002, 0.004, 
0.008, 0.016, 0.032, 0.064 and 0.128%).  Transactivation capacity was scored from weak to 
strong according to the amount level of color (red being little transactivation and white being 
strong transactivaiton) for three biological replicates.  Shown are examples of functional 
fingerprints for WT p53 and several change-in-spectrum mutations at 4 levels of protein 
expression.  At high expression levels (0.128%) several mutations were found to display an 
altered spectrum of REs regulated in comparison to WT p53, for example, P151A and 
R283P.  However, several mutants, such as, L130V, appear indistinguishable from WT p53 
in transactivation capacity.  Reducing the levels of expression with the rheostatable promoter, 
exaggerated the subtle transcriptional effects of these mutations and distinguished them from 
WT p53 and other mutations in transactivation capacity. 
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Figure 4.2 
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Figure 4.2 Assessment of WT and mutant p53 transactivation towards the p21-5’ RE 
using a luciferase assay in growing cells.  Diploid yeast strains containing GAL1::p53 (WT 
or mutant) crossed with the p21-5’ RE-luciferase reporter strain were grown overnight in 
complete medium, diluted, washed and inoculated into selective medium containing either 
raffinose (2%) or raffinose (2%) plus increasing concentrations of galactose (0 – 0.024%) 
overnight at which point the cells are late log. Protein lysates were obtained and a 
quantitative luciferase assay was used to determine the transactivation capacity for the p53 
variants from the p21-5 RE’. The strength of transactivation was calculated as relative light 
units/ug protein. Depicted are the mean and standard error of measurement (SEM) for 7 
independent experiments.  Transactivation kinetics show basal, linear-increase, and plateau 
phases of the transactivation response which is dependent on the p53 variant.  Many p53 
missense mutations associated with breast cancers, i.e. R174W and R267Q, do not affect the 
maximal level of transactivation towards the strong p21 5’ RE in comparison to WT p53. 
However, transactivation can be altered at low levels of p53 expression. Several mutants, 
such as L194P, were shown to modulate the levels of transactivation at all concentrations of 
expression. C242S is a loss-of-function mutation.  
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Figure 4.3 
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Figure 4.3 Transactivation from the GADD45 RE distinguishes altered function 
mutants from WT p53.  The ability of p53 (WT and mutant) to transactivate from the 
GADD45 RE was measured 24 hours after inoculation into increasing concentrations of 
inducing media with a quantitative luciferase assay (see Figure 4.2). The strength of 
transactivation was calculated as relative light units/ug protein.  Presented are the mean and 
standard error of measurement (SEM) for 6 independent experiments.  Interestingly, 
transactivation from the GADD45 RE can differentiate mutant p53 alleles that looked similar 
to WT p53 in the ADE2 plate assay.  H214R has an increased ability to transactivate from the 
RE in comparison to WT p53 at low and high levels of expression.   
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Figure 4.4 
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Figure 4.4 Altered function mutations at the same codon in the tetramerization domain 
display different transactivation capacities.  Transactivation capacities were obtained for 
the R337C and R337H mutations towards the p21-5’, 14-3-3σ, and GADD45 REs at 
increasing levels of expression with the quantitative luciferase assay.  The levels of 
transactivation were severely diminished with R337C.  R337H required an increased amount 
of p53 expression to stimulate transactivation.  The magnitude of effect upon transactivation 
capacity for the individual mutations appeared dependent on the RE. 
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Figure 4.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p21-5’
Y220C
14-3-3σ
C242S
WT
Tr
an
sa
ct
iv
at
io
n
(x
10
-4
)
(li
gh
t u
ni
ts
 /u
g
pr
ot
ei
n)
1
10
100
1000
0.1
Galactose concentrations (%)
0.0250.0150.005
Tr
an
sa
ct
iv
at
io
n
(x
10
-4
)
(li
gh
t u
ni
ts
 /u
g
pr
ot
ei
n)
Tr
an
sa
ct
iv
at
io
n
(x
10
-4
)
(li
gh
t u
ni
ts
 /u
g
pr
ot
ei
n)
Tr
an
sa
ct
iv
at
io
n
(x
10
-4
)
(li
gh
t u
ni
ts
 /u
g
pr
ot
ei
n)
 
Figure 4.5 Change-in-spectrum p53 missense mutations can eliminate REs from the p53 
transcriptional network.  To verify that change in spectrum mutations can alter the 
transcriptional network through eliminating several REs under certain conditions in vivo, 
transactivation was assessed for WT and Y220C p53  from the p21-5’ and GADD45 REs.  
Diploid yeast strains were grown overnight in complete medium, diluted, washed and 
inoculated into induction media (see Figure 4.2). Protein lysates were obtained from 
overnight cultures and a quantitative luciferase assay was used to determine the 
transactivation capacity for the p53 variants from the p21-5 RE’. The strength of 
transactivation was calculated as relative light units/ug protein. Depicted are the mean and 
standard error of measurement (SEM) of 6 independent experiments.  Y220C is capable of 
transactivating from the p21-5’ RE albeit to levels comparable to WT p53 transactivation 
from the weaker 14-3-3σ RE. However, Y220C was not capable of transactivating from the 
14-3-3σ suggesting this target gene may be eliminated from the p53 transcriptional network 
in the presence of this particular mutation. 
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 Supplemental Figure S4.1 
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Supplemental Figure S4.1 Functional fingerprint of 21 altered-function p53 missense 
mutations.  Transactivation capacities of WT and mutant p53 were assessed from 11 REs 
with the ADE2 plate color assay at variable levels of p53 induction.  Single colony isolates 
grown on YPDA plates containing glucose and high levels of adenine and grown at 30ºC 
were replicated onto a series of plates containing synthetic medium with low levels of 
adenine [5 mg/L], 2% raffinose and incremental increases in galactose.  Transactivation 
capacity was assessed through colony pigmentation and scored according to the extent of 
transactivation from weak to strong (see Figure 4.1).   
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Supplemental Figure S4.2 WT and mutant p53 expression.  A.  To assess if the variation 
in transactivation capacity towards the biological REs by mutant p53 was due to variable 
protein levels, the relative expression of p53 mutants was compared to WT p53.  Diploid 
yeast strains containing GAL1::p53 (WT or mutant) crossed with the p21-5’ RE-luciferase 
reporter were grown overnight in complete medium, diluted, washed and inoculated into 
selective medium containing raffinose (2%) plus 0.024% galactose.  Overnight cultures, 
corresponding to late log phase, were harvested and 50 ug of total protein was run on 4-12% 
BisTris NuPAGE as described in the Materials and Methods.  The p53 protein was detected 
with a mix of DO7 (BD BioSciences Pharmenigen) and pAb1801 (Santa Cruz) antibodies.   
Bands were detected using horseradish peroxide-conjugated secondary antibodies (Santa 
Cruz) and the enhanced chemiluminescence (ECL) detection system (Amersham, Cleveland, 
OH, USA).  Membranes were stained with Ponceau S to determine efficiency of protein 
loading. B.  Longer exposures lengths show there are detectable levels of p53 protein with 
the Y220C, M237I, E385K and R337C mutants.  N239D is a loss-of-function mutation. 
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Supplemental Figure S4.3 Transactivation from the p21-5’ RE by p53 missense 
mutations with reduced protein expression.  A. Western analysis was performed on the 
p53 mutants expressing reduced levels of p53 in comparison to WT and R337H using the 
combined D0-7 (BD BioSciences Pharmenigen), pAb240 (Santa Cruz) and p53 (Ab-1) 
(Santa Cruz) antibodies to detect p53.  The pAb240 and P53 (Ab-1) antibodies recognize 
different epitopes from those previously used.  Similar to previous results, the protein 
expression was detectable, but reduced in comparison to WT p53. B. Transactivation from 
the p21-5’ RE was assessed for WT and p53 mutants with the luciferase assay.   
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Supplemental Table S4.1 
 
Supplemental Table S4.1 Response element sequence and biological function of 
associated target gene. 
 
Sequence Response 
 Element 
Function 
Half-site Spacer Half-site 
p21-5' Cell cycle cAACATGTTg  GGACATGTTC
P53R2 DNA repair tGACATGCCC  AGGCATGTCT
PCNA DNA repair GAACAAGTCC  GGGCATaTgT
PUMA BS2 Apoptosis ctGCAAGTCC  tGACTTGTCC
GADD45 DNA repair GAACATGTCT  AAGCATGCTg
CYCLIN G Cell cycle AGGCTTGCCC  GGGCAgGTCT
14-3-3σ Cell cycle tAGCATTAGCCC  AGACATGTCC
AIP1 Apoptosis tctCTTGCCC  GGGCTTGTCg
tcACAAGTTa G AGACAAGCCTBAX A+B Apoptosis 
AGACAAGCCT  GGGCgTGggC
GGtCAAGTTg  GGACAcGTCCMDM2  
RE1+RE2 
p53 
regulation GAGCTAagTC C tGACATGTCT
MMP2 angiogenesis AGACAAGCCT  GAACTTGTCT
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Supplemental Table S4.2 
 
Supplemental Table S4.2 Functional status determined by in vivo transactivation assays 
vs. structure based predictions. 
 
MUTATION FUNCTIONAL 
STATUSa 
Jordan et al. 
FUNCTIONAL 
STATUSb 
Kato et al. 
STRUCTURE  
BASED 
PREDICTIONc 
RESIDUE 
FUNCTIONd 
T125R ALTERED NONFUNCTIONAL NONFUNCTIONAL BURIED 
L130V ALTERED NONFUNCTIONAL NONFUNCTIONAL PARTIALLY 
 EXPOSED 
C135F LOSS NONFUNCTIONAL NONFUNCTIONAL BURIED 
C135Y LOSS NONFUNCTIONAL NONFUNCTIONAL BURIED 
A138V FUNCTIONAL PARTIALLY FUNCTIONAL PARTIALLY 
 EXPOSED 
C141W ALTERED NONFUNCTIONAL NONFUNCTIONAL BURIED 
P151A ALTERED NONFUNCTIONAL NONFUNCTIONAL BURIED 
P151H FUNCTIONAL NONFUNCTIONAL NONFUNCTIONAL BURIED 
G154S ALTERED PARTIALLY NONFUNCTIONAL PARTIALLY 
 EXPOSED 
V173L LOSS NONFUNCTIONAL NONFUNCTIONAL BURIED 
R174K ALTERED FUNCTIONAL FUNCTIONAL PARTIALLY 
 EXPOSED 
R174W FUNCTIONAL NONFUNCTIONAL NONFUNCTIONAL PARTIALLY 
 EXPOSED 
C176F LOSS PARTIALLY NONFUNCTIONAL ZN BINDING 
H179R LOSS NONFUNCTIONAL NONFUNCTIONAL ZN BINDING 
R181P LOSS NONFUNCTIONAL FUNCTIONAL EXPOSED 
S183L LOSS FUNCTIONAL FUNCTIONAL PARTIALLY  
EXPOSED 
P190L ALTERED PARTIALLY NONFUNCTIONAL PARTIALLY  
EXPOSED 
L194P ALTERED NONFUNCTIONAL NONFUNCTIONAL BURIED 
L194R LOSS NONFUNCTIONAL NONFUNCTIONAL BURIED 
H214R ALTERED NONFUNCTIONAL NONFUNCTIONAL BURIED 
Y220C ALTERED NONFUNCTIONAL NONFUNCTIONAL BURIED 
M237I ALTERED NONFUNCTIONAL NONFUNCTIONAL BURIED 
C238F LOSS NONFUNCTIONAL NONFUNCTIONAL ZN BINDING 
N239D LOSS NONFUNCTIONAL FUNCTIONAL DNA BINDING 
N239T LOSS NONFUNCTIONAL NONFUNCTIONAL DNA BINDING 
S241C LOSS NONFUNCTIONAL NONFUNCTIONAL DNA BINDING 
C242F LOSS NONFUNCTIONAL NONFUNCTIONAL ZN BINDING 
C242S LOSS NONFUNCTIONAL NONFUNCTIONAL ZN BINDING 
C242Y LOSS NONFUNCTIONAL NONFUNCTIONAL ZN BINDING 
M243T LOSS NONFUNCTIONAL FUNCTIONAL DNA BINDING 
G244V LOSS NONFUNCTIONAL NONFUNCTIONAL EXPOSED 
G245S LOSS NONFUNCTIONAL NONFUNCTIONAL BURIED 
M246A LOSS NO RESULTS NONFUNCTIONAL BURIED 
M246T LOSS NONFUNCTIONAL NONFUNCTIONAL BURIED 
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R248L LOSS NONFUNCTIONAL NONFUNCTIONAL DNA BINDING 
R249G LOSS NONFUNCTIONAL NONFUNCTIONAL BURIED 
R249S LOSS NONFUNCTIONAL NONFUNCTIONAL BURIED 
D259V LOSS NONFUNCTIONAL NONFUNCTIONAL BURIED 
G266R LOSS NONFUNCTIONAL FUNCTIONAL BURIED 
R267Q ALTERED PARTIALLY NONFUNCTIONAL BURIED 
V272L FUNCTIONAL NONFUNCTIONAL NONFUNCTIONAL BURIED 
R273C LOSS NONFUNCTIONAL NONFUNCTIONAL DNA BINDING 
R273H LOSS NONFUNCTIONAL NONFUNCTIONAL DNA BINDING 
P278A ALTERED NONFUNCTIONAL NONFUNCTIONAL BURIED 
D281E LOSS NONFUNCTIONAL NONFUNCTIONAL BURIED 
R283P ALTERED NONFUNCTIONAL NONFUNCTIONAL DNA BINDING 
E285K FUNCTIONAL NONFUNCTIONAL NONFUNCTIONAL PARTIALLY  
EXPOSED 
K305M LOSS NONFUNCTIONAL N/A ACETYLATION 
SITE 
R337C ALTERED NONFUNCTIONAL N/A TETRAMER-
IZATION 
R337H ALTERED PARTIALLY N/A TETRAMER-
IZATION 
 
All mutations reside in the DNA binding domain of the protein except for K305M which is 
an acetylation site and R337C and R337H which are in the tetramerization domain. 
aBased on transactivation capacity from 11 biological REs assessed with the plate color assay 
and luciferase assay.  
bTransactivation assessed by Kato et al. [8, 13], based on median transactivation, represented 
as a percentage of WT p53, from 8 REs.  A mutation was considered partially functional if 
the median for the 8 REs was greater than 20%.   
cData for the structure based predictions was acquired from the IARC p53 mutant database 
and derived by Mathe et al. [8, 74], using a four-body potential score from Delaunay tessellations. 
dResidue function information was acquired from the IARC p53 mutation database [8, 74]. 
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Supplemental Table S4.3 
 
Supplemental Table S4.3 Oligonucleotides with p53 mutation of interest for CORE 
replacements 
 
MUTATION OLIGONUCLEOTIDE 5’? 3’ 
T125R CAC AGG GCA GGT CTT GGC CAG TTG GCA AAA CAT CTT 
GTT GAG GGC AGG GGA GTA CCT GCA AGT CAC AGA CTT 
GGC TGT CCC AGA ATG  
L130V AAG TCT GTG ACT TGC ACG TAC TCC CCT GCC GTC AAC 
AAG ATG TTT TGC CAA CTG GCC AAG ACC TGC CCT GTG 
C135F ACT TGC ACG TAC TCC CCT GCC CTC AAC AAG ATG TTT TTC 
CAA CTG GCC AAG ACC TGC CCT GTG CAG CTG TGG GTT 
C135Y ACT TGC ACG TAC TCC CCT GCC CTC AAC AAG ATG TTT TAC 
CAA CTG GCC AAG ACC TGC CCT GTG CAG CTG TGG GTT 
A138V ACT TGC ACG TAC TCC CCT GCC CTC AAC AAG ATG TTT TGC 
CAA CTG GTC AAG ACC TGC CCT GTG CAG CTG TGG GTT 
GAT 
C141W TGC ACG TAC TCC CCT GCC CTC AAC AAG ATG TTT TGC CAA 
CTG GCC AAG ACC TGG CCT GTG CAG CTG TGG GTT GAT 
TCC ACA CCC 
P151A TGC CCT GTG CAG CTG TGG GTT GAT TCC ACA GCC CCG 
CCC GGC ACC CGC GTC CGC GCC ATG GCC ATC TAC AAG 
CAG TCA CAG CAC ATG ACG GAG GTT GTG A 
P151H C AAC AAG ATG TTT TGC CAA CTG GCC AAG ACC TGC CCT 
GTG CAG CTG TGG GTT GAT TCC ACA 
 CAC CCG CCC GGC A 
G154S CAG CTG TGG GTT GAT TCC ACA CCC CCG CCC AGC ACC 
CGC GTC CGC GCC ATG GCC ATC TAC AAG CAG TCA CAG 
CAC ATG ACG GAG GTT GTG 
V173L GGC ACC CGC GTC CGC GCC ATG GCC ATC TAC AAG CAG 
TCA CAG CAC ATG ACG GAG GTT CTG AGG CGC TGC CCC 
CAC CAT GAG CGC TGC TCA GAT 
R174K GGC ACC CGC GTC CGC GCC ATG GCC ATC TAC AAG CAG 
TCA CAG CAC ATG ACG GAG GTT GTG AAG CGC TGC CCC 
CAC CAT GAG CGC TGC TCA GAT 
R174W GGC ACC CGC GTC CGC GCC ATG GCC ATC TAC AAG CAG 
TCA CAG CAC ATG ACG GAG GTT GTG TGG CGC TGC CCC 
CAC CAT GAG CGC TGC TCA GAT 
C176F GGC ACC CGC GTC CGC GCC ATG GCC ATC TAC AAG CAG 
TCA CAG CAC ATG ACG GAG GTT GTG AGG CGC TTC CCC 
CAC CAT GAG CGC TGC TCA GAT AGC GAT 
H179R TGC CCC CAC CGT GAG CGC TGC TCA GAT AGC GAT GGT 
CTG GCC CCT CCT CAG CAT CTT ATC CGA 
R181P GGC ACC CGC GTC CGC GCC ATG GCC ATC TAC AAG CAG 
TCA CAG CAC ATG ACG GAG GTT GTG AGG CGC TGC CCC 
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CAC CAT GAG CCC TGC TCA GAT 
S183L GTG AGG CGC TGC CCC CAC CAT GAG CGC TTA GAT AGC 
GAT GGT CTG GCC CCT CCT CAG CAT CTT ATC CGA GTG 
GAA GGA AAT TTG CGT GTG 
P190L GAG CGC TGC TCA GAT AGC GAT GGT CTG GCC CTT CCT 
CAG CAT CTT ATC CGA GTG GAA GGA AAT TTG CGT GTG 
GAG 
L194P GAG CGC TGC TCA GAT AGC GAT GGT CTG GCC CCT CCT 
CAG CAT CCT ATC CGA GTG GAA GGA AAT TTG CGT GTG 
GAG 
L194R GAG CGC TGC TCA GAT AGC GAT GGT CTG GCC CCT CCT 
CAG CAT CGT ATC CGA GTG GAA GGA AAT TTG CGT GTG 
GAG 
H214R GAG TAT TTG GAT GAC AGA AAC ACT TTT CGA CGT AGT 
GTG GTG GTG CCC TAT GAG CCG CCT GAG GTT GGC TCT 
GAC TGT ACC ACC ATC CAC TAC 
Y220C AAC ACT TTT CGA CAT AGT GTG GTG GTG CCC TGT GAG 
CCG CCT GAG GTT GGC TCT GAC TGT ACC ACC ATC CAC 
TAC 
M237I CGA CAT AGT GTG GTG GTG CCC TAT GAG CCG CCT GAG 
GTT GGC TCT GAC TGT ACC ACC ATC CAC TAC  AAC TAC 
ATA TGT AAC AGT TCC TGC ATG GGC GGC 
C238F T GTG GTG GTG CCC TAT GAG CCG CCT GAG GTT GGC TCT 
GAC TGT ACC ACC ATC CAC ATG TTT AAC AGT TCC TGC 
ATG GGC GGC ATG AAC CGG 
N239D TAC ATG TGT GAC AGT TCC TGC ATG GGC GGC ATG AAC 
CGG AGG CCC ATC CTC ACC ATC ATC ACA CTG 
N239T TGT ACC ACC ATC CAC TAC AAC TAC ATG TGT ACC AGT 
TCC TGC ATG GGC GGC ATG AAC CGG AGG CCC ATC CTC 
ACC ATC ATC ACA CTG GAA GAC TCC AGT G 
S241C ACC ATC CAC TAC AAC TAC ATG TGT AAC AGT TGC TGC 
ATG GGC GGC ATG AAC CGG AGG CCC ATC CTC ACC ATC 
ATC ACA CTG GAA GAC TCC AGT GGT AAT 
C242F ATC CAC TAC AAC TAC ATG TGT AAC AGT TCC TTC ATG 
GGC GGC ATG AAC CGG AGG CCC ATC CTC ACC ATC ATC 
ACA CTG GAA GAC TCC AGT GGT AAT 
C242S ATC CAC TAC AAC TAC ATG TGT AAC AGT TCC TCC ATG 
GGC GGC ATG AAC CGG AGG CCC ATC CTC ACC ATC ATC 
ACA CTG GAA GAC TCC AGT GGT AAT 
C242Y ATC CAC TAC AAC TAC ATG TGT AAC AGT TCC TAC ATG 
GGC GGC ATG AAC CGG AGG CCC ATC CTC ACC ATC ATC 
ACA CTG GAA GAC TCC AGT GGT AAT 
M243T ATC CAC TAC AAC TAC ATG TGT AAC AGT TCC TGC ACG 
GGC GGC ATG AAC CGG AGG CCC ATC CTC ACC ATC ATC 
ACA CTG GAA GAC TCC AGT GGT AAT 
G244V ATC CAC TAC AAC TAC ATG TGT AAC AGT TCC TGC ATG 
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GTC GGC ATG AAC CGG AGG CCC ATC CTC ACC ATC ATC 
ACA CTG GAA GAC TCC AGT GGT AAT 
G245S ATC CAC TAC AAC TAC ATG TGT AAC AGT TCC TGC ATG 
GGC AGC ATG AAC CGG AGG CCC ATC CTC ACC ATC ATC 
ACA CTG GAA GAC TCC AGT GGT AAT 
M246A TAC ATG TGT AAC AGT TCC TGC ATG GGC GGC GCG AAC 
CGG AGG CCC ATC CTC ACC ATC ATC ACA CTG GAA GAC 
TCC AGT GGT AAT 
M246T TAC ATG TGT AAC AGT TCC TGC ATG GGC GGC ACG AAC 
CGG AGG CCC ATC CTC ACC ATC ATC ACA CTG GAA GAC 
TCC AGT GGT AAT 
R248L TGT AAC AGT TCC TGC ATG GGC GGC ATG AAC CTG AGG 
CCC ATC CTC ACC ATC ATC ACA CTG GAA GAC TCC AGT 
GGT AAT 
R249G AAC AGT TCC TGC ATG GGC GGC ATG AAC CGG GGG CCC 
ATC CTC ACC ATC ATC ACA CTG GAA GAC TCC AGT GGT 
AAT 
R249S AAC AGT TCC TGC ATG GGC GGC ATG AAC CGG AGT CCC 
ATC CTC ACC ATC ATC ACA CTG GAA GAC TCC AGT GGT 
AAT 
D259V ATG GGC GGC ATG AAC CGG AGG CCC ATC CTC ACC ATC 
ATC ACA CTG GAA GTC TCC AGT GGT AAT CTA CTG GGA 
CGG AAC AGC TTT GAG GTG CGT GTT TGT G 
G266R ATG GGC GGC ATG AAC CGG AGG CCC ATC CTC ACC ATC 
ATC ACA CTG GAA GAC TCC AGT GGT AAT CTA CTG CGA 
CGG AAC AGC TTT GAG GTG CGT GTT TGT  G  
R267Q ATG GGC GGC ATG AAC CGG AGG CCC ATC CTC ACC ATC 
ATC ACA CTG GAA GAC TCC AGT GGT AAT CTA CTG GGA 
CAG AAC AGC TTT GAG GTG CGT GTT TGT G 
V272L GGT AAT CTA CTG GGA CGG AAC AGC TTT GAG TTG CGT 
GTT TGT GCC TGT CCT GGG AGA GAC CGG CGC ACA GAG 
GAA GAG AAT CTC CGC AAG AAA GGG GAG 
R273C AGC TTT GAG GTG  TGT GTT TGT GCC TGT CCT GGG AGA 
GAC CGG CGC ACA GAG GAA GAG AAT CTC CGC AAG AAA 
GGG 
R273H AGC TTT GAG GTG CAT GTT TGT GCC TGT CCT GGG AGA 
GAC CGG CGC ACA GAG GAA GAG AAT CTC CGC AAG AAA 
GGG 
P278A AAC AGC TTT GAG GTG CGT GTT TGT GCC TGT GCT GGG 
AGA GAC CGG CGC ACA GAG GAA GAG AAT CTC CGC AAG 
AAA GGG 
D281E GAG GTG CGT GTT TGT GCC TGT CCT GGG AGA GAG CGG 
CGC ACA GAG GAA GAG AAT CTC CGC AAG AAA GGG 
R283P GTT TGT GCC TGT CCT GGG AGA GAC CGG CCC ACA GAG 
GAA GAG AAT CTC CGC AAG AAA GGG 
E285K GTT TGT GCC TGT CCT GGG AGA GAC CGG CGC ACA AAG 
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GAA GAG AAT CTC CGC AAG AAA GGG  
K305M CAG TGG TTT CTT CTT TGG CTG GGG AGA GGA GCT GGT 
GTT GTT GGG CAG TGC TCG CAT AGT GCT CCC TGG GGG 
CAG CTC GTG GTG AGG 
R337C CC CTT CAG ATC CGT GGG CGT GAG TGC TTC GAG ATG TTC 
CGA GAG CT 
R337H CC CTT CAG ATC CGT GGG CGT GAG CAC TTC GAG ATG TTC 
CGA GAG CT 
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CHAPTER 5 
Con-A: A SUPER-TRANSACTIVATING RESPONSE ELEMENT FOR p53 
TRANSACTIVATION 
Abstract  
Based on in vitro binding studies, the ability of p53 to function as a transcription 
factor from target response elements (REs) is expected to be a function of the amount of p53 
with stronger binding elements requiring less protein.  Using a recently developed yeast-
based model system that addresses the in vivo potential for p53 to transactivate from target 
RE sequences, we established that low basal levels of p53 expression could result in 
transactivation of a linked reporter and that regardless of the RE a common level of p53 was 
needed before increased induction of transactivation could be first detected.  Further 
increases in p53 led to increased transactivation in a manner that was dependent on the 
specific RE. A surprising response was obtained with the previously reported RE sequence 
GGGCATGTCC GGGCATGTCC known as Con-A. Transactivation was exceedingly high 
under conditions of very low levels of p53 as compared with p21-5’ RE, one of the strongest 
REs known. While it is possible the perfect consensus sequence Con-A may induce structural 
features similar to a palindrome, the basal level response was not apparent when 
transactivation was assessed from a related perfect palindrome sequence. This novel in vivo 
interaction between p53 and the Con-A target which is much less dependent on p53 
concentration than other targets requires p53 tetramerization.  Because of its strong capability 
for transactivation, Con-A and a related sequence provide a useful tool for addressing p53 
function and the functionality of p53 mutant proteins. In light of previous studies with super-
transactivating mutants, these findings suggest novel interactions that can drive 
transactivation at greatly reduced levels of WT and mutant p53s.  The absence of Con-A and 
the related sequence within the human genome may reflect its strong potential for binding  
and/or transactivation. 
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Introduction 
Transcription factors and target response element sequences (REs) are central to any 
master regulatory network. The combination of a rheostatable promoter and luciferase 
reporter that we developed (described in Chapter 2) provides a highly sensitive system for 
assessment of WT and mutant p53 function, as well as interactions with target REs.  Based 
on in vitro binding experiments, if all factors are constant the in vivo responses are expected 
to strongly depend on intracellular concentration of p53 as well as the specific RE examined, 
especially since p53 acts as a tetramer. Within the cell, other factors such as chromatin and 
associated transcription components also play a role in p53-dependent transactivation, but 
under the isogenomic conditions used in the yeast-based system described in Chapter 2, their 
effects are proposed to be relatively constant (although further studies would be warranted to 
specifically address this issue).   
As shown in Chapter 2 and presented in Figure 5.1, there are three phases to 
transactivation that can be revealed by analyzing function at increasing protein 
concentrations with the rheostatable promoter system in yeast.  The first phase is a p53 
dependent, low level response that is due to basal levels of expressed p53 when only a small 
number of molecules are present.  Importantly, this low level response would not be observed 
with typical over-expression systems or with in vitro binding assays.  The 2nd phase 
corresponds to substantial increases in amount of p53 and the 3rd corresponds to a plateau in 
transactivation due to a constant level of p53 (discussed in Results). 
 We have found that the initial induction of transcription, corresponding to the 
beginning of the 2nd phase, extrapolates to comparable levels of p53 protein for 26 REs 
examined, regardless of the biological role of the associated target gene or calculated in vitro 
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binding affinity.  However, the kinetics or increase in the 2nd phase with increasing p53 and 
maximal level of transactivation at the 3rd phase of transactivation by p53 is strongly 
dependent on RE sequence.  The common transition/transactivation point to the 2nd phase 
suggests an additional factor (possibly a conformational change in the binding sequence or 
tetrameric protein) is required for efficient activity from specific binding elements with 
increased levels of p53.   
We discovered a sequence, referred to as Con-A [1], had unusual properties for p53 
driven transactivation.  It was extremely sensitive to basal levels of p53 such that high levels 
of transactivation were observed relative to all other REs examined and yet the maximum 
response (3rd phase) was comparable to that for transactivation from other highly responsive 
REs such at p21-5’.  Thus, sequence itself can strongly affect p53 transactivation even under 
conditions where the number of p53 molecules is small and suggests novel interactions with 
p53.  Previously, we had described super-trans mutants that can increase transactivation from 
a RE, also under low expression conditions.  This study complements those findings in 
demonstrating that both sequence and protein can be modified to greatly enhance 
transactivation under conditions of low levels of p53 expression. 
 
Results 
RE-dependence of transactivation with varying levels of p53  
The rheostatable system provides a unique opportunity to address p53 interactions 
with target sequences at variable levels of expression and define transactivation activity at 
low levels of p53 expression.  Analysis of the kinetics of transactivation from 23 biological 
REs (see chapter 2) in terms of the three phases of transactivation revealed several distinct 
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patterns of transactivation for WT p53 relative to transactivation from the p21-5’ RE (Figure 
5.1).  The three patterns of transactivation reiterated the existence of a low level phase of 
transactivation followed by induction and plateau of activity.   First, overlapping patterns of 
transactivation at basal, inducing and maximal levels of expression were observed for 
several REs, as demonstrated with the p21-5’ and P53R2 REs.  Second, variable basal 
transactivation followed by similar maximal transactivation was observed (i.e., p21-5’ vs. 
PUMA and PA26).  The strength of induction from the RE with a weaker basal response 
appears to reach levels similar to the p21-5’ RE quickly.  However, measurements at 
additional low level protein concentrations between 0.004% and 0.012% will be required to 
verify this observation.  Finally, multipliers of transactivation were observed where 
transactivation from a specific RE was proportionately reduced at all levels of p53 expression 
(i.e., p21-5’ vs. MDM2 RE1).  Importantly, variation in basal level response at low p53 
expression appeared to be dependent upon the specific sequence of the RE.  For example, the 
p21-5’ and P53R2 REs which have overlapping low level response both contain strong core 
sequences containing “CATG” in both decamers, whereas, the REs with a decreased basal 
response lacked a strong core in either half-site.  As shown in Figure 5.1, MDM2 RE1 which 
has a mismatch within the “WW” of the core motif had the weakest basal response of those 
depicted.      
 
Con-A: a highly responsive RE to very low levels of p53 
In addition to the above REs, which correspond to target sequences in human 
promoters, we also examined sequences that were fully matched to the established p53 
consensus (i.e., two decamers of RRRCWWGYYY).  One of these, Con-A [GGGCATGTCC 
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GGGCATGTCC] had previously been used in structure-studies of p53 bound to REs [1].  
This sequence, which does not exist in the human genome, was derived from three tandem 
repeats of the upstream p53 binding element of the human RGC sequence 
(CCAGGCAAGT)3  with all possible nucleotide substitutions in an attempt to determine the 
DNA binding sequence specificity of wild-type p53 [1].  Murine WT p53 bound with the 
highest affinity to this sequence in competitive gel shift assays.  
High levels of WT p53 can transactivate Con-A and p21-5’ RE to similar levels in the 
ADE2 color plate assay (data not shown) and luciferase transactivation assays in diploid 
yeast (Figure 5.2).  However, unlike all other REs, Con-A is highly transactivated by p53 at 
basal levels of expression when p53 is grown in raffinose or at low levels of galactose 
(0.002%, 0.004%, and 0.008%), as shown in Figure 5.3A which summarizes results from 
over 75 experiments.  Furthermore, within the ADE2 plate color assay, WT p53 
transactivation from the Con-A RE resulted in white colonies when cells were grown on 
raffinose plates (data not shown). 
Low level transactivation from the Con-A sequence was p53-dependent (Figure 
5.3B).  Transactivation activity at non-induced conditions (2% raffinose) was significantly 
increased in comparison to activity under repressed conditions (glucose).  Furthermore, if the 
p53 cDNA was interrupted by a CORE cassette (see Figure 2.5), transactivation activity from 
the sequence was not observed, suggesting the activity from the Con-A RE at low levels of 
p53 was due to p53 and not other factors interacting with the sequence.  
The basal level of p53 in the cells grown in raffinose media corresponds to only 
~250-500 p53 molecules per cell, compared to ~5,500 p53 molecules at the point (0.008% 
galactose) where increases in p53 lead to increased transactivation (Figure 2.6C).  The 
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number of molecules for cells grown on glucose is likely to be <50 to 100.  The strong ability 
of a tetramer protein to transactivate with small numbers of molecules suggests novel 
properties of the Con-A RE that cannot be simply explained from in vitro measurements of 
Kd where the Kd is only a factor of 1.5 different from that for the strongly binding p21-5’ RE 
(Veprintsev and Fersht, personal communication).  Other REs often require at least ten times 
more p53 to achieve even low levels of transactivation.  Furthermore, several weak REs 
required approximately 100 times more p53 protein over basal level to reach transactivation 
levels comparable to that obtained from Con-A at basal amounts of p53 expression.  We 
conclude that there is a special relationship between p53 and the Con-A target sequence in 
terms of transactivation at low levels of p53 expression.   Because of its highly responsive 
nature, we refer to Con-A as a super-transactivating RE.  Previously, we had described 
super-trans p53 mutants that were highly efficient at transactivation at low levels of p53 [2].   
 
Con-A basal level response requires a p53 tetramer functioning from a full-site RE 
 While the p53 tetramer is the functional unit essential for high level transactivation, 
dimers have been shown to bind consensus sequences in vitro albeit with a high off-rate [3].  
To ascertain if the basal response was the result of p53 dimer binding and functioning from 
the Con-A sequence at low levels of p53 expression, we analyzed transactivation by p53 
mutations that are compromised for oligomerization: ΔTet, L334A and L334P.  Only 
monomeric p53 protein is formed with ΔTet (deletes residues 325-357), while the L344P and 
L344A mutations result in monomeric and dimeric proteins, respectively (see Chapter 3).  As 
shown in Figure 5.4A, these mutant proteins were not able to drive transactivation from the 
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Con-A sequence at low or even high levels of p53.  Thus, low level transactivation is not due 
to p53 functioning as a dimer protein. 
 Transactivation by WT p53 was also examined from ¾-site and ½-site noncanonical 
versions of Con-A.  While WT p53 could transactivate from the ¾-site consensus elements to 
approximately 15-25% of the maximal levels of transactivation obtained from the full 
element at high levels of transactivation, there was very little response at low levels of p53 
(Figure 5.4B).  Similarly, WT p53 was not able to produce a functional response at low 
expression from a half-site consensus where the response at high levels (0.024% galactose) 
was ~1.7% of the response achieved from the full-site RE at maximal induction.  
[Transactivation from the Con-A half-site relative to the Con-A full-site yielded a slightly 
greater response in comparison to that for WT p53 transactivation from either of the p21-5’ 
half-sites relative to the p21-5’ full-site (see Figure 3.3).]  Therefore, the low level p53 
capability for transactivation from the super-trans Con-A RE is dependent on a tetrameric 
p53 and a full-site RE.    
 
Low level transactivation is sequence dependent 
 We next investigated the sequence specific requirements necessary for efficient basal 
level transactivation by assaying several additional consensus sequences for low level 
response. As shown in Figure 5.5A, changing the core from CATG to CTAG or CAAG 
decreased transactivation at high levels of p53 by ~45 - 50% (average light units per ug 
protein at 0.024% galactose for 8 biological repeats were ~1,250,000, ~ 698,000, ~640,000 
for Con-A, Con B and Con C, respectively).   In addition, there was a dramatic reduction in 
the responsiveness to basal levels of p53, where altering the core and/or flanking sequence 
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diminished the lower level transactivation to ~ 5% or less of that obtained from the Con-A 
sequence at low levels of p53 expression (2% raffinose, 0.002% and 0.004% galactose). 
Although the core CATG is necessary for basal levels of transactivation, analysis of 
the flanking sequences revealed that it was not sufficient for the super-trans low level 
response.  While there is still a complete match to consensus, a change in the flanking 
sequences GGG….TCC to AGG….CCT or GGA….TCC resulted in a reduction of 
transactivation at basal p53 levels to that found for p21-5’ as shown in Figure 5.5B.  
However, the flanking sequence GGG….CCC also resulted in strong transactivation at low 
levels of p53 (Figure 5.6).  Similar to Con-A, this RE [GGGCATGCCC GGGCATGCCC], 
referred to as crystal I [4] was not found in the genome.  Subsequently, based on fluorescence 
anisotropy titration experiments, Veprintsev and Fersht identified the sequence 
GG(A/G)CATGCCC GGGCATG(T/C)CC (which includes the crystal I sequence) as having 
the highest affinity for p53 [5]. 
    
Spacers between Con-A half-sites greatly decrease its super-trans response   
The crystal I RE that contained a 2 nt spacer between the decamers was recently 
employed in crystal studies that addressed the structure of p53 tetramer bound to target 
sequence  [4].  We, therefore, determined the impact that the 2 nt spacer might have on 
transactivation.  Contrary to transactivation from full-site p21-5’, REs containing a 1 or 2 nt 
spacer (Fig. 3.2A), a 2 nt spacer between the decamers did not diminish maximal 
transactivation from the crystal I sequence (Figure 5.6).  However, the 2 nt spacer abolished 
the low, basal level p53 response.  Importantly, the loss of basal transactivation by the 
(crystal I + 2 nt) RE indicates that the super-trans response at Con-A to low level p53 is not 
 181
related to some palindrome–forming feature of the sequence since the 2 nt insertion would 
have enhanced any secondary structure of this complete palindrome.  In agreement with this 
view, transactivation was also low towards the consensus RE referred to as “Con cam” 
composed of two half-sites that are mirror images of itself (Figure 5.6).  Furthermore, the 
crystal II and crystal III sequences (Figure 5.5B) which also create complete palindromes 
were shown to have a weaker basal level response in comparison to the quasi-palindrome 
Con-A sequence. 
 Since the 2 nt spacer did not affect maximal transactivation from the crystal I 
sequence, the impact of spacer upon WT p53 transactivation from the Con-A sequence was 
systematically investigated for the impact of spacers.  Addition of a single nucleotide spacer 
between the Con-A half-sites did not dramatically affect maximal levels of transactivation as 
seen for the p21-5’ RE (see Figure 3.2); however, the 1 nt spacer caused a 50% decrease in 
response to low levels of p53 (Figure 5.7).  Similarly, addition of a second nucleotide did not 
significantly reduce transactivation at higher levels of expression; however, it further 
decreased p53 transactivation at low p53 levels.  Increasing the spacer to 5 nt affected 
transactivation at both low and high levels of p53: 5% and 30%, respectively, when 
compared with no spacer.  Thus, the Con-A super-trans response is strongly dependent on 
spacer and specific consensus sequences.     
 
Transactivation capacity of p53 mutants from Con-A   
Since the Con-A sequence strongly responds to low levels of WT p53, we addressed 
the ability of various p53 mutants to transactivate from this sequence versus other target REs, 
in addition to the altered structure mutants described above.  Mutants with very low 
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transactivation capabilities may be more responsive with the super-trans Con-A RE. We 
examined the 50 missense p53 mutants associated with breast cancer which had been 
analyzed for functional fingerprints in response to 11 human target REs (Chapter 4) for their 
ability to transactivate from the Con-A RE.  Within that group none of the 29 loss-of-
function mutants were capable of transactivating from Con-A in the ADE2 color assay (Table 
2.1; data not shown).  However, all but one of the 21 p53 missense mutations that retained 
any function were capable of nearly WT transactivation at high levels of p53 induction 
(Figure 5.8).  While WT p53 was effective at transactivation from Con-A at very low and 
basal levels, only 2 (P151H and R174K) among the 21 mutants were capable of near WT 
levels of transactivation at basal levels (0% galactose) of p53 expression.  There was 
considerable variation in response between the mutants at intermediate levels of p53 
expression (Figure 5.8). Thus, transactivation from the Con-A can reveal subtle 
transcriptional defects of p53 mutants.     
Transactivation of Con-A was also examined in the luciferase assay for 13/21 of the 
functional p53 mutants (T125R, L130V, A138V, C141W, P151A, G154S, R174W, P190L, 
M237I, R267Q, E285K, R337C and R337H).  As shown in Figure 5.9A, many p53 missense 
mutations including C141W, G285K, and P151A eliminated the basal level response yet 
retained good induction at higher levels of p53.  None of the breast cancer associated mutants 
exhibited a super-trans response at basal levels of p53 followed by no increase with increased 
p53 levels.  For many mutants such as L194P and R337C, there was a general modulation of 
transactivation in comparison to WT (data not shown and Figure 5.9B).  As expected due to 
the compromised ability to form tetramers, neither of the tetramerization mutants at R337 
displayed a high activity from Con-A at low p53 expression.  However, transactivation 
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analysis from Con-A further distinguished the different pattern of transactivation by R337H 
in comparison to WT p53 and other mutants, represented by R174W, where greater levels of 
R337H protein were required for transactivation.  Similar to results from other REs, R337C 
appeared to diminish overall transactivation (Figure 5.9B).  
We also examined an additional 3 mutants (not among the 50 mutants in the breast 
cancer study), V122A, C277R, and G279R which had previously been described as “super-
trans” because of their ability to transactivate from the p21-5’ RE at lower levels of 
expression in comparison to WT p53 when assessed with the plate assay (see Table 2.3)[2].  
At high levels of expression, all three of these mutants were also toxic [6].  Similar to several 
of the breast cancer mutants, C277R and G279R had a reduced low level response from Con-
A in comparison to WT p53, but similar transactivation at higher expression (data not 
shown).  Interestingly, the response for V122A towards Con-A did not differ from wild type 
(Figure 5.9C); all three phases of transactivation were equivalent.  Preliminary results 
suggests V122A has an elevated basal level response from p21-5’ in comparison to WT p53 
(data not shown). 
 
Discussion 
Many studies have addressed the function of p53 mutants towards a variety of REs 
that have different capabilities in supporting transactivation.  Using a system that examines 
p53 function over a broad range of protein expression, we have discovered that the 
previously described Con-A sequence was highly effective at supporting transactivation even 
under extremely low expression conditions, thereby greatly increasing the functionality of 
p53.   
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The super-transactivation nature of Con-A requires a full-site consensus binding 
element and is dependent on the ability of p53 to form a tetramer, the same structural 
requirement necessary for high level response.  As reported for other REs, a CATG core 
domain is required for a strong response by the super-trans RE. Flanking sequences that 
match consensus are important, but not sufficient for low level response. Surprisingly, the 
super-trans RE response does not require that the sequence be a palindrome although a 
second sequence, crystal I, had this feature. In fact, the addition of a spacer consisting of 2 
complementary bases negated the super-trans effect. Since the closely related palindromic 
consensus sequences crystal II, crystal III and Con cam were not super-trans REs, sequence 
is important to the strong transactivation responses.  
The observation that neither of the super-trans REs are found in the genome (the 
closest sequence found has 17 of the 20 nucleotides without a mismatch) suggests that these 
are sequences from which p53 would not be able to sufficiently regulate activity.  Binding 
predictions suggest that approximately 1.5 fold more p53 protein would bind Con-A in 
comparison to p21-5’ under identical conditions [5] (Veprintsev and Fersht, personal 
communication).  However, the 1.5 fold difference in binding does not explain the large 
discrepancy in low level transactivation between the two sequences.  [In agreement with the 
predictive binding constants, fluorescence anisotrophy in vitro binding assays have 
determined p53 binding affinity towards Con-A was comparable to that for other strong 
binding REs including p21-5’ at high levels (Veprintsev and Fersht, personal 
communication)[5].]  Interestingly, the “Con cam” sequence which did not have a basal 
response comparable to Con-A was proposed to be 7-fold more active than Con-A based on 
theoretically predictions of binding affinities (Veprintsev and Fersht, personal 
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communication).  Thus, the basal transactivation results may indicate a novel in vivo binding 
mechanism at low levels of p53 protein.  Possibly the super-trans response at low p53 levels 
is due to unique chromatin structures influenced by the Con-A or crystal I sequences. 
The super-trans Con-A sequence appears diagnostic of residual transactivation 
function of mutant p53 proteins.  If a mutant is able to transactivate from Con-A, then it can 
also transactivate from at least one additional RE.  However, if a mutant p53 fails to 
transactivate from Con-A, even at high p53 expression, it is also incapable of transactivating 
from any of an additional 11 REs studied.  Importantly, transactivation from the Con-A 
sequence appears to distinguish the transcriptional capacity between many p53 mutations 
associated with breast cancers and WT p53.  The observation that no mutants were identified 
that affected transactivation at high p53 levels but not super-trans activity at low expression 
levels, indicates that there are common features of the p53 protein required for the two 
activities.  
The mutation V122A which exhibits high basal level response with Con-A had 
previously been identified as a change-in-spectrum mutation that was also toxic to the yeast.  
The toxicity may indicate a gain in binding affinity towards additional binding sites within 
the genome in comparison to WT protein.  This may be plausible since V122A is positioned 
within the L1 loop of the protein which contacts the major groove of DNA.  (The two other 
toxic mutants, C277R and G279R are located adjacent to or in the H2 helix).  It is interesting 
to speculate if the V122A mutation can increase low level response from other REs, then the 
ability to regulate the associated downstream targets within the network will be 
compromised.  Although C277R and G279R appeared super-trans for the p21-5’ RE, these 
mutations did not display high levels of basal activity from Con-A.  This suggests the high 
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basal response is not a general phenomenon to change-of-spectrum, toxic mutations.  Yet, it 
will be interesting to evaluate basal response for mutations such as S121F that are found to 
be super-trans for all the REs.  Furthermore, the variation in Con-A transactivation by 
V122A and C277R or G279R may differentiate toxic mutants that enhance a proteins affinity 
towards DNA from those mutations that increase protein-protein interactions within the cell. 
The super-trans REs along with super-trans mutants establish that small amounts of 
p53 can be highly effective at transactivation.  Thus, alterations in the genome or p53 can 
dramatically change the rules of engagement [7] and make p53 much more efficient at 
transcription.  While the underlying mechanism remains to be established, it is possible that 
either of these two super-trans conditions arise from novel interactions that greatly reduce the 
off-rate of the protein.  We are currently exploring this and other possible mechanisms in 
yeast and human cells.  
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Figure 5.1 
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Figure 5.1 Three phases to transactivation by p53.  Luciferase assays reveal distinct 
patterns of transactivation kinetics for WT p53 towards REs.  Despite sequence specific 
differences in the maximal levels of transactivation obtainable from a specific RE, there are 
three phases of transactivation.  Phase 1 was classified as a low level response where 
sequence-dependent basal levels of transactivation were observed.  Phase 2 corresponds to 
the increase in transactivation associated with increasing amounts of p53.  Phase 3 was a high 
level p53 response, where sequence dictated the maximal transactivation levels.  Three 
patterns of transactivation were identified between REs: a) similar overall response; b) 
differing basal transactivation with similar maximal transactivation; c) simple modulator 
(multiplier) of transactivation.   
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Figure 5.2 
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Figure 5.2 WT p53 transactivation is similar from the Con-A and p21-5’ REs at high 
levels of p53 expression.  The ability of WT p53 to transactivate from the Con-A and p21-5’ 
REs was measured 24 hours after incubation in media containing increasing amounts of 
galactose. The luciferase assay shows WT p53 transactivates from both sequences to a 
similar level at high levels of transactivation.  However, WT p53 has the ability to 
transactivate from Con-A at low levels of p53 expression.  Presented are the mean and SEM 
for 4 biological repeats. 
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Figure 5.3A 
 
 
 
 
Con-A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3A WT p53 transactivation from Con-A vs p21-5’ REs at low levels of 
expression.  To address the reproducibility of high basal level by p53, transactivation from 
the Con-A and p21-5’ REs was compared at levels of p53 induced by 0, 0.002, 0.004, and 
0.008% galactose.  Presented is the strength of transactivation calculated as light units/ug 
protein for a minimum of 75 biological repeats at each concentration of galactose.  The black 
line indicates the mean value of the biological repeats.   
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Figure 5.3B 
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Figure 5.3B Low level transactivation is p53-dependent.  To ascertain if the low level 
transactivation from the Con-A sequence was dependent on p53, transactivation from Con-A 
was assessed for WT p53 (+) and a strain where the p53 DNA contained a CORE cassette (-).  
Individual diploid colonies were grown overnight in YPDA complete media, washed, diluted 
and inoculated into synthetic media containing 2% glucose or 2% raffinose which 
corresponds to repressed and non-induced conditions, respectively.  Overnight cultures were 
harvested and transactivation was assessed with a quantitative luciferase assay.  Depicted is 
the mean and SEM for 8 biological replicates 
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Figure 5.4A 
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Figure 5.4A p53 tetramerization is required for the super-transactivation at low levels 
of p53.  To determine if the low level p53 response was due to a p53 dimer binding and 
transactivating from the Con-A sequence, several mutations that affected the ability of the 
protein to oligomerize were assessed for transactivation.  344A is a dimer protein, 344P is a 
monomer and ΔTet eliminates the tetramerization domain.  As determined with a luciferase 
assay, the three mutations were not able to function from the Con-A RE at any level of p53 
analyzed.  Presented are the mean and SEM of 8 biological repeats.   
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Figure 5.4B 
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Figure 5.4B Super transactivation at basal levels of p53 requires a full-site RE.  To 
assess if WT p53 could maintain a low level response with noncanonical REs, the ability of 
WT p53 to transactivate from a Con-A half-site or either derivation of the ¾-site was 
compared to its ability to transactivate from the full-site RE.  Arrows indicate a ¼-site, 
GGGCATGTCC.  Depicted is the mean and SEM of 8 biological replicates analyzed by a 
luciferase assay.  
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Figure 5.5A 
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Figure 5.5A Super-transactivation at low levels of p53 requires a CATG core.  To 
determine the sequence requirements for basal transactivation, the central core of the dimer 
was altered from CATG to with CTAG or CAAG.  WT p53 transactivation was assessed 
with a luciferase assay using cells from overnight cultures growing in media with various 
levels of galactose. Depicted are four biological replicates mean and SEM.    
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Figure 5.5B 
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Figure 5.5B Flanking sequences affect basal transactivation by WT p53.  To assess the 
sequence dependent nature of the super-trans response of p53 to Con-A, the flanking 
sequence surrounding a CATG core was altered.  Presented are the mean and SEM of 4 
biological repeats for WT p53 transactivation from the p21-5’, crystal II and crystal III REs 
as determined with a luciferase assay. Crystal II and crystal III are sequences used in recent 
crystal structures where human p53 complexed to various binding sequences was analyzed 
[4].  Transactivation from crystal II and crystal III REs show comparable levels of 
transactivation to the p21-5’ RE at low levels of expression.  These results suggest CATG is 
essential, but not sufficient for super-transactivation at low levels of p53.  Depicted is the 
mean and SEM of 4 biological replicates.  
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Figure 5.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 Crystal I: a second super-trans RE from which p53 can transactivate at low 
levels.  Super-transactivation, as assessed with a luciferase assay, was also observed when 
the CATG flanking region consisted of GGG….CCC, but not for GAA….TCT (Con cam).  
A 2 nt spacer between the crystal I decamer half-sites, which would increase a secondary 
structure of the perfect palindrome, did not decrease the maximal levels of transactivation, 
but did reduce the low level response.  Depicted is the mean and SEM of 4 biological 
replicates. [4]. 
 
 
 
 
 
 
GGGCATGCCC    GGGCATGCCC
GGGCATGCCC gc GGGCATGCCC
cAACATGTTg GGACATGTTC p21-5’
crystal I
crystal I + 2 nt
Tr
an
sa
ct
iv
at
io
n
(x
10
-4
)
(li
gh
t u
ni
ts
 /u
g
pr
ot
ei
n)
1
10
100
1000
0.1
0.0250.0150.005
Galactose concentrations (%)
GAACATGTCT    AGACATGTTC Con cam
Tr
an
sa
ct
iv
at
io
n
(x
10
-4
)
(li
gh
t u
ni
ts
 /u
g
pr
ot
ei
n)
Tr
an
sa
ct
iv
at
io
n
(x
10
-4
)
(li
gh
t u
ni
ts
 /u
g
pr
ot
ei
n)
 197
Figure 5.7 
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Figure 5.7 Small increases in spacer affects Con-A super-trans response at low levels of 
p53. Spacers of 1, 2 and 5 nucleotides were inserted between the decamer half-sites of the 
Con-A RE to determine the impact of spacer on p53 transactivation. The ability of p53 to 
transactivate from these sequences was measured with a luciferase assay 24 hours after p53 
induction.  Presented is the mean and SEM for 8 biological repeats. Addition of a 1 and 2 nt 
spacer between the decamer half-sites of Con-A did not effect maximal transactivation, but 
reduced basal level transactivation to increasing degrees.  Insertion of a 5 nt spacer decreased 
transactivation with basal levels of p53 as well under conditions of maximal p53 expression. 
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Figure 5.8 
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Figure 5.8 Subtle defects of p53 missense mutations revealed by transactivation from 
Con-A. Transactivation capacities of WT and mutant p53 were assessed from the Con-A RE 
using the ADE2 plate color assay at decreasing levels of p53 induction.  Single colony 
isolates grown at 30ºC on YPDA plates containing glucose and high levels of adenine were 
replica plated onto a series of plates containing synthetic medium with low levels of adenine 
[5 mg/L], 2% raffinose and incremental increases in galactose.  Transactivation capacity was 
assessed through colony pigmentation and scored according to the extent of transactivation 
from strong to weak responses.   
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Figure 5.9A 
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Figure 5.9A Impact of p53 missense mutations transactivation from Con-A.  
Transactivation capacities of several p53 missense mutations from the Con-A sequence were 
assessed with the luciferase assay. Several p53 mutations (including data not shown) in the 
DNA binding domain of the protein reduced transactivation from Con-A only at low levels of 
p53.   Presented are the mean and SEM of 4 biological.   
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Figure 5.9B 
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Figure 5.9B Compromised tetramerization diminishes basal response.  Mutations at 
R337 which compromise tetramerization were assessed for the ability to transactivate from 
Con-A.  As expected, both mutants lack a low level response. Presented are the mean and 
SEM of 4 biological repeats.  Interestingly, transactivation from Con-A further differentiates 
the kinetics of transactivation for R337H which requires greater protein for transactivation 
(see Chapter 4).  While R337C diminishes transactivation from the site, it appears to begin to 
induce transctivation at similar protein levels as WT p53 and R174W. 
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Figure 5.9C 
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Figure 5.9C Transactivation by the toxic mutant V122A.  The toxic mutant p53 protein is 
super-transactivating towards several REs including p21-5’ at low levels of p53 [2, 6].  
However, transactivation from Con-A was similar to WT p53. Shown are the mean and SEM 
of four biological repeats. 
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CHAPTER 6 
DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phenotypic diversity within the p53 transcriptional network occurs as a result of a 
variety of factors including cell type, post-translational modifications, co-factor 
availability, target sequence and stress inducing stimuli.  We have sought to understand 
how p53 expression level, target binding sequence and mutations in the p53 protein 
contribute to the differential regulation of gene expression within the p53 transcriptional 
network.  Based on this concept, the integrated diploid yeast rheostatable system was 
developed to determine the influence of binding motifs and sequence on transactivation 
capacity when REs were assessed outside of their endogenous genomic context. The 
diploid yeast system expands a previously established plasmid-based haploid yeast 
system by integrating both p53 and the REs into specific loci, allowing a single copy of a 
p53 variant to be rapidly assessed for transactivation capabilities from many REs simply 
by taking advantage of the yeast mating types.  In contrast to in vitro biochemical assays, 
the yeast assay has the advantage of comparing p53 variants in a constant chromatin 
environment--under isogenomic conditions--for activity towards individual REs. 
Although additional factors (i.e., post-translational modifications or protein binding 
partners) not available in the yeast cell may further influence a biological response in 
mammalian cells analysis, the isogenomic model system addresses the potential for wild 
type and mutant p53 to bind and transactivate from various response elements derived 
from human genes.   
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Small changes in sequence can lead to dramatic differences in transactivation  
When analyzed in isogenic systems, the sequence of the RE has been shown to 
contribute to the ability of p53 to differentially transactivate target genes, where variation 
in sequence can greatly affect transactivation capacity [1].  The Resnick lab has focused 
on determining the “rules of p53 transactivation” to understand what constitutes a 
functional p53 target sequence, as well as what attributes are required for strength of 
transactivation [2]. Results from the integrated diploid yeast system are consistent with 
the rules of transactivation previously determined in a haploid-plasmid based system and 
mammalian cell lines for transactivation from canonical REs.  Interestingly, the number 
of mismatches in the consensus sequence does not correlate with strength of activity.  For 
example, WT p53 can only moderately transactivate from the MMP2 RE which does not 
deviate from the consensus sequence, but can strongly transactivate from the P53R2 and 
p21-5’ RE which contain mismatches.  Previous studies have determined no more than 4 
alterations from the consensus sequence are associated with functionality [3].  Within the 
decamer half-site [RRRCWWGYYY], changes in the conserved C and G at the 4th and 
7th position greatly decreases transactivation (i.e., p21-3’MDM2 RE2, and PCNA).  In 
addition, the nucleotides in the CWWG motif influence the level of transactivation where 
CATG is most active followed by CAAG and CTTG then CTAG which is associated 
with inhibitory effects.  GADD45 and 14-3-3σ site 1 are the only two canonical REs 
examined that contain CATG in both half-sites which did not display strong 
transactivation however, the reduced transactivation is attributed to negative affects of the 
flanking sequence.  The two inner most purines and pyrimidines flanking the core affect 
transactivation more than the outer nucleotides with GG/CC being the most active and 
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AG/CT most inactive.  Finally, most functional REs occur within 5-10 kb of 
transcriptional start sites [1, 3, 4]. 
 
Noncanonical REs expand the p53 transcriptional network 
The present study expands upon the “rules of p53 transactivation” by 
deconstructing and reconstructing the canonical p53 consensus sequence in an attempt to 
determine the essential requirements within a binding element from which p53 can 
function in vivo.  In agreement with previous results [5, 6], we have shown a large spacer 
may allow for the synergistic transactivation between full REs.  However, the spacer 
length between decamer half-sites strongly influences strength of transactivation, where 
small increases in distance between decamer half-sites were shown to greatly reduce p53 
transactivation.  These results are particularly interesting because spacers would not have 
been predicted to affect the binding affinity of p53 towards the sites through established 
in vitro binding assays.  When binding was measured for p53 towards the p21-5’ RE 
containing a 0, 1, 2, 5, or 10 nucleotide spacer with fluorescence anisotropy there was not 
a significant difference between the binding affinities (data not shown; personal 
communication with D. Veprintsev and A. Fersht).  In fact, both the predicted and 
measured binding affinities for the p21-5’ RE containing a 1 nt and 10 nt spacer were 
identical.  Thus, while in vitro biochemical assays may predict the potential for binding 
under ideal conditions with purified components, it appears p53 function must be 
assessed within the context of a cellular environment.  Interestingly, the effect of spacer 
upon binding could be distinguished with a newly developed, semi-in vitro microsphere 
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binding assay that utilizes human cell nuclear extracts containing induced levels of p53 
and additional transcriptional co-factors.   
Further in vivo functional assays within the yeast and mammalian systems 
revealed there can be substantial sequence dependent transactivation from noncanonical 
¾-site and ½-site REs.  Similar to transactivation from full site REs, efficient 
transactivation from these noncanonical elements requires a tetrameric p53.  Through 
deconstruction and transactivation assays of REs originally classified as biologically-
relevant REs, including PIDD and APAF1, it becomes apparent many canonical REs are 
actually noncanonical ¾-site REs. This suggests ¾-site REs play a significant role within 
the p53 transcriptional network.  Furthermore, a recent study from the Resnick lab 
showed such weaker elements have been evolutionarily conserved and selected for in 
terms of function [7].  Ongoing studies are focusing on the functional assessment of ½-
site REs and the role of half-sites in p53-dependent response.  Intriguingly, it has been 
determined that p53 can function from ½-site REs such as FLT1 in a synergistic manner 
with other sequence specific transcription factors to co-regulate the activity of target 
genes [8, 9].   
Currently, the accepted or canonical consensus element consists of two decamer 
half-sites separated by up to 13 nucleotides.  However, our studies should encourage a 
reevaluation of transcriptional targets of p53 in two ways.  First, when considering 
functional targets, the parameters of a full-site sequence should limit the spacer length 
between decamers to 3 nucleotides.  Second, the p53 binding site should be extended to 
include ½-site and ¾-site REs as possible downstream targets.  Importantly, while our 
research has expanded the universe of possible p53 downstream target genes, functional 
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assessment from ½- and ¾-sites will be required before an associated target gene is 
placed within the p53 transcriptional network.  It is interesting to speculate that these 
noncanonical sites have been selected for as a means to fine-tune the p53-dependent 
response at upper levels of expression and/or longer durations of the accumulated protein.  
Furthermore, if p53 transactivation follows a “selective context model” [10] it is 
reasonable to speculate the primary interaction between p53 and the DNA, which is 
impacted by the sequence and organization of the RE, will influence the remaining 
factors or “rules of engagement” required to elicit a functional and/or unique response 
from a given RE.  As shown by recent crystal structures [11], the RE sequence dictates 
the p53-DNA interactions and subsequently its binding surface interfaces.  The 
identification of the super-trans consensus sequence Con-A which displays a unique basal 
level response and super-trans mutants which appear more efficient than WT p53 towards 
some REs can be used as tools to understand the most efficient interactions between p53 
and DNA to achieve function.     
 
Functional mutations diversify the p53 transcriptional network 
Consistent with its important biological role, p53 status and level of expression 
have been considered promising prognostic factors in multiple forms of cancer, including 
breast cancer.  Functional assays estimate that approximately 20 – 30% of mutations in 
p53 will mitigate the protein’s ability to regulate its downstream targets rather than 
render it inactive [3, 12].  Modifications in the p53 transcriptional network are 
hypothesized to change genome stability, repair, replication, apoptosis and the efficacy of 
chemotherapeutic agents. We have employed the rheostatable diploid system to 
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determine the functional fingerprints of 50 p53 missense mutations found in breast 
cancers, particularly those associated with BRCA1/2 cancers and LFS, and define how 
p53 mutants impact the ability of p53 to transactivate from target gene REs.  Among the 
selected pool of mutants, 42% retained function and had a unique functional fingerprint 
in comparison to WT p53 and in terms of transactivation from 12 target REs, including 
Con-A.  Interestingly, most of the mutations displayed subtle transactivation defects that 
were only apparent at low levels of p53.  Importantly, while assessing p53 function, the 
Con-A sequence has been identified as a possible diagnostic tool for identifying p53 
mutations with retained function. 
These studies which are aimed at correlating p53 status in breast cancer to 
prognosis should be expanded to consider the impact of specific mutations upon 
tumorigenesis.  Presently, we are participating in a collaborative attempt to correlate the 
functional status of p53 mutants with physiological response to treatment.  Furthermore, 
the biological consequences of alterations in p53 regulation towards a variety of cellular 
endpoints, such as apoptosis and survival, can be analyzed in human cell functional 
assays.  It is predicted the biological impact will be dependent upon the specific mutation 
and the degree of functionality retained by the mutant [13].  This study will further assess 
the predictability of yeast assays towards the effects of p53 mutations on human cellular 
responses that may be important in the onset or advancement of tumorigenesis.   
 
Conclusions 
This research which utilizes the combination of transactivation results with 
various mutants and sequences along with information about semi-in vitro binding is 
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providing unique opportunities to address the p53 master regulatory network.  Based on 
results with the various REs obtained under isogenomic conditions, we demonstrate that 
RE sequence, organization and level of p53 can strongly impact p53-mediated 
transactivation, thereby changing the view of what constitutes a functional p53 target. In 
addition, mutations in the protein itself have been found to further diversify the network 
by altering the spectrum of target genes, as well as the intensity to which the downstream 
targets can be regulated.  The results will provide valuable insight toward understanding 
the biological role this prominent tumor suppressor plays in the multiple pathways it can 
influence as a master regulatory gene.   
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CHAPTER 7 
MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Construction of isogenomic diploid yeast strains containing p53 inducible reporters 
The delitto perfetto site-directed mutagenesis system (Figure 2.5) [1, 2] was used to 
generate a panel of isogenic “p53-host” strains and a panel of response element (RE) reporter 
strains in the budding yeast, S. cerevisiae. Each p53-host strain, yAT-iGAL::p53 (MATa 
leu2-3,112 trpl-1 his3-11,15 can 1-100 ura3-1, trp5::pGAL1:p53:cyc1-Ter, lys2::HygroR), 
contains the wild type p53 cDNA controlled by the inducible, “rheostatable” GAL1 promoter 
[3] integrated at the TRP5 locus on chromosome VII. p53 mutations were constructed using a 
derivative of the p53 host strain containing a CORE cassette (CO, counterselectable, 
KLURA3; RE, reporter, KanMX4 resistance gene) integrated within the p53 cDNA at various 
nucleotide positions (Table 2.1) [4]. Modifications of p53 were performed using the delitto 
perfetto approach [1, 2] where the CORE cassette was replaced with an oligonucleotide 
containing the mutation of interest to generate a full-length mutant p53 cDNA or the desired 
deletion of the C-terminus. Replacement of the CORE was confirmed by selection on 5-FOA 
and kanamycin sensitivity. Specific p53 alterations were confirmed by colony PCR and 
sequencing (Big dye, Applied Biosystems, Foster City, CA). 
The second panel of isogenic strains containing p53 REs upstream of the CYCl 
minimal promoter and the firefly luciferase reporter were obtained starting from the yLFM-
ICORE strain, as previously described [5]. The reporter strains are also isogenic with the p53 
host strains, but LYS2 and Hygros. 
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Mating of the reporter and p53-host strains followed by selection for diploid cells on 
Lys- Hygro+ plates, results in isogenomic, yeast that enable the assessment of the 
transactivation potential for WT or mutant p53 proteins towards individual REs in the p53 
transcriptional network. Strains differ only by the mutation of interest and nucleotide 
variation in the RE (note that a half-site or tandem REs are more nucleotides). 
 
Qualitative ADE2 color assay 
Single colony isolates of the p53-inducible RE-ADE2 reporter strains were streaked 
onto an YPDA control plate containing glucose and high levels of adenine and grown to 
equivalent amounts at 30ºC.  The plates were then replica plated onto a series of 9 
experimental plates containing selective media with low levels of adenine [5 mg/L ], 2% 
raffinose and incremental increases in galactose (0, 0.001, 0.002, 0.004, 0.008, 0.016, 0.032, 
0.064 and 0.128%).  Transactivation capacities for the p53 mutants were determined after 
three days of growth at 30°C by the ability of the mutant to produce a change in colony 
pigmentation.  Transactivation of the ADE2 gene, which is a direct readout of p53 interaction 
with the specific RE, results in large white colonies where decreased or loss-of-
transactivation of the ADE2 results in pink and red colonies, respectively.  Transactivation 
capacities for the p53 WT and mutants were determined after three days of growth at 30°C 
by the ability of the mutant to produce a change in colony pigmentation.  Colony 
pigmentation was scored on a scale of 1 to 5, where 1 is no apparent transactivation (red 
colonies) and 5 is strong transactivation (white colonies). 
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Quantitative luciferase assay  
Individual colonies of cells with the p53-inducible RE reporter were inoculated into 
5ml rich media, YPDA plus adenine [200 mg/L], and grown overnight at 30°C with shaking. 
The overnight culture was diluted 1:50 in H2O. For each measurement, 1 ml of the diluted 
culture was spun down, washed of residual glucose with H2O and re-suspended in 2mL 
synthetic complete - LYS  media (plus 2% raffinose or raffinose supplemented with 
increasing amounts of galactose (0, 0.002, 0.004, 0.008, 0.010, 0.012, 0.016, 0.020, 0.024, 
0.028 or 0.032%). These cultures were grown overnight (~ 18 hr) at 30°C to ~2 – 4 x 107 per 
ml (late log early stationary).  The 2 ml cultures were spun down and the supernatant was 
aspirated. The remaining pellet was resuspended in 100 μl reporter lysis buffer (Promega, 
Madison, WI) and an equivalent amount of 425-600 micron acid-washed, glass beads was 
added (Sigma, St. Louis, MO). Samples were homogenized for 30 seconds in the Biospec 
Products, Inc. mini-bead beater (Bartlesville, OK), briefly incubated on ice and spun for 20 
minutes at 16k relative centrifugal force (rcf) in an Eppendorf 5415R centrifuge (Batavia, IL) 
to separate the soluble protein fraction. The standard protocol recommended by the 
manufacturer (Promega; Madison, WI) was performed for the luciferase assay system 
starting with 10 μl of protein extract. Luciferase activity was measured from 96-well, white 
optiplates (Perkin Elmer, Waltham, MA) in a Wallac Victor2 multilabel counter (Perkin 
Elmer, Waltham, MA). Light units were standardized per μg protein as determined by a Bio-
Rad protein assay (Bio-Rad; Hercules, CA). Luciferase assays in haploid strains were 
performed as previously reported [6].     
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Human cell lines 
Human SaOS2 (HTB-85, ATCC) osteosarcoma cells were grown in McCoy’s A5 
medium supplemented with 10% FBS and 1X penicillin /streptomycin (Gibco, Carlsbad, 
CA). All cultures were incubated at 37°C with 5% CO2. Human lymphoblastoid cells were 
grown in RPMI 1640 media supplemented with 15% heat-inactivated fetal bovine serum 
(Invitrogen, Carlsbad, CA) and incubated at 5% CO2 at 37˚C with 1% penicillin-
streptomycin antibiotics (Invitrogen).  The lymphoblast cell lines GM12824 and GM12825 
used in the semi-in vitro binding assay were purchased from Coriell Cell Repositories 
(Camden, NJ).  Results with human cells included in the noncanonical paper of Chapter 3 
were largely accomplished through a collaboration with Dr. Daniel Menendez in the Resnick 
lab and were guided by results in yeast.   
 
Transfections and luciferase assays in human cell lines 
  Plasmids pC53-SN3 [7] coding for human p53 cDNA under the control of CMV 
promoter and the control vector pCMV-Neo-Bam were kindly provided by Dr. Bert 
Vogelstein. p53 mutations within the pC53-SN3 vector were generated by site-directed 
mutagenesis (QuickChange site-directed mutagenesis kit, Stratagene) and were confirmed by 
sequencing. Luciferase reporter constructs containing the p53 REs were constructed in 
pGL3-Promoter backbone (Promega, Madison, WI). Partially complementary 
oligonucleotides containing the RE and five additional flanking nucleotides from both sides 
were annealed in vitro to yield double-stranded molecules that would be compatible for an in 
vitro ligation reaction with XhoI/BamHI double digested pGL3-promoter vector. Ligation 
products were transformed into XL1 blue E. coli cells, purified, amplified and sequenced. 
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pRL-SV40, a reporter plasmid coding for Renilla reniformis luciferase (Promega, Madison, 
WI) was used as a control of transfection efficiency in the luciferase reporter assay.  
For luciferase assays SaOS2 cells were seeded in 24-well plates 24 hours before 
transfection. Cells were transfected using Fugene-6 (Roche, Indianapolis, IN) according to 
manufacturer´s instructions at ~80% confluence (with 200 ng of reporter constructs). When 
appropriate, 25ng of the p53 was co-transfected. Total plasmid DNA per well was adjusted to 
an equal level by adding the empty vector pCMV-Neo-Bam. Forty-eight hours post 
transfection, extracts were prepared using the Dual Luciferase Assay System (Promega) 
following the manufacturer’s protocol and luciferase activity was measured on a Victor 
Wallac multilabel plate reader (PerkinElmer). For each construct, relative luciferase activity 
is defined as the mean value of the firefly luciferase/Renilla luciferase ratios obtained from at 
least three independent experiments. 
 
Chromatin Immunoprecipitation (ChIP) assays 
 SaOS2 cells were seeded in 10-cm dishes and transfected at 80% confluence with WT 
p53 expression vector along with the pGL3-P reporter plasmid containing the p21 5’RE or its 
derivatives. ChIP on plasmid assays were performed as described previously [8] using the 
ChIP kit (Upstate Biotechnology) following the manufacturer’s instructions. A mouse 
monoclonal anti-p53 antibody DO7 (Pharmigen, BD) was used. PCR amplifications were 
performed on immunoprecipitated chromatin using a pair of primers to amplifya specific 
region in the pGL3-P backbone containing the p53 REs (5'-
ATAGGCTGTCCCCAGTGCAA-3' and 5'-TGGAATAGCTCAGAGGCCGA-3'). The PCR 
cycles were as follows: an initial 10 min Taq Gold polymerase at 95°C followed by 40 cycles 
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of 95°C for 15 s and 60°C for 1 min. The PCR products were then run on a 1.8% agarose gel 
and quantified with IMAGEQUANT V5.1 (Molecular Dynamics-GE, Piscataway, NJ). 
 
Semi-in vitro binding assay with human nuclear extracts 
To evaluate the sequence-specific p53-DNA binding interactions, the semi-in vitro 
fluorescent microsphere binding assay as previously described [9] was used. Briefly, 
lymphoblast cells were grown to ~ 8.5 X 105 cells/mL before exposing to 0.6ug/mL (1mM) 
doxorubicin (Sigma, St. Louis, MO) for 18 hours at 37˚C. Nuclear protein was extracted 
from non-treated and treated cells using a Nuclear Extraction Kit  according to 
manufacturer’s protocol (Active Motif, Carlsbad, CA) and protein concentration was 
measured in triplicate using the BCA Protein Assay Kit (Pierce, Rockford, IL), followed by a 
plate read using a Perkin Elmer HTS 7000 BioAssay Reader. All the oligonucleotides 
reported in this study were synthesized by Invitrogen (Carlsbad, CA). Fluorescent 
microspheres bearing double stranded DNA fragments containing a sequence of interest, 
were multiplexed and incubated for 1 hour  in the presence of 1.75 ug of nuclear protein 
extracts from either treated or non-treated cells. Following incubation in cell extracts, the 
beads were incubated with p53 antibodies (DO-7, BD Biosciences, San Jose, CA) and 
secondary antibodies conjugated with phycoerythrin(R-phycoerythrin-coated goat anti-
mouse) for 30 minutes. The p53 interaction with each bead was measured on a BioPlex 
Machine (BioRad) as raw fluorescence intensity signal generated from phycoerythrin-
conjugated secondary antibody to mouse anti-p53. For signal normalization, an aliquot of the 
DNA-conjugated beads was treated separately with phycoerythrin-conjugated streptavidin for 
20 minutes in the absence of any nuclear extracts. All binding reactions were conducted in 
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triplicates. For each bead type in every multiplex set of beads, relative binding signal was 
obtained by normalizing the absolute binding signals of extract-treated beads (mean of 3 
replicates) to mean signals obtained from the same set of beads that had been independently 
treated with phycoerythrin-conjugated streptavidin (mean of 3 replicates). This normalization 
accounts for bead type-specific oligo content. Net binding for each oligo is the numerical 
difference between NT and DOX-treated signal obtained for this oligo.  Results with the bead 
system included in the noncanonical paper of Chapter 3 were largely accomplished through a 
collaboration with the Doug Bell lab at NIEHS and were guided by results in yeast.   
 
Western analysis 
Yeast cells. Individual yAT x yLFM diploid colonies were inoculated into YPDA 
media and grown overnight. Overnight cultures were diluted 1:50 in H2O and 1 ml of the 
culture was spun down for each sample treatment, washed with 2 ml of H2O and inoculated 
into 2 ml synthetic media (lys-) with either glucose (2%), raffinose (2%) or raffinose plus 
increasing amounts of galactose in media (0.002 – 0.032% galactose). Cultures were grown 
24 hours at 30°C with vigourous shaking. Protein extracts were prepared in 35 ul reporter 
lysis buffer  (Promega, Madison, WI) plus 2% protease inhibitors (cocktail for use with 
fungal and yeast extracts; Sigma, St. Louis, MO). An equivalent amount of 425-600 micron 
acid-washed, glass beads (Sigma, St. Louis, MO) were added prior to the samples being 
homogenized for 30 seconds in the Biospec Products, Inc. mini-bead beater (Bartlesville, 
OK). Following homogenization, samples were briefly incubated on ice and spun for 20 
minutes at 16k rcf in an Eppendorf 5415R centrifuge (Batavia, IL) to purify soluble proteins. 
Protein concentrations were measured with the Bio-Rad protein assay according to the 
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standard protocol (Bio-Rad; Hercules, CA). 50 μg of total protein extracts were run on SDS-
PAGE gels and transferred as previously described [3]. p53 was detected with the mouse 
monoclonal antibodies DO-1 and pAb1802 (Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA) according to the manufacturer’s protocol. GAPDH was detected with the rabbit 
polyclonal GAPDH antibody (HRP) (Abcam, Cambridge, MA). 
 Human cells. Whole cell extracts from SaOS2 transfected cells were obtained using a 
cell culture lysis reagent (Promega) following the manufacturer’s instructions. Equal 
amounts of whole cell extracts were separated on 4-12% BisTris NuPAGE and transferred to 
polyvinylidene difluoride membranes (Invitrogen). The blots were probed with primary 
antibodies (Santa Cruz) for p53 (pAb1801 and DO-1) and Actin (C-11). Bands were detected 
using horseradish peroxide-conjugated secondary antibodies (Santa Cruz) and the enhanced 
chemiluminescence (ECL) detection system (Amersham, Cleveland, OH, USA). 
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